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Epidemiology and treatment of early–stage breast cancer
Breast cancer is the third most frequently diagnosed type of cancer in the Netherlands 
(1), and the most common type of cancer diagnosed in women (1). In 2015, a total of 
14.449 women were diagnosed with invasive breast cancer in the Netherlands (1). Due 
to advances in treatment and earlier detection of tumors, survival has improved over the 
past decades (1). Overall five-year survival rates are about 90% and 10-year survival 
is on average about 70% (1). Unfortunately, in the Netherlands on a yearly basis still 
more than 3.000 women die due to breast cancer (1).
 
The primary treatment for breast cancer is radical excision of the tumor (via a mastec-
tomy or breast conserving surgery). Surgery is commonly supplemented with adjuvant 
treatments, i.e., radiotherapy and systemic therapy (2). The focus of this thesis is on 
the systemic therapy modalities for early-stage breast cancer, namely chemotherapy 
alone or in combination with biological response modifiers (e.g., trastuzumab) and/or 
endocrine therapy. These treatment modalities are intended to decrease the proba-
bility of the cancer recurring and consequently improving patients’ long-term survival 
(3-5). However, they are also associated with side-effects that can significantly impact 
patients’ quality of life (3,4,6,7).
Prediction tools and communication of risks
Adjuvant treatment modalities essentially target a risk and not demonstrable disease. 
This means that a proportion of patients who undergo treatment do so unnecessarily 
as they either had already been cured by the resection of the primary tumor or would 
have developed a disease recurrence and/or distant metastases in spite of adjuvant 
treatment. Notwithstanding the advancements in medical science, it is not (yet) pos-
sible to predict a priori whether an individual patient will be amongst the patients that 
profit from adjuvant systemic therapy. Eligibility for systemic therapy is currently based 
on consensus amongst medical experts about how much survival gain is minimally 
needed for the benefits of treatment to outweigh the loss in quality of life due to its 
side-effects. The uncertainty about whether or not treatment is necessary is one of the 
factors that can make decision-making about adjuvant systemic therapy complex for 
oncologists. Current (inter-) national clinical breast cancer treatment guidelines deem 
3-5% absolute 10-year survival gain sufficient to discuss adjuvant systemic therapy 
with patients (2,8,9). This means that minimally about one in every 20-30 patients 
treated should benefit from the treatment. For some subgroups of patients, e.g., those 
with Her2-positive disease, benefits smaller than 3% are also deemed acceptable in 
clinical guidelines (2,8,9). 
Clinical decision-making about adjuvant systemic therapy relies, among others, on 
statistical evidence to assess the risk of disease recurrence and death. Many tools, 




clinicians’ decision-making process. Such tools use clinical characteristics (e.g., tumor 
size and the presence of nodal metastases) or biomolecular markers to estimate relapse 
and/or mortality risk with/without the potential treatment benefit. Well-known prediction 
tools are for example Adjuvant! (10), PREDICT (11), MammaPrint (12), and Oncotype Dx 
(13). The use of Adjuvant! (2,8,9), and Oncotype Dx (8) to support decision-making is 
endorsed by clinical guidelines. These tools seem to meet a need in clinical practice, as 
the be it limited evidence available on the use of for example Adjuvant!, suggests that 
it is commonly used by clinicians (14,15). However, evidence is lacking on clinicians’ 
reasons for using such tools and how and when they use them.
Although most prediction tools were primarily developed to aid clinicians’ decision-mak-
ing, they can be used during consultations with patients. A frequently uttered argument 
against the use of prediction tools to inform patients about their prognosis is that people 
generally struggle to understand probabilistic information. The literature underscores 
this (16). It is feared that patients might not grasp the fact that the estimates provided by 
prediction tools are just that – estimates. Patients might cling too much to the numbers 
and not realize that it is not possible to predict the outcome a priori, and that there is 
a margin around the survival estimates. Risk communication experts argue from an 
ethical perspective that if oncologists communicate survival estimates from prediction 
tools to patients, then they should also explicitly discuss the uncertainty associated 
with these estimates (17). It is unclear whether or not oncologists explicitly discuss 
these uncertainties during patient consultations. Also, it is unclear whether patients 
are aware of the uncertainty associated with the survival estimates. 
Decision-making about adjuvant systemic therapy
The expected survival gain due to treatment can be modest for patients with early-stage 
breast cancer, especially those with stage I disease, and treatment is associated with 
side-effects. Foregoing treatment is therefore, also a medically viable option. These 
treatment decisions are preference-sensitive, there is usually no ‘right’ choice regarding 
systemic therapy, and decision-making needs to be guided by patients’ values and 
their informed preferences. Oncologists are tasked with helping their patients to form 
a judgement on whether treatment is worthwhile or not. Firstly, oncologists must make 
their patients aware that a treatment decision needs to be made and that patients’ 
input is essential. Secondly, to facilitate patient participation in the decision-making 
process, oncologists need to inform them about all the relevant pros and cons of the 
viable treatment options – including the option to forego treatment. It is crucial that 
information provision is comprehensive and balanced. Finally, once patients are made 
aware of the pros and cons of treatment, oncologists should ascertain how their patient 
weighs the pros and cons. This discussion should be the basis for decision-making, 
irrespective of who makes the final treatment decision. 
16
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The steps described above are the cornerstones of shared decision making (SDM), 
which is advocated as an ideal approach to clinical decision-making. Although, these 
steps might seem straightforward and clinicians indicate they practice SDM, available 
evidence suggests that the implementation of SDM in clinical practice is limited (18). For 
example, Kunneman et al. (19) evaluated the implementation of the first step of SDM in 
oncology consultations where preference-sensitive treatment decisions needed to be 
made. In only 3 out of 100 consultations oncologists explicitly stated that a treatment 
decision needed to be made (19). The focus of this thesis will be on the second step 
of SDM. Thus, information provision and the potential barriers to balanced information 
provision in the context of adjuvant systemic therapy for breast cancer.
Thorough and balanced information provision is crucial to help patients weigh the pros 
and cons and develop informed treatment preferences. However, providing patients with 
balanced and comprehensive information is difficult. Presenting all available information 
is not always possible or desirable. Adjuvant systemic therapies for breast cancer, for 
example, are associated with numerous potential side-effects. It is thus unfeasible, 
ineffective and arguably unnecessary to discuss all these side-effects with patients. 
Oncologists need to find a way to inform their patients without overwhelming them with 
too much information, thus choices must be made with regards to which information is 
provided and how it will be presented. Current clinical breast cancer guidelines do not 
offer guidance on what information should minimally be discussed (2,8,9). Therefore, 
oncologists must make a judgement call about what information is essential for patients 
to know in order to decide about treatment. This lack of guidance on what minimally 
needs to be communicated can cause unwanted variability in information provision 
between (and also within) oncologists. Indeed, this has been shown in the literature 
(20). Oncologists’ valuation of what information is relevant for patients to know in the 
context of decision-making, need not match the patient’s needs and preferences (21). 
For example, side-effects deemed irrelevant by oncologists, might be perceived as an 
unacceptable burden on their quality of life by patients. In order to determine whether 
it is relevant to communicate a specific side-effect, it is important to have some insight 
into the patients’ personal situation and their preferences. The literature suggests that 
clinicians rarely explore patients’ personal situation and the veracity of their assumptions 
with regard to what is relevant for the patient to know (18,22).
Further, the use of tools such as Adjuvant!, can help oncologists and patients get a 
better grasp on the magnitude of the potential treatment benefits. However, Adjuvant! 
(like other tools) does not provide information about side-effects. Thus, the use of pre-
diction tools could shift the focus of the consultation towards the survival probabilities 
to the detriment of information provision about side-effects. This imbalance in infor-
mation provision could prevent adequate valuation of the trade-off involved between 




how the use of prediction tools influences information provision. 
The choices oncologists make with regard to which information they convey or omit 
and how they frame the information presented to patients, could (unconsciously) be 
influenced by their preferences/beliefs about which treatment option is in their patients’ 
best interest. It is perhaps unrealistic to expect that clinicians are conscious of their 
preferences and preconceptions and are able to put these aside during consulta-
tions, and provide patients with information not colored by their (clinical) experiences 
and beliefs. Even if oncologists consciously tailor their information to steer patients 
towards the treatment option they favor, they most likely act in what they believe is 
in their patient’s best interest. Hence, is framing a cause for concern? Especially, in 
clinical situations where there is no obvious best option from a medical perspective 
(i.e., a preference-sensitive treatment decision), the choices clinicians make, can have 
important unwanted consequences. From the oncologist’s selection and way of pre-
senting the information, patients might for example, get the impression that the option 
their oncologist seems to favor is the best option, and might therefore feel compelled 
to consent to a treatment plan that does not fit with their own goals and preferences. 
Systematic evaluation is lacking of whether implicit value judgements are used in 
information provision about adjuvant systemic therapy. There are indications from other 
settings that such behaviors are used in clinical practice (23,24).
 
Aim of this thesis
Patient participation in the treatment decision-making process is widely advocated and 
essential in the context of preference-sensitive treatment decisions. A key requirement 
to achieve this goal is thorough and balanced information provision about the benefits 
and harms of the viable treatment options. There are many factors that can negatively 
influence information provision in clinical practice. Unfortunately, insights in information 
provision during real-time patient consultations involving preference-sensitive decisions 
is limited. The objective of the work presented in this thesis is to assess information 
provision about adjuvant systemic therapy during consultations between early-stage 
breast cancer patients and medical oncologists in general. In this era of personalized 
medicine, prediction tools (e.g., Adjuvant!) are becoming an integral part of information 
provision during patient consultations. However, evidence is lacking about a) how prev-
alent the use of such tools is during patient consultations, and b) whether and how the 
use of such tools influences information provision. Therefore, this thesis in addition to 
assessing the availability and the quality of prediction tools for the early-stage breast 
cancer setting, also zooms in on the use of such tools during patient consultations and 
their impact on the content of consultations. 
Outline of this thesis 
This thesis consists of three parts. In Part I, two studies are presented that investigate the 
availability and accuracy of risk prediction models for decision-making about adjuvant 
18
Chapter 1 
systemic therapy for early-stage breast cancer. An essential prerequisite for the use 
of such tools, is that their estimates have to be accurate. In Chapter 2 we provide a 
systematic overview of published risk prediction models for adjuvant systemic therapy 
selection in early-stage breast cancer. This review provides insight in the strengths 
and weaknesses of the identified models. Most prediction tools were developed to 
inform clinicians’ decisions, yet they are also used to inform patients. Therefore, in this 
chapter we also assessed the required literacy level to comprehend the content of the 
output provided by these tools. In Chapter 3 we assessed the prognostic accuracy of 
Adjuvant! and PREDICT’s 10-year all-cause mortality estimates in breast cancer patients 
aged <50 years at diagnosis. These are two well-known freely available prognostic 
tools used in clinical practice. We now focus on young patients as previous validation 
studies had too few young patients (e.g., (25)), and/or the follow-up time was too brief 
(e.g., (26)) to draw conclusions about the accuracy of these tools in this younger patient 
population. Available studies do suggest that Adjuvant! underestimates mortality in 
young patients (e.g., (27)).
The second part consists of two studies in which we assessed oncologists’ attitudes 
towards and self-reported use of tools to communicate the benefits of adjuvant systemic 
therapy for early-stage breast cancer. In Chapter 4 we assess oncologist’s perception 
of the minimal benefit that makes treatment worthwhile given the side-effects. Clinical 
guidelines indicate that 3-5% is the minimum benefit that makes treatment worth 
considering given its side-effects (2,8,9). We assessed whether oncologists’ minimally 
required benefit to tip the scale in favor of treatment is in line with the guidelines. 
These insights are relevant as oncologists’ preferences and beliefs can influence their 
information provision and treatment recommendations. Further, little is known about 
oncologists’ perceptions of and reasons for using prediction tools, and views on com-
municating the uncertainty associated with prognostic estimates from such tools. 
Therefore, we investigated this in the study reported in Chapter 5. 
The third part consists of three studies assessing information provision about the 
benefits and harms of adjuvant systemic therapy for early-stage breast cancer during 
real-time patient consultations. In Chapter 6 we assessed the frequency and the influ-
ence of the use of Adjuvant! on information provision about the benefits and harms 
of adjuvant systemic therapy, and whether the use of this tool is associated with the 
likelihood of reaching a decision during the consultation. In Chapter 7 we zoom in 
on a controversial element of risk communication, namely the communication of the 
uncertainty associated with the prognostic estimates provided by prediction tools. There 
currently are no generally accepted guidelines on whether and how to communicate 
uncertainty, and evidence on whether uncertainty is communicated in clinical practice 
is also lacking. In the study reported in this chapter, we assessed whether and which 




was used. We also assessed how patients perceived the uncertainty associated with 
the prognostic estimates communicated during the consultation. Finally, in Chapter 8 
we explored whether the presentation of information about adjuvant systemic therapy 
during the consultation contained implicitly persuasive elements. Such behaviors could 
inadvertently steer patients facing preference-sensitive decisions towards a particular 
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It is a challenge for oncologists to distinguish breast cancer patients who can forego 
adjuvant systemic treatment without negatively affecting survival from those who 
cannot. Risk prediction models (RPM) have been developed for this purpose. Oncolo-
gists seem to have embraced RPM (particularly Adjuvant!) in clinical practice, and often 
use them to communicate prognosis to patients. We performed a systematic review 
of published RPM, and provide an overview of the prognosticators incorporated and 
reported clinical validity. Subsequently, we selected the RPM that are currently used 
in the clinic for a more in-depth assessment of clinical validity. Finally, we assessed 
lay comprehensibility of the reports generated by RPM.
Methods
PUBMED, EMBASE and Web of Science were searched. Two reviewers independently 
selected relevant papers and extracted data. Agreement on paper selection and data 
extraction was achieved in consensus meetings.
Results 
We identified RPM based on: clinical prognosticators (N=6) and bio-molecular features 
(N=14). Generally predictions from RPM appear to be accurate, except for patients ≤50 
years or ≥75 years at diagnosis, and Asian populations. RPM reports contain much 
medical jargon or technical details, which are seldom explained in lay terms.
Conclusions 
The accuracy of RPM’s prognostic estimates is suboptimal in some patient subgroups. 
This urgently needs to be addressed. In their current format RPM reports are not condu-
cive to patient comprehension. Communicating survival probabilities using RPM might 
seem straightforward, but it is fraught with difficulties. If not done properly, it can back-
fire and confuse patients. Evidence to guide best communication practice is needed.
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Introduction
Breast cancer is a heterogeneous disease with great diversity in morphology and 
clinical behavior (1). A major challenge for oncologists is determining which patients 
might benefit from adjuvant systemic therapy. Prognosis estimates, the basis for 
selecting patients who might benefit from systemic therapy, are usually based on 
traditional clinicopathological factors, such as nodal status and hormone receptor 
status. Increased awareness, screening, and improvements in breast cancer diagnosis 
have led to early detection of smaller tumors without lymph node involvement. Using 
the traditional clinical prognosticators, one would assume that these tumors have a low 
recurrence risk, and more patients might be spared systemic therapy without adversely 
affecting survival. Yet, small tumors have also been shown to have metastatic potential, 
and the lack of sufficiently discriminating predictors has led to the broadening of the 
indication for systemic therapy (1-4). Nowadays, virtually all breast cancer patients 
meet eligibility criteria for adjuvant systemic therapy (5, 6). It has been argued that up 
to 60% of these patients, treated according to current guidelines, only experience loss 
of quality of life due to toxicity with little or no survival benefit (5). 
In light of patients’ loss of quality of life and financial costs to society, reducing over-
treatment is an important goal to patients, oncologists, and policy-makers alike. As a 
result, many risk prediction models (RPM) have been developed to help oncologists 
select patients who might derive benefit from systemic therapy. RPM are primarily 
designed to provide oncologists with standardized, reproducible, and evidence-based 
tools to aid clinical decision-making. The earliest models were solely based on (a 
subset of) the traditional clinicopathological factors, e.g. Nottingham Prognostic Index 
(NPI) (7) and Adjuvant! (8). In the last decade RPM based on genetic profiles or other 
bio-molecular features were introduced, such as Oncotype Dx (9) and MammaPrint 
(10). RPM generally provide pretreatment prognostic information to quantify the benefit 
that patients can obtain from various available adjuvant systemic therapies and/or 
classify patients according to their risk of death and/or cancer recurrence. RPM can 
be valuable and reliable aids in decision-making for oncologists, but they face two 
major challenges. First, RPM differ in what information they use to predict prognosis 
and adjuvant treatment benefit. Therefore the choice of RPM can affect the probabil-
ities given for an individual patient. Second, communicating probabilities from these 
models to patients is difficult.
Small surveys in the US (11) and UK (12) found that the majority of oncologists (>95%) 
used Adjuvant!. Two thirds frequently discuss the RPM estimates with patients (12). 
Studies have reported that less than half of breast cancer patients provided with prog-
nostic estimates from Adjuvant! were able to accurately indicate their prognosis after 
the consultation (13, 14). 
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RPM often provide a report or a graphical representation of the probability estimates 
that could facilitate the presentation of this type of information to patients. A small UK 
survey found that 20% of oncologists frequently provide patients with a printout of 
the Adjuvant! report (12). However, since the target audience of RPM are oncologists 
rather than patients, it remains unknown to what extent patients understand the RPM 
reports and whether they benefit from these graphical presentations.
The number of RPM has increased steadily. As we expect their use to become even 
more common, insight into their clinical validity is becoming increasingly relevant. The 
aim of this review is threefold. Firstly, we provide a systematic overview of all published 
RPM that aim to aid adjuvant systemic therapy selection in early-stage breast cancer. 
For the identified RPM we describe a) the prognosticators incorporated, b) reported 
prognostic strengths and weaknesses, and c) presentation of the model estimates. 
Secondly, for the RPM most frequently used in clinical practice we assessed a) the 
characteristics of the validation populations, and b) reported accuracy of the prognostic 
estimates. Thirdly, we discuss the content of the RPM reports, and assess the required 
literacy level to comprehend them.
29







































Aim 1: Systematic overview of RPM
Selection of published RPM and data extraction
Relevant papers in English were identified through searches in PUBMED, EMBASE 
and Web of Science, up to July 2012. We wanted to include all papers describing the 
development of RPM estimating breast cancer prognosis, aiming to aid the selection 
of patients for adjuvant systemic therapy, irrespective of whether they were based on 
clinical prognosticators or bio-molecular features. RPM were excluded if they a) were 
specifically developed for the neo-adjuvant setting, and b) only aimed to determine a 
single clinical or bio-molecular feature, such as tumor grade. Our search strategy con-
sisted of search terms for a) prognostic models (including names of known prognostic 
models), b) breast cancer and c) adjuvant systemic therapy. Web appendix 1 contains 
the terms used in each database. Two appraisers (E.G.E. and A.M.S.) independently 
selected papers that met the inclusion criteria based on titles and abstracts. If there 
was disagreement or doubt about eligibility, the paper was included in the selection for 
which the full-text was independently reviewed by two appraisers (E.G.E. and M.M.G.) 
and inclusion was determined by consensus. For included papers details on the a) 
aim of the model, b) development process, c) characteristics of the development and 
validation population(s) (if applicable), and d) reported clinical validity were retrieved. 
Aim 2: Assessment of clinical validity of frequently used RPM 
We define clinical validity as the accuracy of the RPM’s estimate of overall (OS) or 
recurrence-free (RFS) survival compared to observed OS or RFS (15). When we refer 
to validation studies, we mean studies in which clinical validity of a RPM was assessed 
in a population other than the one it was developed in. Our focus is the accuracy of 
the prognostic estimates and not the accuracy of the RPM predictions of treatment 
response (if that was also an aim of the RPM). 
Selection and data extraction from validation studies
We performed an extensive assessment of the RPM to which (international) clinical 
guidelines refer as an indication of their actual use in clinical practice. Guidelines we 
used were: ESMO (16); NCCN (17); NICE (18, 19); and St. Gallen (20); and the report 
of the consensus meeting on the influence of molecular genotyping (21). We searched 
PUBMED for all validation studies for the selected RPM: the NPI, Adjuvant!, MammaPrint 
and Oncotype Dx and consulted the references of papers retrieved and previously 
published reviews. Two appraisers (E.G.E. and M.M.G.) independently reviewed the 
papers retrieved and extracted details on a) characteristics of the validation popula-
tion(s), including adjuvant treatment allocation and prevalence of recurrence, and b) 
clinical validity in patient subgroups. 
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Aim 3: Assessment of the RPM reports 
Retrieval of RPM report
We sought to retrieve the report generated by each of the RPM identified by searching 
the manufacturer’s website, Google or the link (if provided) to the model itself. If neces-
sary, we contacted the author of the paper. We extracted information on a) the type of 
estimates reported, b) estimates of the uncertainty surrounding the survival estimates 
and c) graphical presentation formats if applicable. Moreover, to ascertain the minimal 
literacy level required to comprehend the RPM reports, two reviewers independently 
classified the use of medical or other technical jargon in the report as low, moderate 
or high. Disagreements in assessment of jargon use were resolved in consensus mee-
tings. Additionally, we calculated a score for six frequently used readability indicators 
to provide an overall indication of the text difficulty with the Readability Test Tool (RDT) 




Aim 1: Systematic overview of RPM
We identified 996 papers, which yielded 20 relevant RPM (Figure 1). Of the 26 devel-
opment papers initially selected we excluded six after reading the full-text because 
the aim of the model described did not meet our inclusion criteria. 
Six of the 20 RPM (7, 8, 23-26) are based solely on classical prognostic factors, while 
the others (9, 10, 27-38) are genetic profiles or based on novel bio-molecular factors 
(Table 1). Three (7, 8, 23) RPM based on clinicopathological features and all 14 
bio-molecular signatures aim to predict relapse-free survival. Seven RPM (9, 26, 29, 30, 
35, 37) are only intended for use in node-negative early stage breast cancer patients. 
Oncotype Dx (9), Mammostrat (34) and Theros BCI (30) are only intended for use in 
estrogen receptor (ER) positive patients. Of the RPM based on clinicopathological 
features, only CancerMath (25) and PREDICT (24, 39) take HER2-status into account 
when calculating prognosis estimates. All development studies identified reported that 
overall the clinical validity of the RPM was good or excellent in their target population 
(Table 1). Some studies did not report any limitations.
Aim 2: Assessment of clinical validity of frequently used RPM 
The RPM currently most often used are: the NPI, Adjuvant!, MammaPrint and Oncotype 
Dx. In total we retrieved 42 validation studies (Figure 1). Two of those were excluded 
as they did not report a model validation. The studies retrieved reported on two types 
of model validations: comparisons of the estimates provided by the RPM of interest 
to 1) the observed survival (N=27) and/or 2) the estimates of other RPM and/or (inter) 
national clinical guidelines (N=13). To assess clinical validity, we restricted our in-depth 
analyses to validation studies that compared estimated to observed survival. Since 
comparisons between RPM and/or (inter) national clinical guidelines are prevalent and 
informative, we also briefly describe the findings of these types of comparisons (not 
incorporated in overview Tables 1-5). 
Overview of studies comparing RPM estimates to observed survival
Table 2 provides an overview of the study design, population characteristics, and 
reported clinical validity for the 27 validation studies retrieved. Barring one case-control 
study (40), all validation studies had a retrospective design. Ten (40-49) of the validation 
studies were independent validation studies. The validation populations were mostly 
hospital-based, but Adjuvant! (50) and Oncotype Dx (51) were also validated in 
population-based cohorts. Also, MammaPrint was only validated on fresh frozen tissue, 
while Oncotype Dx was only validated on fixed paraffin-embedded tissue. Validation 
populations consisted mostly of patients diagnosed in the 1980s and 1990s. Only a 
small proportion of the patients in the validation populations were younger than 40 
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or older than 70 years. All validation studies retrieved, except for Buyse et al. (52), 
used patients who were treated systemically (chemotherapy and/or hormonal therapy) 
according to clinical guidelines applicable at the time the patients were diagnosed. 
Thus these validations are not ‘pure validations’, where RPM estimates are compared 
to observed survival in the absence of treatment or where treatment is allocated based 
on the outcome of the RPM of interest. Table 3 presents an overview of treatment 
allocation and the prevalence of recurrence according to patient classification by 
NPI, MammaPrint and Oncotype Dx. Buyse et al. (52) assessed the clinical validity of 
MammaPrint in an untreated cohort, and reported that 16% of the patients classified 
as low risk and 30% of those classified as high risk developed recurrences. In the 
cohorts of treated patients, Oncotype Dx classified about 30% of patients as high risk, 
whereas MammaPrint classified about 50%-60% as high risk. MammaPrint classified 
73% of the predominantly post-menopausal patients in the validation by Wittner et al. 
(49) as high risk. Oncotype Dx classified a significant proportion of patients as having 
an intermediate risk, but the clinical implications of this category are unclear (53-55). 
Figures 2a and 2b provide an overview of the variance in sensitivity, specificity and 
positive and negative predictive values between validation studies for MammaPrint and 
Oncotype Dx respectively (we do not show these estimates for the NPI, as useable 
data was retrieved for only 2 studies).
NPVPPVSpecificity*Sensitivity*
Buyse  et al
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As shown in Table 4 (also see Figure 3), four (44, 46, 50, 56) of the six validation studies 
found that Adjuvant!’s estimates were less accurate in patients ≤40 years or ≥75 years 
at diagnosis. OS was overestimated by 9% up to 30% for patients ≤40 years and in 
elderly patients (>65 years) by 12% (43, 44, 46). Two studies (44, 50) reported the 
difference between predicted and observed RFS. The largest discrepancies reported 
were a 19% underestimation of RFS for patients 76 years at diagnosis and a 14% 













Albain  et al
Oncotype Dx
PPV= positive predictive value; NPV= Negative predictive value
*Sensitivity and specificity for low risk classification by Oncotype Dx
Page 1
PPV= positive predictive value; NPV= negative pr dictive value
Sensitivity and specificity for low risk classification by Oncotype Dx
Figure 2b Variance in sensitivity, specificity and predictive value between studies for Oncotype Dx
The NPI, Adjuvant!, MammaPrint and Oncotype Dx were developed in European and/
or North American populations. Clinical validity was also assessed in non-western 
populations (Table 2). A validation study (43) in a Malaysian population (N=631) found 
that Adjuvant! was especially overoptimistic in Malay women ≤ 40 years at diagnosis, 
overestimating OS by 20% (43). Oncotype Dx’ performance in Japanese patients was 
assessed in a small case control study, that found that a higher Oncotype Dx’ recur-
rence score (RS) was associated with disease recurrence (N= 40; RS in patients with 
recurrence 40.0 (95%-CI= 21.1-58.9 ); RS in patients without recurrence 17.8 (95%-
CI= 13.8-21.9)) (40). Ishitobi et al. (57) reported that MammaPrint classified 80% of 
42
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patients as high risk, a greater proportion of high risk cases than reported in European 
validation populations (see Table 3). In the latter study only 18% of the high risk cases 
had a recurrence, however 70% of these patient received hormonal therapy and 33% 
received chemotherapy. It is thus unclear whether the high percentage of high risk 
classification is accurate and that the relatively low recurrence rate is (partly) explained 
by treatment, or that the current cut-offs for the MammaPrint risk categories are not 
valid for the Japanese population (57). 
43
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3 Overall survival predicted by Adjuvant! versus observed
Comparisons between RPM or RPM compared to clinical guidelines
Thirteen studies compared MammaPrint to NPI and Adjuvant!, and/or to existing inter-
national guidelines, such as the St. Gallen consensus guidelines and the NIH guidelines 
(58-61). MammaPrint was reported to provide additional prognostic information espe-
cially in ER-positive lymph node negative breast cancer patients deemed to have a low 
clinical risk by Adjuvant! and/or NPI (58). A small-scale study in a German population 
(>60 years) found a discordance rate between MammaPrint and Adjuvant! of 48% 
(n=60) if these RPM were used separately (60). Instead of using them separately, if 
MammaPrint was used in combination with the clinicopathological factors from 
Adjuvant!, the recommendation differed in 11 of the 60 (18%) patients in the study. 
This would have led to six additional patients being advised adjuvant chemotherapy 
and five patients being spared systemic treatment (60). Gevensleben et al. (59) found a 
similar discordance, namely of 41%, between MammaPrint and Adjuvant! in a German 
population (N=140) (59). They reported that combining the MammaPrint results with 
clinicopathological factors would have resulted in altered treatment recommendations in 
41% of the patients (57 of 140). Of these patients 45 were classified as having a ‘high’ 
recurrence risk by Adjuvant!, while MammaPrint classified them as low risk; hence 41% 
of patients were potentially over- or undertreated (59). A small study in Korean patients 
(N=36) comparing MammaPrint classification to other clinicopathological classifications, 
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reported that MammaPrint classified almost 90% of patients as high risk, which is a 
significantly larger proportion than in European patient cohorts (61).
Aim 3: Assessment of the RPM reports
We retrieved the reports for 12 of the 20 RPM identified (for a description see Table 
5). They generally consisted of the survival probability described for one or more time 
periods, a risk category and/or a form of graphical representation of the risk estimates. 
MammaPrint (10), Oncotype Dx (9) and Theros BCI (30) reports provide the confidence 
interval around the survival probability. 
Ten of the 12 RPM for which we retrieved a report provide a graphical representation 
of probabilities. CancerMath (25) provides users with the option to choose in which 
graphical format they want the probabilities presented. Six (9, 10, 25, 30, 34, 36) models 
report survival curves and three molecular profiles provide technical graphs, e.g. heat 
maps1 (10, 36) and normalization curves2 (33). 
Ten (8-10, 23-25, 30, 32, 34, 36) reports were intended for both oncologists and patients. 
Not all of these explicitly stated that they were also intended for patients. Yet, on the 
RPM developers’ websites patients are provided tools to help them read the RPM report. 
On the Oncotype Dx website for example, patients can watch a video that explains 
what the information contained in the report means. In the disclaimer all developers 
urge patients to consult their oncologist to discuss the content of the RPM report.
To be able to read and comprehend any of the RPM reports , literacy at least at high 
school level is required (Web appendix 2). All the reports of the bio-molecular profiles 
provide information on the technical aspects of the assay, its development, validation 
and literature references. Especially these sections have a high use of medical jargon 
and technical biomedical details, which was rarely explained in lay terms. For example: 
“The test is performed using a microarray-based gene expression profile. An unbiased, 
supervised analysis of the entire human genome, ~25,000 genes, followed by a leave-
one-out cross-validation procedure …”. 
1 A heat map is a graphical representation of data where the individual values contained in a data matrix are represented as 
colors.
2 Normalization means to adjust microarray data for effects which arise from variation in the technology rather than from 




The aim of this review was to identify available RPM that intend to aid adjuvant sys-
temic treatment selection in breast cancer, provide an overview of the reported clinical 
validity of their prognostic estimates, and assess how comprehensible the presentation 
of estimates is. We identified 20 RPM that aim to help oncologists answer the same 
question, namely: “Will this specific patient potentially benefit from systemic treatment 
(and if so how large is the survival gain)?”. The main difference between RPM lies in the 
elements they utilize to generate their estimates and in how they present their results. 
None of the RPM based on genetic profiles incorporates clinical factors, while there is 
some evidence suggesting that traditional clinicopathological variables, namely tumor 
size, nodal status, histologic grade, and, to a lesser extent, age at diagnosis retain 
independent prognostic value (54, 63). An effort to create a new model that combines 
the Oncotype Dx recurrence score with clinicopathological factors was reported. The 
resulting Recurrence Score Pathology-Clinical score (RSPC-score) was found to refine 
the assessment of distant recurrence risk, and, most important, reduce the number 
of patients classified in the intermediate risk category (64). However, the RSPC-score 
cannot currently be calculated for an individual patient because the model has not yet 
been fully specified and, most important, has not yet been externally validated in fully 
independent datasets (65). 
The authors of the validation studies retrieved reported that their RPM showed good to 
excellent clinical validity. However, these validation studies were mostly retrospective 
validations in cohorts of patients treated according to clinical guidelines at the time 
they were diagnosed. We found significant variations in the prevalence of recurrences 
and treatment allocation between studies. Unfortunately, a number of studies used 
(a subset of) the same population for multiple validations (e.g. (66-69)). They did not 
provide sufficient data for us to be able to appropriately quantify the data on patient 
characteristics, which would have further facilitated comparisons. Also, we provide a 
graphic overview of the variation in RPM performance statistics (i.e. sensitivity, spec-
ificity, and predictive value). However, the influence of treatment on observed survival 
could not be taken into account, as the validation studies generally did not provide 
information on the distribution of recurrences within high and low risk patients stratified 
by treatment allocation. Thus, the RPM performance statistics should be interpreted 
cautiously. We realize that withholding or allocating systemic therapy based on the pre-
dictions of insufficiently validated RPM is not ethical, and it is difficult to find untreated 
patients nowadays. Therefore, until prospective trials where treatment is allocated 
according to RPM predictions become available, this is the best evidence we have, in 
spite of its limitations. 
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Two subgroups, for which the accuracy of the prognostic estimates of RPM based 
on clinical prognosticators are suboptimal, are women ≤40 or ≥65 years at diagnosis. 
Further, the clinical validity of Adjuvant!, and MammaPrint’s prognostic estimates in 
Asian patients was inferior. Adjuvant! overestimated OS by almost 20%. MammaPrint 
classified ≥80% of patients as high risk, where in the European validation populations 
<60% of patients was classified as high risk. The observed difference in prevalence 
of high risk classification by MammaPrint could point to a gene disparity between 
Asians and Europe ans (57, 61). Also, the seemingly low recurrence rate in the patients 
classified as high risk could be (partly) explained by systemic treatment. Large-scale 
studies are required to assess the validity of the prognosticators used in these RPM 
in Asian breast cancer patients (57, 61). 
Overall, we found that the assumption that the currently available RPM’s are clinically 
valid does not hold in certain patient subgroups, and that most RPM seem to have 
similar shortcomings. There are ongoing international efforts to assess the accuracy 
of available RPM based on clinical or molecular profiling, such as the 
Sage Bionetworks-DREAM Breast Cancer Prognosis Challenge.3 These initiatives can 
help improve existing RPM or lead to the development of more accurate models, using 
the wealth of data already available. 
Standardization of the terminology used in this field would also be beneficial. Varying 
study designs are used and the terms used as keywords vary greatly. Therefore, we 
might have missed some relevant papers, even though we also attempted to manually 
track references. 
The underlying assumption of RPM is that accurately estimated probabilities improve 
decision-making and consequently patient outcomes. The justification of this assump-
tion can only be assessed in impact studies, which quantify the effect of using versus not 
using RPM. Hornberger et al. (70) reviewed studies on the effect of the use of Adjuvant!, 
MammaPrint and Oncotype Dx on clinical recommendations and decisions. Overall, 
use of RPM led to a change in treatment recommendation ranging from 1% - 74%. 
However, there was considerable heterogeneity between studies. 
RPM reports might seem straightforward as the essence of all the information contained 
in these reports is often summarized with a risk category, which is clearly provided. 
However, to truly understand what it means to be in the ‘low risk’ category, and to 
3 Sage Bionetworks-DREAM Breast Cancer Prognosis Challenge (http://www.the-dream-project.org/challenges/sage-bionet-
works-dream-breast-cancer-prognosis-challenge): the goal of the breast cancer prognosis Challenge is to assess the accuracy of 
computational models designed to predict breast cancer survival, based on clinical information about the patient’s tumor as 
well as genome-wide molecular profiling data including gene expression and copy number profiles.
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be able to make a deliberate choice to undergo or forego treatment (partly) based on 
these results, a patient has to have insights in how large the mortality or recurrence 
risk associated with this category is. In their current format the content of the 12 RPM 
reports we assessed are too difficult to understand for most patients and it begs the 
question whether the addition of technical graphs (e.g. heatmaps) provides support 
to patients or even to oncologists. It is not advisable to provide patients with such a 
report without adequate explanation by a trained health professional. If developers 
wish for their model to be implemented in the clinical encounter and/or for patients 
to receive a report, they might consider creating a report specifically intended for 
patients containing only relevant information in lay terms. Developers should consider 
collaborating with cognitive and social psychologists to design risk communication 
and presentation strategies (71).
An advantage of RPM is that the risks are tailored to individual patient and tumor 
characteristics. People provided with individualized risks have been shown to become 
more motivated to engage in the communication process, and to have more accurate 
risk perception and better knowledge (72). RPM thus have the potential to empower 
patients by allowing them to become better informed participants in the decision-making 
process. However, focusing on the recurrence probabilities with and without therapy 
can also sidetrack patients from paying attention to side effects, which are part of the 
tradeoff involved in choosing therapy. 
Observational studies of the communication process between oncologists and patients 
involving RPM are lacking, as are studies investigating patients’ understanding of the 
uncertainties involved. In spite of the lack of research, some lessons can already be 
learned. Oncologists should be aware that most, but not all patients wish to receive 
prognostic information and that information preferences are difficult to predict (73, 74). 
It is therefore recommended to ask patients whether they wish to know the specific 
prognosis from RPM. If a patient wishes to hear the probabilities, communication of 
these probabilities can be optimized by using pictographs (75, 76). 
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Web appendix 1 Search strategy per database
Source Search terms
PUBMED (“Individualized Medicine”[Majr] OR “Personalized medicine”[tiab]  OR 
“Decision Support Techniques”[Majr:NoExp] OR “Decision Making, Computer-
Assisted”[Majr:NoExp] OR “prognostic model”[tiab] OR “prognostic software 
model”[tiab]  OR “Prognostication”[tiab] OR “decision aid”[tiab] OR “individualized risk 
information”[tiab] OR “patient-specific decision aid”[tiab] OR “decision aids”[tiab] OR 
((“therapeutic efficacy”[tiab] OR “therapeutic resistance”[tiab] OR “prognosis”[tiab] 
OR “Prognostic”[tiab] OR “Predictive”[tiab] OR “Predictor”[tiab] OR “Predictors”[tiab] 
OR “Prediction”[tiab] OR “Predictions”[tiab] OR “Predict”[tiab] OR “Predicts”[tiab] OR 
“Decision”[tiab] OR “Decide”[tiab] OR “Decides”[tiab]) AND (“tool”[tiab] OR “tools”[tiab] 
OR “molecular”[tiab])) OR “OncotypeDX”[tiab] OR “oncotype dx”[tiab] OR “21-gene 
assay”[tiab] OR “70-gene signature”[tiab] OR “mammaprint”[tiab] OR “Predict”[tiab] 
OR “nomogram”[tiab] OR “PAM50”[tiab] OR “MapQuant Dx”[tiab] OR “Theros Breast 
cancer Index SM”[tiab] OR “BLN assay”[tiab] OR “Arup breast bioclassifier”[tiab] OR 
“Celera Metastatic Score”[tiab] OR “Exagen Breast cancer tm”[tiab] OR “Invasive 
gene signature”[tiab] OR “Mammostrat”[tiab] OR “Epi/Doc”[tiab] OR “Van Nuys 
prognostic index”[tiab] OR “VNPI”[tiab] OR “Genomic grade index”[tiab] OR “GGI”[tiab]) 
AND (“breast neoplasms”[Majr] OR ((“breast”[tiab]) AND (“neoplasms”[tiab] OR 
“neoplasm”[tiab] OR “cancer”[tiab] OR “tumor”[tiab]OR “tumour”[tiab] OR “tumors”[tiab] 
OR “tumours”[tiab] OR “malignancy”[tiab] OR  “malignancies”[tiab]))) AND “adjuvant 
therapy”[tiab]
EMBASE (*”personalized medicine”/OR “Individualized medicine”.ti,ab. OR “Personalized 
medicine”.ti,ab.  OR *”decision support system”/ OR “Decision Support Techniques”.
ti,ab. OR “prognostic model”.ti,ab. OR “prognostic software model”.ti,ab.  OR 
“Prognostication”.ti,ab. OR “decision aid”.ti,ab. OR “individualized risk information”.
ti,ab. OR “patient-specific decision aid”.ti,ab. OR “decision aids”.ti,ab. OR ((“therapeutic 
efficacy”.ti,ab. OR “therapeutic resistance”.ti,ab. OR “prognosis”.ti,ab. OR “Prognostic”.
ti,ab. OR “Predictive”.ti,ab. OR “Predictor”.ti,ab. OR “Predictors”.ti,ab. OR “Prediction”.
ti,ab. OR “Predictions”.ti,ab. OR “Predict”.ti,ab. OR “Predicts”.ti,ab. OR “Decision”.
ti,ab. OR “Decide”.ti,ab. OR “Decides”.ti,ab.) AND (“tool”.ti,ab. OR “tools”.ti,ab. OR 
“molecular”.ti,ab.)) OR “OncotypeDX”.ti,ab. OR “oncotype dx”.ti,ab. OR “21-gene 
assay”.ti,ab. OR “70-gene signature”.ti,ab. OR “mammaprint”.ti,ab. OR “Predict”.ti,ab. 
OR “nomogram”.ti,ab. OR “PAM50”.ti,ab. OR “MapQuant Dx”.ti,ab. OR “Theros Breast 
cancer Index SM”.ti,ab. OR “BLN assay”.ti,ab. OR “Arup breast bioclassifier”.ti,ab. OR 
“Celera Metastatic Score”.ti,ab. OR “Exagen Breast cancer tm”.ti,ab. OR “Invasive gene 
signature”.ti,ab. OR “Mammostrat”.ti,ab. OR “Epi/Doc”.ti,ab. OR “Van Nuys prognostic 
index”.ti,ab. OR “VNPI”.ti,ab. OR “Genomic grade index”.ti,ab. OR “GGI”.ti,ab.) AND 
(exp *”breast tumor”/OR ((“breast”.ti,ab.) AND (“neoplasms”.ti,ab. OR “neoplasm”.ti,ab. 
OR “cancer”.ti,ab. OR “tumor”.ti,ab.OR “tumour”.ti,ab. OR “tumors”.ti,ab. OR “tumours”.
ti,ab. OR “malignancy”.ti,ab. OR  “malignancies”.ti,ab.))) AND “adjuvant therapy”.ti,ab.
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TS=((“personalized medicine” OR “Individualized medicine” OR “Personalized medicine”  
OR “decision support system” OR “Decision Support Techniques” OR “prognostic 
model” OR “prognostic software model”  OR “Prognostication” OR “decision aid” OR 
“individualized risk information” OR “patient-specific decision aid” OR “decision aids” 
OR ((“therapeutic efficacy” OR “therapeutic resistance” OR “prognosis” OR “Prognostic” 
OR “Predictive” OR “Predictor” OR “Predictors” OR “Prediction” OR “Predictions” OR 
“Predict” OR “Predicts” OR “Decision” OR “Decide” OR “Decides”) AND (“tool” OR 
“tools” OR “molecular”)) OR “OncotypeDX” OR “oncotype dx” OR “21-gene assay” OR 
“70-gene signature” OR “mammaprint” OR “Predict” OR “nomogram” OR “PAM50” OR 
“MapQuant Dx” OR “Theros Breast cancer Index SM” OR “BLN assay” OR “Arup breast 
bioclassifier” OR “Celera Metastatic Score” OR “Exagen Breast cancer tm” OR “Invasive 
gene signature” OR “Mammostrat” OR “EpiDoc” OR “Van Nuys prognostic index” OR 
“VNPI” OR “Genomic grade index” OR “GGI”) AND (“breast tumor” OR ((“breast”) AND 
(“neoplasms” OR “neoplasm” OR “cancer” OR “tumor” OR “tumour” OR “tumors” OR 
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Online prognostication tools such as PREDICT and Adjuvant! are increasingly used in 
clinical practice by oncologists to inform patients and guide treatment decisions about 
adjuvant systemic therapy. However, their validity for young breast cancer patients is 
debated.
Objective
To assess first, the prognostic accuracy of PREDICT’s and Adjuvant! 10-year all-cause 
mortality, and second, its breast cancer-specific mortality estimates, in a large cohort 




General and cancer hospitals. 
Participants
A consecutive series of 2,710 patients without a prior history of cancer, diagnosed 
between 1990-2000 with unilateral stage I-III breast cancer aged <50 years.
Main outcome measures
Calibration and discriminatory accuracy, measured with C-statistics, of estimated 
10-year all-cause and breast cancer-specific mortality.
Results
Overall, PREDICT’s calibration for all-cause mortality was good (predicted versus 
observed) meandifference: -1.1% (95%CI: -3.2% to 0.9%) (P= 0.28)). PREDICT tended 
to underestimate all-cause mortality in good prognosis subgroups (range meandifference: 
-2.9% to -4.8%), overestimated all-cause mortality in poor prognosis subgroups (range 
meandifference: 2.6% to 9.4%), and underestimated survival in patients < 35 by -6.6%. 
Overall, PREDICT overestimated breast cancer-specific mortality by 3.2% (95%CI: 0.8% 
to 5.6%) (P= 0.007)); and also overestimated it seemingly indiscriminately in numerous 
subgroups (range meandifference: 3.2% to 14.1%). Calibration was poor in the cohort of 
patients with the lowest and those with the highest mortality probabilities. Discriminatory 
accuracy was moderate-to-good for all-cause mortality in PREDICT (0.71 (95%CI: 0.68 
to 0.73)) and the results were similar for breast cancer-specific mortality. Adjuvant!’s 
calibration and discriminatory accuracy for both all-cause and breast cancer-specific 
mortality were in line with PREDICT’s findings.
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Conclusions
Although imprecise at the extremes, PREDICT’s estimates of 10-year all-cause mor-
tality seem reasonably sound for breast cancer patients <50 years; Adjuvant! findings 
were similar. Prognostication tools should be used with caution due to the intrinsic 
variability of their estimates, and because the threshold to discuss adjuvant systemic 
treatment is low. Thus, seemingly insignificant mortality over- or underestimations of 




In 2015, a total of 14,449 women were diagnosed with invasive breast cancer in The 
Netherlands, of which 20% were younger than 50 years at diagnosis (1). Available 
evidence strongly suggests that breast tumors are more aggressive in young (especially 
those <40 years) than in post-menopausal women (2-5). This is partly due to the 
over-representation of aggressive biological features (e.g., estrogen receptor (ER) 
negative, grade 3 in young patients (2-5). Yet, even after controlling for known biological 
factors indicative of tumor aggressiveness, young age in itself remains an independent 
predictor of poor cancer-specific survival, and strongly correlates with the risks of 
local recurrence and contralateral breast cancer (4,6,7). Therefore, pending better 
molecular characterization of tumors in young women, young age itself and classical 
tumor characteristics, remain important prognosticators. 
Accurate quantification of long-term disease outcome and potential adjuvant systemic 
treatment benefit could help oncologists and patients in tailoring treatment decisions, 
also considering the potential side-effects of and possibly reduced quality of life during/
after systemic therapy. Furthermore, adequately informing patients about such prob-
abilities as well as the side-effects of treatment could empower them to choose the 
treatment option that best fits their preferences. Adjuvant! (8,9) and PREDICT (10,11) 
are online prognostication tools, that provide personalized 10-year all-cause and/or 
breast cancer-specific mortality estimates for the adjuvant treatment setting. Both 
tools base their predictions on patient (e.g., age) and tumor (e.g., size, nodal status, 
ER-status, and grade) characteristics.
Clinicians reported common use of Adjuvant! during consultations with patients (12,13); 
PREDICT’s average user access is 10,000 per month as per February 2016, and currently 
probably higher as Adjuvant! has been offline for some time. Further, the Dutch national 
breast cancer guideline based its treatment recommendations on Adjuvant!’s estimates 
and leading British and American guidelines endorsed Adjuvant!’s use to quantify prog-
nosis (14-16). Adjuvant! and PREDICT have mainly been externally validated in North 
American and European populations, but also in Asian populations (17-19). Generally, 
their estimates seem accurate for Western patients diagnosed between 50-65 years 
(17-19). A recent analysis within the POSH study of about 600 women diagnosed 
<40 years with ≥10-year follow-up has shown that overall PREDICT overestimated all 
cause 10-year mortality by 8%, and that in women aged 31- 35 years at diagnosis it 
underestimated all-cause mortality by 5%18. Overall, the evidence on Adjuvant! and 
PREDICT’s performance in young patients is not strong, as the number of young patients 
(with sufficient follow-up) included in the validation studies was small; but it suggests 
that both tools significantly underestimate mortality in patients diagnosed <50 years, 
with the largest discrepancies observed in patients diagnosed ≤35 years (17-21). These 
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findings are concerning; especially as Adjuvant! already adjusts its mortality estimates 
for ER-positive breast cancer patients ≤35 years by a factor of 1.5 (9). In view of the 
limited evidence on their performance in patients <50 years, and the impact that these 
tools can have on oncologists’ and patients’ decision-making, our primary aim was to 
assess the prognostic accuracy of PREDICT and Adjuvant!’s 10-year all-cause mortality 
estimates in a large cohort of young breast cancer patients, and secondarily to assess 









































































































We used data from a hospital-based cohort of consecutive females diagnosed <50 years 
of age with invasive breast cancer, identified through medical registries of participating 
hospitals or the Netherlands Cancer Registry. We selected all patients diagnosed 
between 1990-2000 with unilateral stage I-III breast cancer without a previous cancer 
diagnosis (except non melanoma skin cancer), for whom complete data on tumor 
size, nodal status, receipt of adjuvant systemic therapy, and follow-up was available 
(Appendix Figure 1; Appendix A).
Procedures 
Data collection has been described previously (22), in short: information about diag-
nosis and treatment, e.g., histological tumor grade, stage, adjuvant chemotherapy 
and endocrine systemic treatment (before summer 2005 no adjuvant trastuzumab 
was administered), estrogen (ER) and progesterone receptor status (PR), Her2-neu, 
and angiolymphatic invasion were gathered from original pathology reports and/or 
determined using reviews of whole slides and staining of tumors in tissue micro arrays. 
Follow-up data, such as date of last follow-up, vital status, and cause of death were 
obtained from the medical registries from the participating hospitals and/or linkage with 
the Dutch municipal registry through the Netherlands Cancer Registry (last follow-up 
update in 2013). Patients with unknown vital status (N=16) and follow-up time ≤10 
years (N=21) were excluded (Appendix Figure 1; Appendix A).
Predicted all-cause and breast cancer-specific mortality were calculated for each 
patient individually by entering prognosticators in PREDICT (version-1.3) and Adjuvant! 
(version-8.0) batch processors, with blinding to patient outcomes. After the calculation 
of the mortality estimates, we received a revision of the systemic therapy data which 
showed that for N=219 patients whether they had received systemic therapy or not, 
and to a lesser extent which type of systemic therapy they had received had been 
misclassified. We recalculated PREDICT’s estimates, but not for Adjuvant!, since the 
latter tool was no longer available. In essence, the direction of the difference did not 
change, nor did our conclusions. 
Adjuvant! requires data on comorbidity, which was not available, therefore we set comor-
bidity to minor problems (default setting). Patients <50 years at diagnosis are unlikely 
to have significant comorbidities, consequently the setting used will give average out-
comes reflecting the general health of our sample. KI67-status was set to unknown, 
and mode of disease detection was set to symptomatic, in the PREDICT analyses. 
Also, we used the Prognostic Factor Impact Calculator incorporated in Adjuvant! to take 
Her2-status into account in the calculation of the all-cause and breast cancer-specific 
70
Chapter 3 
mortality probabilities. We assumed a relative risk for high vs. low risk group of 1.5 
and that on average 20% of patients had Her2-positive disease (23-25). For patients 
without Her2 overexpression we used the low risk probability estimates, for those 
with Her2 overexpression we used the high risk estimates and for those with unknown 
Her2-status we used the unadjusted estimates automatically generated by Adjuvant!. 
Statistical analysis
PREDICT’s batch processor cannot calculate prognostic estimates if ER-status is 
unknown, thus patients with unknown ER-status were excluded from all analyses of 
PREDICT’s estimates, leaving 2,073 and 1,076 patients in the all-cause and breast 
cancer-specific mortality analyses respectively. In the all-cause mortality analyses of 
Adjuvant! all 2,710 patients that met the inclusion criteria were included. In the breast 
cancer-specific mortality analyses, hospitals for which cause of death data was missing 
were excluded leaving 1,535 patients in the analyses.
Deciles with <100 cases were merged. 
Error bars are standard errors (SE).
Figure 2 Observed vs. PREDICT estimates of 10-year all-cause and breast cancer specific mortality
We compared the average observed and the average predicted 10-year all-cause and 
breast cancer-specific mortality using one-sample T-tests for proportions. We used a 
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1,000 resamples bootstrap for calculation of the 95%-confidence interval, and bootstrap 
p-values were directly calculated from the bootstrap sampling using the percentiles and 
simple sampling method. The prognostication tool’s average predicted mortality was 
the fixed value (i.e., assumed to be true based on the model used), and the average 
observed mortality the comparison variable. We compared the concordance between 
the observed and predicted estimates for the whole population and for subgroups of 
relevant prognostic characteristics, which were determined a priori.
Additionally, we evaluated model calibration by plotting averages of observed versus 
predicted mortality, grouped by deciles of predicted outcomes. If there were <100 
patients in a decile, it was merged with adjacent decile(s) to ensure sufficiently large 
numbers in all deciles. The slope of the fitted line was compared with the slope of the 
line indicating a perfect relationship (y=x). We evaluated discriminatory accuracy using 
receiver-operator curves (ROC) and corresponding c-indices derived by calculating the 




Patients in the all-cause mortality analyses had a mean age of 42 years (range: 22-50) 
and an average of 13.5 years follow-up (Appendix Table 1). Overall, 61% of patients 
had stage II disease (Appendix Table 2), and on average patients ≤40 years more often 
had ER-negative, grade 3 and/or node-positive disease compared to those who were 
41-50 years at diagnosis.
Calibration of 10-year all-cause mortality for the whole population
Calibration was assessed using the mean difference between predicted an observed 
mortality. PREDICT tended to underestimate all-cause mortality, but the overall dif-
ference was not statistically significant (-1.1, 95%-CI: -3.2 to 0.9; P=0.28) (Figure 1; 
Appendix Table 3). Adjuvant! also underestimated all-cause mortality (-2%, 95%-CI: 
-3.7 to -0.3; P=0.02) (Appendix Table 4). The PREDICT batch processor did not allow for 
inclusion of patients with unknown ER-status, therefore these patients were excluded 
(N= 637 (23.5%). However, Adjuvant!’s expected mortality did not change when we 
excluded the patients with unknown ER-status (27.0% versus 26.7%). 
Calibration of 10-year all-cause mortality for key prognostic subgroups
PREDICT underestimated all-cause mortality in the two youngest age groups by -6.6% 
to -4.9 (Figure 1; Appendix Table 3). It also underestimated mortality in subgroups of 
patients with good prognosis, e.g., stage I, T1, and N0 disease, the mean range of 
difference was between -2.9% to -4.8%. PREDICT tended to overestimate mortality 
for poor prognosis subgroups (e.g., N1, stage III, T3) by 2.6% to 9.4%. PREDICT also 
overestimated mortality in the Her2-negative subgroup by 2.2%. Adjuvant!’s perfor-
mance was comparable to PREDICT’s (Appendix Figure 2; Appendix Table 4). Neither 
PREDICT nor Adjuvant! take angiolymphatic invasion into account, but we did evalu-
ated the prognosis estimates for subgroups in our dataset. Both tools underestimated 
mortality in patients with extensive angiolymphatic invasion (range mean difference: 
-4.0% to -9.3%) (Appendix Tables 3-4).
Calibration of 10-years breast cancer-specific mortality estimates
PREDICT overestimated breast cancer-specific mortality by 3.2% (95%-CI: 0.8 to 
5.6; P=0.007) (Figure 1; Appendix Table 3). Adjuvant!’s estimates did not significantly 
differ from observed breast cancer-specific mortality (P=0.23) (Appendix Figure 3; 
Appendix Table 4). However, both PREDICT and Adjuvant! seemed to indiscriminately 
overestimate rates across subgroups (range mean difference: 3.0% to 14.1%) (Figure 
1; Appendix Figure 3; Appendix Table 3-4). 
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The calibration curves for PREDICT and Adjuvant! were similar, and showed that 
overall both tools’ predictions of all-cause mortality were accurate for patients with 
20% to 40% mortality probability (Figure 2; Appendix Figure 4). However, the fit was 
inferior in the cohort of patients with the best (<20% mortality probability) and poorest 
(>40% mortality probability) prognosis (Figure 2; Appendix Figure 4). We found a similar 
pattern for breast cancer-specific mortality probability estimates for both tools (Figure 
2; Appendix Figure 4). 
Discriminatory accuracy
PREDICT’s discriminatory accuracy for all-cause (C-statistic: 0.71) and breast cancer-
specific mortality (C-statistic: 0.74) was moderate in the whole population (Figure 
3: panel-A, panel-D). To assess the discriminatory accuracy in the absence of a 
treatment effect, we ran these analyses in untreated patients. Patients with relatively 
good prognosis were overrepresented in this subgroup; there were more patients with 
ER-positive (72%), grade 1 (22%), T1 tumors (62%), N0 status (85%) and stage I (58%) 
disease (compared to whole cohort: see Appendix-Table 2). The discriminatory accuracy 
in the subgroup of untreated patients was moderate (Figure 3: panel-B, panel-E). 
Adjuvant!’s discriminatory accuracy is in line with PREDICT in the whole population 
and in the cohort of untreated patients (Appendix Figure 5). 
In our analyses we accounted for Her2-status, which is not automatically done by 
Adjuvant!. To gauge Adjuvant!’s discriminatory accuracy in a subgroup where we did 
not use this adjustment, we ran these analyses in patients with unknown Her2-status. 
Adjuvant! and PREDICT discriminatory accuracy for all-cause and breast cancer-
specific mortality in this subgroup was also moderate (Figure 3: panel-C, panel-F; 
Appendix Figure 5).
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Discussion
The prognostic accuracy of PREDICT and Adjuvant!’s 10-year all-cause and breast 
cancer-specific mortality estimates were evaluated in a large cohort of Dutch patients 
diagnosed <50 years of age between 1990 and 2000. We mainly focus on PREDICT’s 
results as Adjuvant! has been offline for some time, therefore we were unable to update 
it estimates after receiving new data about adjuvant systemic therapy. However, the 
updated data about adjuvant systemic therapy did not lead to differences in the direction 
of the under- or overestimation by PREDICT, therefore, we used the Adjuvant! results 
to substantiate our findings in PREDICT. Overall, PREDICT tended to underestimate 
all-cause mortality, but the difference was not statistically significant. It did significantly 
underestimated all-cause mortality for patients ≤40 years by up to -6.6%. Further, 
PREDICT underestimated all-cause mortality for patients with good prognosis, and 
overestimated it for those with poor prognostic characteristics. Adjuvant!’s calibration 
and discriminatory accuracy in our population was in line with PREDICT’s. Although the 
absolute differences observed were small, they might nonetheless be clinically relevant. 
Given that the minimum treatment benefit generally required to be eligible for adjuvant 
systemic treatment is only 3-5%, an absolute overestimation of treatment benefit of 
2% may already affect treatment decisions, and reflects a relative overestimation of 
almost 30%. 
Many young patients (especially those ≤35 years) with favorable prognostic characteris-
tics (e.g., N0 or T1) had a high tumor grade. This could partly explain PREDICT’s (and 
Adjuvant!’s) underestimation of all-cause mortality in the good prognosis subgroups. 
Also, it has been described that tumors in young patients have a greater tendency to 
metastasize, even in case of favorable prognostic characteristics (4). Given the high 
probability of poor outcomes in patients ≤40 years, it has been argued that most or all 
are candidates for adjuvant chemotherapy, solely based on age at diagnosis (4). Indeed, 
treating all patients diagnosed ≤40 years with adjuvant chemotherapy seems to be 
the tendency in clinical practice, which inevitably means that a substantial proportion 
of patients only experience side-effects and no treatment benefit. Current guidelines 
(14-16) stipulate that independent of intrinsic tumor subtype, all breast cancer patients 
≤35 years with tumors >1cm should receive chemotherapy, and for those who are 
Her2neu-positive (irrespective of age) chemotherapy in combination with trastuzumab 
is also indicated in case of tumors 5-10 mm (T1b). The first international consensus 
guidelines for the treatment of breast cancer in patients ≤40 years, however, strongly 
advocated that age should not be the sole reason to prescribe more aggressive treat-
ment and that tumor biology should be the overriding factor (26). This underscores the 
importance of well-validated tools including all relevant tumor characteristics.
Contrary to our findings that both prognostication tools tended to overestimate all-cause 
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mortality in subgroups with poor prognosis, we found that both tools underestimate 
all-cause mortality especially for patients with extensive angiolymphatic invasion by 
as much as 9.3%. Currently, neither tool takes angiolymphatic invasion into account. 
This is perhaps understandable as angiolymphatic invasion is one of the features that 
pathologists have difficulty scoring in a reproducible manner, which has somewhat 
limited its usefulness when assessing prognosis. However, in view of our findings, it 
might be relevant to investigate whether this factor adds prognostic information. 
Further, PREDICT (and Adjuvant!) tended to underestimate the impact of endocrine 
therapy on survival. As relatively few young patients have ER-positive breast cancer, 
and before 1995 endocrine therapy was not administered to premenopausal patients, 
they are probably underrepresented in the trials on which the treatment effect estimates 
are based. However, nowadays substantially more young patients are treated with 
adjuvant systemic therapy (Appendix Figure 6), including endocrine therapy in case 
of hormone-positive disease, as there is evidence that endocrine therapy is equally 
effective in young/premenopausal and older/postmenopausal patients (27). Our findings 
highlight that these tools need to be updated from time to time, as is currently the case 
for Adjuvant!.
In this young age group, all-cause mortality is likely a close representation of breast 
cancer-specific mortality. Based on our smaller dataset with known cause of death, 
PREDICT significantly overestimated breast cancer-specific mortality, and it (like 
Adjuvant!) seemed to generally indiscriminately overestimate breast cancer-specific 
mortality across subgroups. For a large proportion of our population, data on cause 
of death was not available, limiting the number of patients available for the breast 
cancer-specific mortality analyses and leading to wide confidence intervals in many 
subgroup analyses. Also, where cause of death was known, for 37% of patients in 
our sample it was classified as not breast cancer-related. Considering that these were 
young women, it seems unlikely that such a large proportion of patients would have 
pre-existing comorbid conditions, i.e., competing causes of death. It seems more 
likely that cause of death was not missing at random, and/or at least for a proportion 
of these breast cancer patients and/or the late effects of treatment were the true 
underlying cause of death. Indeed, bias through misclassification of cause of death 
is a well-known problem when assessing cancer-specific mortality (28-30). Moreover, 
differences may exist between health care provided in the Netherlands versus the 
United States and United Kingdom. Therefore, our cancer-specific mortality findings 
should be interpreted cautiously.
A clear strength of our study is our large cohort with complete data about tumor size, 
nodal status and receipt of adjuvant therapy. However, a weakness is that mode of 
disease detection (PREDICT) was missing (but population-based screening starts at 50 
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years), and that Her2neu and KI67-status were not routinely determined at diagnosis, 
and Her2-status was only assessed by immunohistochemistry. Also, we excluded 
patients diagnosed prior to 1990, which reduced our sample size considerably. We 
opted to exclude these patients from our analyses as patients diagnosed during this 
time period had significantly poorer survival compared to those diagnosed between 
1990-2000. Therefore, the findings in this subgroup would not be comparable to those 
of currently diagnosed/treated patients. Further, we cannot disentangle the effect of 
adjuvant systemic treatments on outcome, as treatment decisions were not or not 
always based on PREDICT (or Adjuvant!) estimates, but on local treatment guidelines 
and patient preferences. Yet, since half of our population did not receive adjuvant 
systemic treatment, they can be viewed as a proxy for a validation unbiased by treatment 
effect. In this subgroup PREDICT (like Adjuvant!) performed well with regard to all-cause 
mortality. Additionally, some of the differences observed between the tools might be 
due to differences in exposure to risk factors and/or factors associated with poor 
survival between the populations in which they were developed (31-33), i.e., British for 
PREDICT and American for Adjuvant!. Finally, in order to allow for sufficient follow-up 
time we used a cohort of patients diagnosed up to 2000 in which absolute survival 
might not completely reflect that of recently diagnosed patients (Appendix Figure 7). 
PREDICT’s all-cause mortality estimates seem reasonably sound for young breast 
cancer patients, but further adjustments are especially needed for patients ≤40 years 
and for those in the best and poorest prognosis subgroups. Our data underscores that 
it is important to remain aware of the fact that these tools provide average estimates 
which in certain patients and patient groups might not be accurate, also in view of the 
variability of the disease. These estimates, therefore, are intended to supplement, and 
not to replace clinical judgement and doctor-patient communication, when advising 
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Appendix A supplemental information on the methods used
Number of patients per participating hospital
Included patients were treated between 1990 and 2000 at the Netherlands Cancer 
Institute-Antoni van Leeuwenhoek Hospital (N=683), Erasmus Medical Center-Daniel 
den Hoed Clinic (N=320), which are cancer centers; Leiden University Medical Center 
(N=205), an academic hospital; and Medisch Spectrum Twente Hospital (N=839), PAMM 
Laboratories (N=221), Albert Schweitzer Hospital (N=191), Rijnland Hospital (N=86), 
Viecuri Hospital (N=74), Diaconessenhuis Leiden (N=50), and Elkerliek Hospital (N=41), 
which are regional hospitals.
An update of the clinical and follow-up data revealed that 19 patients included in the 
current study were 50 years at diagnosis, and therefore did not meet the eligibility 
criterion of below 50 years. This shift in age was due to adjustment of the date of 
diagnosis (histological confirmation). Given the small number of patients concerned 
and the fact that the results remained the same irrespective of whether these patients 
were included or not, we decided to keep them in the analyses.
Procedures
Data categorization: age at diagnosis (continuous), tumor size (continuous for PRE-
DICT and for Adjuvant! categorized as: 0.0-1.0 cm, 1.1-2.0 cm, 2.1-3.0 cm, 3.1-5.0 
cm or >5.0 cm), tumor grade (categorized as: Grade 1, Grade 2, Grade 3 or undefined 
if missing), number of positive axillary lymph nodes (continuous for PREDICT and for 
Adjuvant! categorized as: 0 positive nodes, 1-3 positive nodes, 4-9 positive nodes or >9 
positive nodes), ER-status (categorized as: positive, negative or undefined if missing). 
For Adjuvant! if tumor diameter (in mm) was missing, patients were categorized using 
pathological T-stage if available (T1 was categorized as having a tumor of 1.1-2.0 cm, 
T2 was categorized as having a tumor of 3.1-5.0 cm and T3 was categorized as having 
a tumor of >5.0 cm). For Adjuvant! patients with missing data on the number of positive 
axillary lymph nodes were categorized using pathological N-stage if available (N0 was 
categorized as having 0 positive nodes, N1 was categorized as having 1-3 positive 
nodes, N2 was categorized as having 4-9 positive nodes and N3 was categorized 
as having >9 positive nodes). We used weighed mean imputed values to calculate 
PREDICT survival estimates for missing values of grade (imputed value: 2.25), tumor 
size in mm (if pT1a-b: 5mm; pT1c: 1.5mm; pT2: 40mm; pT3: 50mm), and number of 
positive axillary lymph nodes (if pN1: 2 positive nodes; pN2: 7 positive nodes; pN3: 
10 positive nodes). The T, N, and M were determined according to Dutch guidelines 
at the time of diagnosis; for combining these three factors in the stage variable, the 
AJCC TNM staging guidelines of 2002 were used.
81
Discriminatory accuracy and calibration of PREDICT and Adjuvant!
3
According to the clinical cut-off points endorsed in the Dutch breast cancer guideline 
for immunohistochemical staining of receptors, a tumor was considered receptor 
negative using the following cut-offs: ER= ≤10%; PR= ≤10%; Her2-score= 0 or 1+)) 
(21;26;27). Receptor status data was included from Tissue Micro Arrays (TMA) if data 
from pathology reports was not available, for ER the data source was NTMA= 757 and 
Npathology reports= 1316, and for Her2 data source was NTMA= 817 and Npathology reports= 308. 
Patients with a tumor that did not express ER, PR and Her2 were considered to have a 
triple negative tumor. Within the time period that patients in this cohort had been diag-
nosed (i.e. 1990-2000), it was not yet standard practice to routinely assess cell-surface 
Her2 protein expression by immunohistochemistry (Her2-status missing for N= 1,639 
(60%)). Her2 was mostly included from analyses of TMA using Her2 immunohistochem-
istry, however, the number of copies of the Her2-gene was not quantified using an in 
situ hybridization technique (e.g., FISH, CISH or SISH) for patients with an equivocal 
Her2 immunohistochemistry (i.e. 2+ score) to definitively determine Her2-status (N= 
60 (2%)). We opted to include patients with equivocal Her2 immunohistochemistry in 
our analyses and treat them as having Her2-negative disease, based on Kaplan-Meier 
curves analyses that showed that their survival pattern was similar to those with immu-
nohistochemistry Her2-negative disease (data not shown). 
Angiolymphatic-invasion, i.e., tumor formation in blood and/or lymph blood vessels, 
was only available for reviewed tumor H&E slides. A breast pathologist (H. Peterse, 
NKI-AVL) scored the tumors as follows: 0=none, 1=1-3 vessels in the whole slide, 
2=more than three vessels in the whole slide.
Adjuvant systemic treatment was categorized as: none, first generation (if treated with 
cyclophosphamide - methotrexate - fluorouracil (CMF), cyclophosphamide - dox-
orubicin or epirubicin (AC or EC) (four cycles) or if type chemotherapy regime was 
unknown and the patient also received endocrine therapy) and second generation (if 
treated with fluorouracil (5FU) - doxorubicin or epirubicin - cyclophosphamide (FEC 
or FAC) (six cycles), others). In the Adjuvant! analysis sample (N=2,710), in total 1,058 
patients received first generation chemotherapy and 47 patients received second-gen-
eration chemotherapy. In the PREDICT analysis sample (N=2,073), in total 800 patients 
received first generation chemotherapy and 24 patients received second-generation 
chemotherapy. In this population, endocrine treatment only consisted of Tamoxifen.
Analyses
The following hospitals had no data on cause of death and were thus excluded from 
the breast cancer-specific mortality estimates, namely: Elkerliek (N=41), Viecuri (N=74), 







   




















































































































































































   








































































































































   

































































































































































































































































































































































































































































































































































































































































































































































































   





























































































































































































































































































































































































































































































































































































































































































































































































































































   


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Oncologists’ attitudes towards and use of tools to 
communicate the benefits of adjuvant systemic 
therapy for early-stage breast cancer

Chapter 4
Oncologists’ weighing of the benefits and side effects 
of adjuvant systemic therapy:  
has it changed over time?
Ellen G. Engelhardt
Hanneke C.J.M. de Haes








The use of adjuvant chemotherapy and endocrine therapy for early-stage breast cancer 
has substantially increased. The presentation of the Early Breast Cancer Trialists 
Collaborative Group (EBCTCG) meta-analyses of adjuvant systemic treatment effective-
ness, late-1990s, led to a paradigm shift where adjuvant systemic treatment  was no 
longer reserved for patients with (locally) advanced disease, but also became available 
to node negative patients (1). New insights in prognostic factors and improvements 
in treatment have led to further easing of the eligibility criteria for adjuvant systemic 
treatment over time. For example, according to the American National Comprehensive 
Cancer Network (NCCN) breast cancer guidelines, some form of adjuvant systemic treat-
ment could be considered for all breast cancer patients with invasive ductal or lobular 
tumors larger than 0.5 cm. If a patient has Her2-positive disease, adjuvant systemic 
treatment could also be considered for tumors smaller than 0.5 cm (2). Going by these 
NCCN and other (inter)national guidelines, a proportion of early-stage breast cancer 
patients with a clinical indication for adjuvant systemic treatment have a potential overall 
survival benefit of as little as 1% - conversely, 99% of these patients potentially only 
experience side-effects and no survival gain. With the exception of patient subgroups 
deemed at high risk of recurrence and breast cancer mortality (e.g., Her2-positive 
patients or those 40 years or younger at diagnosis), the general rule of thumb applied 
in the Netherlands is that adjuvant systemic treatment is advised if treatment reduces 
the patient’s risk of breast cancer death by at least 4% (absolute). This easing of the 
eligibility criteria for adjuvant systemic treatment is also reflected in the substantial 
increase in its use in Dutch clinical practice from 1990-2011. Where between 1990-1997 
only 37% of early-stage breast cancer patients received adjuvant systemic therapy, 
in 2011 an average of 70% of early-stage breast patients received adjuvant systemic 
treatment (3, 4). 
In 2000, just after the publication of the first EBCTCG meta-analysis, a survey amongst 
Dutch oncologists reported that the majority felt that adjuvant chemotherapy should 
minimally yield 6-10% overall survival benefit to make it worthwhile for patients with 
node negative disease (5). To date no studies have assessed what survival benefit makes 
endocrine treatment worthwhile according to oncologists. Yet, endocrine treatment 
duration has been extended more and more (from 2.5 to 5 years and an extension 
to 10 years is currently topic of debate), whilst studies show non-adherence and/or 
premature discontinuation of treatment of as much as 40% (6-8). 
It has been over a decade since Stiggelbout et al. conducted their survey of oncologists’ 
views on the survival benefit that makes adjuvant chemotherapy treatment worthwhile. 
As patients are increasingly diagnosed at earlier stages the benefits adjuvant chemo-
therapy and endocrine therapy can yield are often small, whereas the potential for 
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side-effects remains undiminished (4). In view of the substantial increase in adjuvant 
systemic treatment use in the past decades, we replicated our study assessing how 
much treatment benefit, given the potential side-effects, Dutch oncologists require to 





This study was conducted as part of a larger project investigating oncologists’ views 
on risk prediction models and their use in clinical practice to guide adjuvant systemic 
treatment decisions (9). Medical and surgical oncologists were eligible to participate in 
the current study. The Comprehensive Cancer Center the Netherlands (IKNL) sent out 
an invitation to complete the anonymous online-survey on our behalf to the members 
of all the medical oncology and breast cancer working parties. IKNL has a nationwide 
coverage, facilitating the recruitment of our target. A reminder was sent four weeks later. 
Measures and data analyses
To determine the minimal adjuvant systemic treatment 10-years overall survival benefit 
participants deemed sufficient, they were asked: “What is the minimal percentage 
treatment benefit that in your opinion makes treatment X worthwhile, given the side-
effects?”. This was a multiple choice question, where participants could choose from the 
following categories: “1-5%”, “6-10%”, “11-20%” or “more than 20%”. If they indicated 
that the treatment benefit they required was between 1-5%, they were asked to provide 
us with the exact percentage. We also assessed some background characteristics 
such as age, type of hospital they work at and level of experience. All analyses were 
performed using SPSS 20. 
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Results
We included forty-two oncologists, of whom half were surgeons. Participants were 49 
years on average (range, 31-64 years), 58% were male and 80% worked in a teaching 
hospital (general or academic) (Table 1).  For privacy reasons we could not access data 
on the size and composition of the IKNL working parties approached for this study; 
hence, we are unable to estimate our response rate. 
Chemotherapy
Half of surgical and medical oncologists indicated that between 6-10% survival gain is 
the minimal percentage benefit that offsets the potential side-effects due to treatment 
(Figure 1). Of the 16 (38%) oncologists who indicated that 1-5% was sufficient survival 
gain, the minimally required benefit ranged from 3% (N=2, 13%) to 5% (N=9, 56%).
Table 1: Oncologists’ characteristics (N (%))
Surgical oncologists Medical oncologists
  N= 20 N=22
Age
≤ 50 years 10 (59) 13 (62)
> 50 years 7 (41) 8 (38)
Gender Male 12 (71) 10 (48)
Experience treating breast 
cancer 
< 5 years 1 (4) 3 (12)
6-10 years 7 (28) 12 (46)
> 10 years 17 (68) 11 (42)
Type of hospital
General 3 (18) 4 (18)
Training 10 (59) 12 (55)
UMC 4 (24) 6 (27)
Participants do not add up to 42 due to missing data.; Differences between surgical and medical 
oncologists were not significant. UMC= University Medical Center
Endocrine therapy
Medical oncologists tended to require greater survival benefits from endocrine therapy 
than surgical oncologists, but the difference was not statistically significant (Figure 1). 
If oncologists (N=21, 50%) thought that 1-5% overall survival benefit was sufficient to 
justify endocrine treatment, the minimally required benefit threshold ranged from 3% 
(N= 9, 43%) to 5% (N=7, 24%).
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Generally, younger (<50 years) and female oncologists more often indicated that a 
minimal overall survival benefit (1-5%) was sufficient to offset potential treatment 
side-effects for both chemotherapy and endocrine therapy (data not shown; differences 
not statistically significant).
Figure 1 Minimal overall survival gain oncologists deem sufficient to justify adjuvant systemic treatment
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Discussion
There was a wide range in the benefit required from adjuvant systemic treatment within 
both surgical and medical oncologists. Most oncologists required 6-10% survival 
benefit to recommend adjuvant chemotherapy. When it came to endocrine therapy 
most surgical oncologists had a lower required benefit threshold (1-5%) compared to 
medical oncologists (6-10%). 
The current study is the first to explore oncologists’ minimally desired treatment benefit 
of endocrine therapy. Although a larger proportion of medical compared to surgical 
oncologists  require an overall survival benefit equal to that of chemotherapy, half of 
our respondents required less treatment benefit to justify endocrine treatment which 
suggests that there is a tendency to underestimate the impact of endocrine therapy. 
Although often perceived as less aggressive, there is substantial non-adherence to 
endocrine therapy, moreover, although side effects may be less severe, treatment lasts 
for a substantially longer time. A recent study showed that overall, patients consider 
the efficacy of treatment to be the most important factor, but it was closely followed 
by side-effects joint and muscle pain and risk of endometrial cancer. About one in six 
patients even felt that the treatment benefits did not outweigh the side-effects (10). 
This illustrates the importance of taking patients’ values into account when deciding 
about treatment. 
Interestingly, even though the eligibility criteria for adjuvant systemic treatment have 
become broader, oncologists’ minimally required benefit from adjuvant chemotherapy 
remains unchanged compared to the findings reported by Stiggelbout et al. well over 
a decade ago. Perhaps this lack of change, is a sign of the overriding sense that by 
casting such a wide net, i.e. having such broad guidelines, more harm is done than 
good, as the vast majority (>60%) of patients currently undergoing adjuvant systemic 
treatment, probably do not need it (11). Unfortunately, the currently available tools are 
not yet sensitive enough to help clinicians determine which patients can forego treat-
ment, without negatively affecting their (recurrence-free) survival (12). 
Regrettably, our sample is small; nonetheless, our findings indicate that for both chemo-
therapy and endocrine therapy, most oncologists agree that treatment is worthwhile 
if the potential survival benefit is 10% or more. There only seems to be a difference 
of opinion if the potential benefit is less than 10%. Oncologists that participated in 
the current study require greater survival benefits from adjuvant systemic treatment, 
than the threshold indicated in the Dutch breast cancer guideline (i.e., ≥ 4%), to deem 
treatment worthwhile. Over the past decades patients are diagnosed at earlier stages 
and have a good prognosis a priori. The fact that during the same period the use 
of adjuvant systemic treatment has virtually doubled, suggests that oncologists do 
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not adhere to their own minimally-desired treatment benefit when recommending 
treatment to patients. This stresses the imperative for oncologists and patients to 
critically mull over whether the potential treatment benefits are worthwhile in light of 
the side-effects associated with treatment. Especially when the potential treatment 
benefit is small, patient preferences could be the overriding factor when deciding about 
treatment. However, to make this possible, patients should be adequately informed 
about all the relevant treatment options (including forgoing treatment), their potential 
benefits and (main) side-effects, and afforded the opportunity to freely discuss their 
thoughts, concerns and any doubts about treatment with their oncologist. Such an 
open exchange of information (oncologist) and considerations (patients) could help 
patients and their oncologists to decide on the best course of action with which both 
parties feel comfortable.
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Risk prediction models (RPM) in breast cancer quantify survival benefit from adjuvant 
systemic treatment. These models (e.g. Adjuvant! Online (Adjuvant!)) are increasingly 
used during consultations, despite their not being designed for such use. As still little 
is known about oncologists’ views on and use of RPM to communicate prognosis to 
patients, we investigated if, why, and how they use RPM.
Methods
We disseminated an online questionnaire that was based on the literature and individual 
and group interviews with oncologists.
Results
Fifty-one oncologists (partially) completed the questionnaire. Adjuvant! is the best 
known (95%) and most frequently used RPM (96%). It is used to help oncologists 
decide whether or not to recommend chemotherapy (>85%), to inform (86%) and help 
patients decide about treatment (>80%), or to persuade them to follow the proposed 
course of treatment (74%). Most oncologists (74%) believe that using Adjuvant! helps 
patients understand their prognosis. 
Conclusion
RPM have found a place in daily practice, especially Adjuvant!. Oncologists think that 
using Adjuvant! helps patients understand their prognosis, yet studies suggest that 
this is not always the case. Our findings highlight the importance of exploring whether 
patients understand the information that RPM provide. 
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Introduction
Deciding about adjuvant systemic therapy for breast cancer can be a difficult balancing 
act between potential survival gains and side-effects. Many risk prediction models (RPM) 
have been developed to primarily aid oncologists’ decision-making about adjuvant 
systemic treatment (1). RPM seem to meet a need and appear to have been widely 
adopted in clinical practice. For example, the Dutch breast cancer adjuvant systemic 
treatment guidelines are largely based on Adjuvant! survival and treatment benefit esti-
mates (2). The American National Comprehensive Cancer Network (NCCN) guidelines 
have incorporated Oncotype Dx in their adjuvant systemic treatment decision-making 
algorithm (2,3). The British National Institute for Health and Clinical Excellence (NICE) 
has incorporated the Nottingham Prognostic Index in their decision algorithm and both 
NICE and NCCN endorse the use of Adjuvant! to support estimations of individual 
prognosis and absolute benefit of adjuvant treatment (4,3).
A 2005 questionnaire amongst American medical oncologists found that 80% had 
ever used Oncotype Dx, and that 78% used Adjuvant! (5). A small questionnaire study 
amongst 25 British medical oncologists from 13 oncology centers found that 96% of 
the participants used Adjuvant! to calculate mortality estimates and 36% also used it to 
calculate relapse probabilities. Most participants (≥84%) were confident that Adjuvant! 
estimates are accurate (6). 
Most RPM offer graphical representations of prognostic information, and this increases 
their appeal for use in the consultation to convey prognostic information to patients. 
The UK-based questionnaire found that 92% of participants regularly discussed the 
survival probabilities and treatment benefit estimates from Adjuvant! with their patients, 
and a quarter also said they provided patients with the printout from Adjuvant! (6). 
Not much is known about such use of RPM during the consultation (i.e., frequency 
and reason for use) and similarly, little is known about how well patients understand 
prognostic information from RPM. The information these models provide is complex 
and could cause confusion if risk communication is not done properly, and increase 
patients’ anxiety. Patients tend to have problems understanding probabilities, in part 
due to limited understanding of health statistics (7,8). Two small studies (<30 patients) 
assessing patients’ understanding of prognostic information before and after receiv-
ing results from Adjuvant! reported that 43% - 65% were not able to accurately recall 
recurrence-free (RFS) and/or overall survival (OS) immediately after the consultation 
with their medical oncologist (9,10). In a few patients the use of Adjuvant! printouts led 
to heightened confusion and decreased comprehension (10). Simplifying Adjuvant!’s 




A drawback of RPM is that the point estimates they provide reflect average outcome 
probabilities derived from  groups of similar patients (7). Adjuvant! provides survival 
estimates as point estimates without the confidence interval surrounding the estimates. 
Knowing the width of the confidence interval could help oncologists gauge how robust 
Adjuvant!’s survival estimates are. Yet, it is unknown if oncologists are interested in this 
type of information and if and how they would disclose the associated uncertainty to 
their patients. Many patients have difficulties understanding uncertainty (7); and the 
effect of and how best to share uncertainty with patients is unknown (12,13).
Given the lack of information on the use of RPM to communicate prognosis to patients, 
and the pitfalls if not done appropriately, we assessed oncologists’ a) familiarity with 
and use, b) reasons for use, for themselves and with patients, c) views on the (dis)
advantages of RPM, and d) wish for uncertainty estimates and views about commu-
nicating these to patients.
117




Given the limited literature on this subject, we first conducted semi-structured interviews 
(N=10) with surgical and medical oncologists. We aimed to conduct a minimum of 10 
interviews, and during the analysis process we also observed that after 10 interviews 
new categories, themes or explanations stopped emerging (data saturation). Subse-
quently, we held two online focus groups with a new group of surgical and medical 
oncologists (8 active participants out of 20 who agreed to participate). Oncologists 
attending the 2011 Dutch Medical Oncology congress and members of the Compre-
hensive Cancer Centre The Netherlands (IKNL) medical oncology and breast cancer 
working parties were invited to participate via e-mail, if they wanted to participate 
they indicated their preference for either an interview or focus group. IKNL has a 
nationwide coverage, facilitating the recruitment of our target population throughout 
The Netherlands.
The themes explored in the interviews were oncologists’ a) familiarity with and use, 
b) reasons for use, both for themselves and with patients, c) views on the (dis)advan-
tages of RPM, and d) wish for  uncertainty estimates and views about communicating 
these to patients. We used the information obtained in the interviews to formulate 
statements, which we posted on a website especially created for these online focus 
groups. The online focus group participants were asked to post their views about the 
statements during a four-week period. They were also able to respond to other par-
ticipants’ posts. Participants were not aware of each other’s identity. The data from 
the interviews and online focus groups were independently coded by two researchers 
using NVivo 9 software, and  an open coding system. Discrepancies in coding were 
resolved by consensus.
Next, we used the data from the interviews and online focus groups to develop an 
online questionnaire. With the online questionnaire we explored all the themes (a-d) 
described above (Appendix 1). We also assessed participants’ a) characteristics, and 
b) general reluctance to disclose uncertainty (14). To limit participants’ time investment, 
most questions were multiple choice; answering categories were based on the findings 




Figure 1 Flowchart of participants
Recruitment of participants online questionnaire
The Comprehensive Cancer Centre The Netherlands sent out an invitation on our 
behalf to the members of all regional medical oncology and breast cancer working 
parties. Medical and surgical oncologists were eligible to participate in the current study. 
Participants could anonymously complete the questionnaire online or on paper. Four 
weeks after sending the initial invitation, a reminder was sent to the working parties.
Data analysis
For privacy reasons we could not access data on the size and composition of the work-
ing parties; and are unable to estimate the response rate. The proportion of surgical 
and medical oncologists in our sample was similar to the distribution of the specialties 
in a reference sample of IKNL-working parties across The Netherlands. Participants 
who only partially completed the online questionnaire were included in the analyses if 
they had answered at least the questions on the (dis)advantages of RPM in general. 
Descriptive analyses were performed, as well as comparisons between groups, using 
Chi Squared or Fisher’s Exact Tests for categorical variables and Student’s T-test for 
continuous variables, all using SPSS 20.
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In the results we will focus on the RPM that the majority of oncologists use most 
frequently, illustrate oncologists’ views on and how they use RPM in general. Further, 





Fifty-one participants were included (Figure 1) and 77% of them completed all ques-
tions. There were no significant differences between the participants who had fully or 
partly completed the questionnaire (Appendix Table 1). On average the participants 
were 49 years old, 44% were female, and 82% worked in teaching hospitals (general 
or university) (Table 1). We found no significant difference in socio-demographic and 
work-related characteristics between surgeons and medical oncologists. 
Familiarity with and use of RPM in clinical practice 
The best-known RPM amongst oncologists were Adjuvant! (95%) and MammaPrint 
(88%). About one-third were familiar with Oncotype Dx and 19% with the Nottingham 
Prognostic Index. Overall, 71% of surgical oncologists reported to sometimes or 
regularly use RPM, compared to 100% of medical oncologists (p= 0.004; Fisher’s exact 
test) (Table 2). Of those who use RPM, medical (100%) and surgical (95%) oncologists 
indicated that they most frequently use Adjuvant!. If MammaPrint was used, in most 
cases it was to supplement Adjuvant!. For example, if the patient and/or the oncologist 
were leaning towards foregoing chemotherapy, the MammaPrint results were decisive 
in determining the probability that forgoing chemotherapy would negatively affect RFS.
We asked participants which estimates, 10-year OS or RFS, they most frequently 
consulted a) before and b) during consultations with patients. Both surgical (63%) and 
medical (71%) oncologists reported that they usually consulted both estimates before 
the consultation. If only one was consulted, it most frequently was OS (21%). The 
majority indicated that they preferred OS because the main aim of adjuvant systemic 
treatment is to improve OS. There were also some concerns about the robustness of 
the relapse estimates, as in Adjuvant! no distinction is made between loco-regional 
and distant recurrences. One in three oncologists indicated that they habitually showed 
patients only the OS estimates and about half reported to show patients both the OS 
and RFS estimates. Oncologists indicated that Adjuvant! estimates are not too diffi-
cult to show to patients (Table 3). Some think that estimates from Adjuvant! should 
always be disclosed to patients, except if the patient strongly objects to hearing this 
information. Most medical (63%) and surgical (74%) oncologists indicated that one 
should ask patients if they want to hear Adjuvant! estimates, and if so, provide them 
with the estimates. 
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Male 12 (71) 10 (48)











Number of  consultations with 





















Total 25 (49) 26 (51)
* = Participants do not add up to 51 due to missing data; No significant differences between surgical and 
medical oncologists, hence p-values not reported.
Of medical oncologists, 42% indicated that they ask patients if they want a printout 
to take home, compared to 11% of surgical oncologists (p= 0,04); Fisher’s exact test). 
Most surgical oncologists (61%) indicated that they do not actively offer a printout, but 
provide it if asked. Moreover, many participants (63% of medical and 47% of surgical 
oncologists) feel that oncologists should disclose Adjuvant! estimates to patients even 
if they forecast a bleak outlook. As an oncologist said: “Before I disclose Adjuvant!’s 
estimates I tell patients that the estimates could be quite hard to stomach and check 
whether they still want to hear it…. if they still do, I discuss them”.
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Never 4 (17) 0
0.007
Ever 3 (13) 0
Sometimes 9 (38) 7 (28)
Regularly 8 (33) 18 (72)
*= Participants do not add up to 51 due to missing data; # = Comparison made using Fisher’s exact test
Reasons for using RPM for themselves or with patients
More than 90% of oncologists sometimes use Adjuvant! to prepare the consultation; 
one in four medical oncologists always use Adjuvant! to prepare the consultation. 
Oncologists predominantly consult Adjuvant! before the consultation, to decide whether 
or not to recommend chemotherapy alone (87%) or in combination with endocrine 
therapy (91%).  Adjuvant! is also consulted to decide about endocrine monotherapy 
(60%). Up to one in four oncologists (surgical more often than medical oncologists) also 
use Adjuvant! to decide about neo-adjuvant systemic therapy. Overall, 85% of surgical 
and 76% of medical oncologists indicated that their treatment preference sometimes 
changed after consulting a RPM. If there was a shift in medical oncologists’ treatment 
preference, it was caused by either viewing the results of Adjuvant! alone (42%) or in 
combination with MammaPrint (58%). 






Disagree Neutral Agree Disagree Neutral Agree
not show Adjuvant! estimates to 
patients as it is too difficult for them
84 16 0 83 17 0
not show Adjuvant! estimates to 
patients as people cling too much to 
the estimates 
53 47 0 75 21 4
never show Adjuvant! estimates to 
patients, it is best to use verbal labels# 
instead 
42 42 16 71 21 8
not show Adjuvant! estimates to 
patients if these estimates are too hard 
to face
47 32 21 63 12 25
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Disagree Neutral Agree Disagree Neutral Agree
only show Adjuvant! estimates to 
highly educated patients as they are 
best capable of understanding this 
information 
63 21 16 83 12 4
offer to show Adjuvant! estimates to 
patients and show the estimates if the 
patient wants to see it
16 10 74 17 20 63
always show Adjuvant! estimates, 
unless the patient absolutely does not 
want to hear this
53 26 21 79 8 13
always show Adjuvant! estimates to 
breast cancer patients ≤ 40 years, as 
this information is most relevant for 
these patients
53 36 11 71 16 13
always show Adjuvant! estimates if 
the patient asks for information on 
prognosis
0 32 68 17 8 75
$ Participants do not add up to 51 due to missing data; # Verbal labels are terms used to denote 
likelihoods, e.g. “small chance that x will happen” or “it is likely that x will happen”; The category 
“disagree” comprises of those that selected either “totally disagree” or “disagree”. And the category 
”agree” comprises of those that selected either “agree” or  “totally agree”; No significant differences 
between surgical and medical oncologists were found, hence p-values Fisher’s exact test are not 
reported.
Surgical oncologists indicated to regularly use Adjuvant! to help patients decide whether 
or not undergoing chemotherapy is worthwhile (73%) (Table 4). Medical oncologists 
stated to use Adjuvant! to provide patients with prognostic information (100%) and/or 
to help patients decide whether or not to undergo chemotherapy (96%). Additionally, 
75% of medical oncologists indicated that they sometimes/regularly use Adjuvant! to 
convince patients that undergoing chemotherapy is not necessary and 83% also use 
it occasionally to convince patients of the benefit of their proposed treatment plan. 
Medical (96%) and surgical (75%) oncologists reported that the output of RPM not only 
influenced their own decisions, but also those of their patients. In all, 56% of surgical 
and 70% of medical oncologists indicated that they frequently observe hesitation with 
regard to chemotherapy, yet after seeing Adjuvant!’s prognostic estimates patients 
change their minds. 
Over 70% of oncologists think that Adjuvant! helps patients to understand their prog-
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nosis better. Conversely, about 14% think that Adjuvant! does not make it easier for 
patients to understand their prognosis, but makes it easier for them to discuss prog-
nosis with patients. 
Views on the (dis)advantages of RPM
The two most frequently cited concerns about RPM were a) estimates only provide 
insights at a group level (34%) and b) those based on genetic profiles, e.g. MammaPrint 
or Oncotype Dx, are not yet sufficiently validated for use in clinical practice (36%). Twelve 
percent of medical oncologists indicated that another important drawback of RPM is 
that they give patients a false sense of security: “As you can imagine, when people 
who feel the need to keep a tight grip on their illness or their life find themselves in a 
situation in which all certainties have been taken away, that they desperately look for 
something to cling to… it’s very hard to get them to put these estimates in perspective”.
We asked oncologists to indicate their main concerns with regard to Adjuvant! spe-
cifically. They consistently indicated that Adjuvant! is one of the best RPM currently 
available, but far from perfect. The accuracy of Adjuvant!’s estimates in some patient 
populations, e.g. in the elderly (>65 years), is possibly suboptimal. Some felt that it 
would be informative, especially for younger patients and those with hormone recep-
tor positive disease, if Adjuvant! were to provide prognostic estimates up to 20-years 
follow-up, instead of only 10-year estimates. The majority (85%) indicated that Adju-
vant! is currently missing important prognostic factors, particularly her2neu receptor 
status. Also, preferably Adjuvant! should take the effect of Trastuzumab into account. 
More than three quarter indicated that the way prognostic factors are categorized in 
Adjuvant! is not ideal, or that it is unclear how the categories should be interpreted. 
Many felt the  categorization of  nodal status too crude (i.e., 0 positive; 1-3 positive; 4-9 
positive and > 9 positive nodes). “A patient with one positive node would reasonably 
be expected to have a better prognosis than a patient with three positive nodes.” It is 
currently unclear how to classify patients with micro-metastases; classifying them as 
node negative might yield prognostic estimates that are too optimistic, but classifying 
them as having 1-3 positive nodes seems to be a gross exaggeration.
It was often mentioned as an asset that Adjuvant! takes comorbid conditions into 
account, but most participants do not know how to interpret the categories Adjuvant! 
uses (i.e., perfect health; minor problems; average for age; major problem +10; major 
problem +20 and major problem +30). “If a patient has well-managed diabetes, is that 
a minor problem or is it a major problem?”. Over 80% of oncologists indicated that 
they tend to use the default setting, namely “minor problems”. However, if a patient has 
significant comorbidities, choosing a comorbidity category is often a bit of guesswork; 
oncologists try out multiple categories to see what happens with the estimates, and 
stick with the one they think yields the most realistic survival estimates. 
125
Oncologists’ self-reported use of prediction models in clinical practice
5
Views on communicating uncertainty around the estimates from RPM
One in three (37%) thought that a confidence interval would be of no added value to 
them, with most indicating that they assume that Adjuvant!’s estimates are sufficiently 
accurate because the Dutch breast cancer guidelines are partly based on Adjuvant!. 
Half (49%) would want to know the width of the confidence intervals to determine for 
themselves how much credence they should give the estimates. 
One in five oncologist are highly reluctant to disclose uncertainty to patients; yet, 95% 
of surgical and 100% medical oncologists discuss the uncertainty associated with Adju-
vant!’s estimates with their patients in general terms. One oncologist said: “Uncertainties 
are a part of consultations with patients. We should not shy away from communicating 
them.” Using an open-ended question, we asked oncologists to describe how they 
communicate uncertainty around Adjuvant!’s estimates to patients. The two most 
frequently reported methods were: a) telling patients that the estimates do not say any-
thing about an individual, they are true at a group level (46%) and b) telling patients the 
estimates are based on statistics (14%). If they were available, over 75% of oncologists 
would disclose the confidence interval surrounding Adjuvant!’s estimates to patients, 
whom they think are capable of understanding this. A medical oncologist pointed out: 
“Sometimes I think patients can’t handle uncertainty, but doctors probably struggle 




We assessed oncologists’ views on RPM and their use of these tools. Adjuvant! is the 
most frequently used RPM, with many oncologists using it to prepare their consulta-
tion and use Adjuvant! in the encounter to inform and/or help patients decide about 
treatment. About half sometimes use Adjuvant! to convince patients of the merits of 
the proposed treatment plan. Surgical and medical oncologists’ role in decision-mak-
ing about adjuvant systemic treatment differs, hence we found some differences in 
frequency and motivation for using RPM.
Unexpectedly, we found that up to a quarter of oncologists also used Adjuvant! to 
decide about neo-adjuvant systemic therapy. Adjuvant! has not been validated for this 
purpose, and it is not known whether the estimates hold in the neo-adjuvant setting. 
MammaPrint was the best-known RPM based on a gene profile, but was rarely used. 
Most oncologists indicated that such RPM do not yet have sufficient scientific under-
pinning to guide treatment decision-making. Many indicated that they are awaiting 
the results of the Mindact trial1 and TAILORx trial2, to know whether high risk patients 
according to Adjuvant! but low risk according to MammaPrint or Oncotype Dx, respec-
tively can be spared chemotherapy without negatively affecting RFS.
Oncologists expressed concern about the validity of Adjuvant!’s estimates in specific 
subgroups and felt some key prognosticators were missing, inappropriately categorized 
or it is difficult to categorize patients into. These views are in agreement with the results 
of our recent systematic review (1). In spite of these limitations, most felt that Adjuvant! 
is a helpful tool and that no matter how complete the RPM, it will always be impossible 
to provide patients with a 100% certainty about disease outcome or treatment effect. 
Most felt that using Adjuvant! during consultations helped patients understand their 
prognosis better. Moreover, in general oncologists did not think that the complex 
nature of Adjuvant!’s estimates and the fact that these estimates could be hard to 
hear for patients, are reasons not to use Adjuvant! during consultations. Oncologists 
even reported high willingness to communicate about the uncertainty surrounding the 
estimates of RPM to patients.
There are not many studies we can compare our findings to. A study that assessed 
the communication of uncertainty about risks and benefits of various treatments in 
1 The MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid ChemoTherapy): http://
www.agendia.com/clinical-trials-mindact/; Date last accessed: 27-05-2014.
2 The TAILORx trial (Trial Assigning IndividuaLized Options for Treatment (Rx)): http://www.cancer.gov/clinicaltrials/note-
worthy-trials/tailorx; Date last accessed: 27-05-2014. 
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outpatient clinics found that uncertainty was discussed in about 1% up to 16% of 
consultations depending on the difficulty of the decision at hand (15). It would be inter-
esting to get insights in how and how often oncologists actually discuss uncertainty in 
daily practice, since there are no guidelines available on how uncertainty should best 
be communicated (12). Moreover, it is unclear to what extent patients understand the 
uncertainty around RPM estimates and how information on uncertainty affects them 
personally as well as their final treatment decision.
Unfortunately, we were unable to determine our response rate. Also, the number of 
participants was relatively small. This is partly explained by the fact that we recruited 
participants via the IKNL-working parties which consist of a highly motivated, yet 
relatively small subgroup of experienced oncologists.   
In conclusion, RPM have found their way into the consultation. It is encouraging that 
oncologists are driven to obtain the best possible prognostic estimates to guide their 
own decision-making and to communicate this information to patients, which in turn 
may facilitate patient participation in decision-making. However, clinicians assume 
that using RPM during consultations helps patients understand their prognosis better. 
Studies on patient understanding of prognosis (10,9) suggest that using Adjuvant! 
does not necessarily facilitate or improve patient understanding.  Large observational 
studies of the communication process between oncologists and patients involving RPM 
are urgently needed to get insight into whether patients indeed understand the risks 
communicated during the consultation, and whether this enhances their participation. 
Additionally, studies assessing patients’ understanding and acceptance of communica-
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Average age in years (range) 49 (31-64) unknown





































Total 39 (77) 12 (24)
No significant differences between surgical and medical oncologists, hence p-values Fisher’s exact test 
are not reported
Appendix 1: Oncologists’ views on and use of risk prediction models 
 
Fill in date 
Please first fill in today’s date? (day/month/year) 
 
/ /  
 
1. What is your specialism? 
 
 Surgical oncologist 
 Medical oncologist 
 Surgical oncologist in training 
 Medical oncologist in training   
 Other, namely: 
 ……………………………………………………………………………………….. 
 
2. Approximately how many new breast cancer patients do you see per month, where initially the treatment 
intent is curative? 
 
 1−2 patients 
 3−5 patients 
 6−10 patients 
 11−15 patients 
 >15 patients 
 
3. How many years experience do you have treating breast cancer patients? 
 
 < 2 years 
 2−5 years 
 6−10 years 
 > 10 years 
 
With the following questions we want to ascertain which risk prediction models you are familiar with, which 
you may use and what you think of them. 
 
4. With which of the risk prediction models below are you familiar? 
 (multiple answers possible) 
 
 Adjuvant! Online 
 MammaPrint 
 Nottingham Prognostic Index 
 Oncotype Dx 
 Other, namely: …………………………………………………………… 
 
Below are a few arguments against the use of risk prediction models that are sometimes made by clinicians. Will 
you indicate for each statement the extent to which you are in agreement. 
 






nor agree Agree 
Totally 
Agree 
is of no added value to me in the clinic      
is not sufficiently scientifically supported for 
use in the clinic      
is not user friendly      
gives false assurances, onto which patients 
unduly cling      
does not say anything about individual 
patients, as it applies to groups      
is too complicated      
makes patients unnecessarily anxious      
based on genetic profiles, such as 
MammaPrint, is not sufficiently scientifically 
supported 
     
 




6. Do you sometimes use a risk prediction model (RPM)? 
 
 No, I have never used a RPM                   Go to question 28  
 Yes, I have ever used a RPM before  
 Yes, I sometimes use a RPM          Go to question 7 
 Yes, I often use a RPM  
 
 
7. Which of the risk prediction models below do you use or have you used before?  
(multiple answers possible) 
 Adjuvant! Online 
 MammaPrint 
 Nottingham Prognostic Index 
 Oncotype Dx 
 Other, namely: …………………………………………………………………… 
 
 
8. If you do not use Adjuvant!Online, please indicate here the reasons you do not use Adjuvant!Online?  
I do not use Adjuvant! Online because: …………………………………………………………………………………………………… 
 
9. Does your preference for whether or not to give adjuvant systemic therapy ever change in response to the 
outcome of a risk prediction model? 
 
 No   Go to question 12  
 Yes   Go to question 10 
 
 
10. You have indicated that your preference for adjuvant systemic therapy sometimes changes 
based on the outcome of a risk prediction model. For which risk prediction model(s) does this 
apply? (multiple answers possible) 
 
 Adjuvant! Online 
 MammaPrint 
 Nottingham Prognostic Index 
 Oncotype Dx 
 Other, namely: ………………………………………………………………… 
11. To which choice does this usually apply? 
 
 whether or not to give chemotherapy 
 whether or not to give endocrine therapy 
 whether or not to add chemotherapy to the endocrine treatment 
 
From interviews with oncologists we found that the prediction model Adjuvant! Online is 
predominantly used in the Netherlands. As you perhaps know, the choice of whether or not to give 




12. Which risk prediction model do you use most frequently? 
 
 Adjuvant! Online 
 MammaPrint 
 Nottingham Prognostic Index 
 Oncotype Dx 




13. For which of the treatment decisions (or considerations) below do you (sometimes) use Adjuvant!Online? 
 Never Seldom Sometimes Often Always 
Whether or not to give adjuvant 
chemotherapy?      












Whether or not to include adjuvant 












Which adjuvant chemotherapy regime 











Which adjuvant endocrine therapy (or 






































14. Below you find a few statements about the use of Adjuvant! Online. Please indicate for each statement the 
extent to which it applies to you? 
 
I currently use Adjuvant! Online: 
 
Never Seldom Sometimes Often Always 
to prepare for the consultation      
during the consultation in order to inform 
patients 
     
to inform patients if they ask for 
information about their prognosis 
     
to convince patients about the usefulness 
of the treatment plan I am proposing 
     
to convince patients that chemotherapy is 
not necessary 
     
if I think that patients can cognitively and 
emotionally deal with the prognosis 
estimates 
     
to also present the chances graphically      
to help patients to make a decision on 
whether or not to undergo chemotherapy 
     
 
Will you indicate the extent to which you think Adjuvant! Online influences the patient’s therapy preference? 
Adjuvant! Online influences patients in 
their preference of whether or not to 












Will you indicate how often the situations below occur in clinical practice?  
A patient who according to the guideline is eligible to receive chemotherapy: 
Wants to undergo chemotherapy, but after 
looking at Adjuvant! Online she does not 











does not want to undergo chemotherapy, 
but after looking at Adjuvant! Online she 

















15. The estimates from Adjuvant! Online can be helpful when communicating prognosis to patients. But, how do 
you determine which patients you do or do not show the estimates from Adjuvant! Online to? Below you find a 
few statements from clinicians about this.  
Please indicate for each statement the extent to which you are in agreement? 
 







nor agree Agree 
Totally 
Agree 
always show them, unless patients 
absolutely do not want this       
offer them to patients and show 
Adjuvant! Online depending on whether 
the patient wants to know or not      
always show them if patients ask about 
prognosis  
      
not show them if they are too hard to 
hear      
not show them, they are better off using 
verbal labels (e.g. possible, probable, 
seldom) to explain prognosis 
 
     
always show younger breast cancer 
patients (younger than 50 years old), 
because these figures are most 
informative for them 
     
not show them, it is too difficult for 
patients 
      
not show them, because the majority of 
patients get hung up on the numbers      
only show them to the higher educated 
patients, because they can at least 




The questions below refer specifically to the prognostic factors upon which Adjuvant! Online bases its estimates. 
 
16. In your opinion, does Adjuvant! Online include all the important prognostic factors? 
 
 Yes 





17. Almost all the prognostic factors in Adjuvant! Online are split into categories. Are the categories used, in your 
opinion, clinically relevant categories? 
 
 Yes 
 No, the following prognostic factors and/or category segments are not relevant,  






18. How do you fill in the variable about comorbidity? 
 
 I always let the variable about comorbidity remain on the default setting (i.e. minor  
      problems)  
 Patients with severe comorbidity are not referred for adjuvant systemic therapy,  
      therefore the variable on morbidity is not relevant.  
 
Unless the patient has severe comorbidity, whereby I need to estimate for myself into which category she best 
fits, I always set the comorbidity variable on: 
 
 Perfect health 
 Minor problems 
 Average for age 
 
 
The questions below refer specifically to the output from Adjuvant! Online. 
 
19. Which results do you usually look at? 
 
 Mortality estimates 
 Relapse estimates 
  Both 
 
20. If you do not usually look at the relapse estimates, for what reason(s) don’t you look at the output?  
 
 I am not convinced of the accuracy of the relapse estimates 
 By adjuvant systemic treatment the mortality estimates are the most relevant 
 Other, namely: ……………………………………………………………………………………………………………………………………………   
 
21. Which output do you let patients see? 
 
 I don’t show the output 
 Mortality estimates (usually) 
 Relapse estimates (usually) 
 Both (usually) 
 
22. Do you give out a printout of the Adjuvant! Online output? 
 
 No, never   
 Yes, if the patient asks for it 
 Yes, if I think the patient is interested in it   
 Yes, I always ask patients if they would like to take it with them  








For some patients it can be difficult to understand risk information. How can you  actually check if the patient has 
understood the information out of Adjuvant! Online during the consultation? Is it necessary to check patient 
understanding? 
 
23. During the consultation my method of determining whether the patient has understood the information 
is: 
 
        ……………………………………………………………………………………………………………………………………………………………… 
        ……………………………………………………………………………………………………………………………………………………………… 
 
 
24. Below you find a few statements from clinicians about checking patient understanding. Please indicate 




25. In your opinion, does using Adjuvant! Online make it easier for patients to understand the information 
about prognosis? 
 
 No, it does not become easier with Adjuvant! Online  
 It does not become easier for patients to understand the information, but it is  
         easier for the clinician to clearly present the information 
 Yes, Adjuvant! Online usually makes it easier for the patient to understand  
         the information about prognosis 
 Other, namely: ……………………………………………………………………………………………………………………………… 
 
Risk prediction models, such as Adjuvant! Online, quantify the chance of a recurrence and of survival. On 
the one hand, this can give more insight into the prognosis of an individual patient. However, these are 
estimates surrounded a confidence interval. Adjuvant! Online, for example, does not report the confidence 
intervals around its estimates.  
 
 
26. Would you personally want to know the confidence intervals around the estimates from Adjuvant! 
Online? 
 
Checking whether patients have understood the information from Adjuvant! Online: 
 Completely 
disagree Disagree Neutral Agree 
Completely 
agree 
is not necessary, because I only show 
Adjuvant! Online if I think she will 
understand the information 
 
     
is not necessary if I take the time to 
explain everything to her  
 
     
is not necessary, because if she 
doesn’t ask questions then it is clear  
 
     
cannot be done, clinicians can tell 
whether a patient has understood the 
information 
 
     
I do it by asking her if she has 
understood everything 
 
     
I do it by asking her to repeat the 
information in her own words  
      
  No, it is of no added value to me because we do not currently have better  
     estimates anyway  
  No, I know that it involves estimates. How wide the confidence intervals are is  
     not important 
  No, the recommendations in the national breast cancer guideline are based on  
     this, therefore I assume that the estimates are accurate (enough)  
  Yes, then I can determine how much I can rely upon Adjuvant! Online’s  
     estimates  
  Yes, that is important to know because the recommendations in the national    
     breast cancer guideline are based on this 
  Other, namely:…………………………………………………………………………………………………………………………………… 
 
 
27. Supposing Adjuvant! Online would indeed provide the confidence intervals around its estimates. Would 
you show this to patients? 
 
 No, absolutely not. That is too complex for most patients     
 Sometimes, if I think that patients could understand it 
 Yes, along with my explanation most patients could understand this 
 Other, namely:………………………………………………………………………………………………………………………………. 
 
 
Regardless of whether you use a risk prediction model or not: 
28. If you communicate prognosis estimates to the patient, do you talk about the uncertainty around these 
estimates?  
 
 Never              Go to question 30 
 Sometimes 




29. You indicated that you (sometimes) discuss the uncertainty around the prognosis estimates with your 
patients. Can you briefly indicate below how you explain this?  
I then say: ………………………………………………………………………………………………..……………………………………………… 
 
 
Each doctor has his/her own preference when it comes to making treatment decisions, and everyone has 
their own way of dealing with the uncertainty which comes with patient care. We would really like to know 
your thoughts about this. With the following two questions, we gain further insight into how you prefer to make 
decisions and how you deal with uncertainty. 
 
30. After being informed about their illness and the possible treatment, some patients prefer to let the doctor 
make the treatment decision, others would prefer to jointly decide. Which statement best fits your ideal? 
 
 The doctor should decide based on everything that is known about the treatments  
 
 The doctor should decide, but also seriously take the patient’s opinion into account  
 
 The doctor and the patient should decide together, as equals  
 
 The patient should decide, but also seriously take the doctor’s opinion into account 
 
 The patient should decide based upon everything that the patient knows or has  
        heard about the treatments 
 
 
31. Will you indicate for the questions below the extent to which you are in agreement? 
 
 Disagree Agree 
 Strongly  moderately  slightly  slightly  moderately  strongly  
When physicians are uncertain of a 
diagnosis, they should share this 
information with their patients. 
      
I always share my uncertainty with my 
patients        
If I shared all of my uncertainties with my 
patients, they would lose confidence in 
me  
      
Sharing my uncertainty improves my 
relationship with my patients       
I prefer patients not know  when I am 















Your answers will be analyzed anonymously. For the research it is important to have insight into the 
characteristics of the participants. Therefore, we ask you to fill in the questions below. 
 
32. In which region do you practice? 
 
 Regio North (i.e. Groningen, Friesland, Drenthe) 
 Regio East (i.e. Gelderland, Overijssel, Flevoland) 
 Regio West (i.e. Noord-Holland, Zuid-Holland, Utrecht) 
 Regio South (i.e. Zeeland, Brabant, Limburg) 
 I prefer not to disclose this 
 
 






34. What is your age?  ……………years 
 
 
35. In what type of hospital do you work? 
 
 General hospital (non-teaching) 
 General hospital (teaching) 
 University medical center 
 Specialized oncology center 
 Other, namely ………………………………………………………………  
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Adjuvant systemic therapy for early-stage breast cancer may improve survival, but has 
side-effects impacting patients’ quality of life. Knowing the magnitude of treatment 
benefits can facilitate oncologists’ and patients’ decision-making. Prediction tools such 
as Adjuvant! may help, but little is known about their use and the implications thereof. We 
assessed a) the prevalence and determinants of Adjuvant! use, b) information provision 
about treatment benefits and side-effects overall and by Adjuvant! use, and c) whether 
Adjuvant! use is associated with the likelihood of reaching a decision. 
Methods
We audiotaped consecutive patient consultations about adjuvant systemic therapy. We 
assessed prevalence of Adjuvant! use in the whole sample (N=287), and determinants 
of use in N=217, excluding consultations by oncologists who always or never used 
Adjuvant!. We assessed differences in information provision and decision-making in a 
random subset of consultations with and without Adjuvant! (N=211).
Findings 
The oncologists used Adjuvant! prior to 70% of consultations, and also or only during 
67% of consultations. Use was less likely the higher the disease stage (P=0.002) and the 
older the oncologist (P=0.03). Relapse reduction probabilities were the most frequently 
communicated treatment benefit (96%). In 39/214 (18%) consultations it was unclear 
to what outcome communicated probabilities related. Generally, fewer side-effects 
were communicated for endocrine therapy (Md.=4 (range: 0-9) than for chemotherapy 
(Md.=7 (range: 1-13), irrespective of Adjuvant! use. Communication about side-effects 
was generally inconsistent. Decision-making was more often postponed if Adjuvant! 
was used (P=0.005).
Conclusion
Adjuvant! was frequently used during consultations with patients, however, its prob-
abilities were not always clearly communicated. Also, there was great disparity in 
information provision about side-effects. Critical assessment of prediction model use 
in risk communication and guidance on information provision about side-effects are 
needed to ensure clear and balanced information in treatment decision making. 
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Introduction
Decisions about adjuvant systemic treatment for stage I-III breast cancer are often 
not straightforward given the impact that side-effects (e.g., alopecia, nausea, loss of 
appetite, fatigue and neuropathy) can have on patients’ short- and long-term quality 
of life (1-4). Current clinical guidelines generally endorse discussing adjuvant systemic 
treatment with early-stage breast cancer patients if the expected absolute survival 
gain is minimally 3-5% (5-7). This also implies that roughly 9 out of 10 patients treated 
either undergo treatment without gain or die in spite of treatment. There generally is 
no ‘best’ treatment option in this setting, thus, treatment decisions need to be guided 
by patients’ informed preferences. 
When weighing the benefits of treatment against its harms, it is helpful to know the 
magnitude of the expected treatment benefit. Prediction tools have been developed 
for this purpose, such as Adjuvant! and PREDICT. Adjuvant! was the most often used 
tool in the Netherlands before being taken offline by the end of 2015 for updates (8). 
It quantifies 10-year recurrence and mortality probabilities with and without adjuvant 
systemic treatment (9,10). Clinical guidelines recommend using Adjuvant! to support 
clinicians in obtaining personalized prognostic information for their patients (5-7). 
Small self-report surveys amongst oncologists suggest that Adjuvant! is regularly used 
during consultations with patients (8,11,12). Three-quarters of oncologists indicated 
in a survey that they felt that using Adjuvant! during consultations helps patients to 
better understand their prognosis (8). Available studies reported though that fewer than 
half of the patients provided with prognostic estimates from Adjuvant! were able to 
comprehensibly articulate their prognosis after the consultation (13,14). 
Unfortunately, evidence on whether and how Adjuvant! use influences information 
provision during real-time consultations is lacking. Yet, the use of Adjuvant! may have 
several important implications. For example, Adjuvant! only provides probabilities 
of the potential benefits of treatment, it does not incorporate information about nor 
probabilities of the potential side-effects. Adjuvant! use during consultations could 
therefore shift the focus of the consultation towards discussing prognosis with and 
without treatment, at the expense of discussing treatment side-effects. Effective 
communication about side-effects may be further complicated by a lack of guidance 
as to which side-effects of adjuvant systemic therapy for breast cancer minimally 
need to be communicated to patients. Available evidence suggests that Adjuvant! not 
only influences oncologists’ treatment recommendations, but also patients’ treatment 
preferences (15,16). If the information provision about benefits and side-effects is 
unbalanced, the potential treatment benefits (i.e., relapse probability reduction and 
mortality reduction) may primarily drive patients’ treatment preferences and ultimately 
decision-making, rather than a trade-off between the benefits and side-effects (17). 
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This may simplify decision-making, but it calls into question the informed nature of 
the decision. Receiving information about treatment benefit and harms might make 
patients aware that there is no obvious choice, and that undergoing therapy does not 
guarantee a good outcome. 
The aim of the current study was to provide insight in information provision about the 
benefits and harms of adjuvant systemic therapy for breast cancer during patient consul-
tations, and the impact of Adjuvant! use on information provision and decision-making 
during these consultations. We specifically investigated 1) the prevalence, and 2) deter-
minants of Adjuvant! use in clinical practice, 3) information provision about treatment 
benefits and side-effects overall and by Adjuvant! use, and 4) whether Adjuvant! use 
influenced the likelihood of reaching a decision.
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Breast cancer patients with stage I-III disease from 7 outpatient clinics were invited to 
participate if they a) did not have a prior history of cancer for which they had received 
systemic therapy, b) were eligible to receive adjuvant systemic chemotherapy and/or 
endocrine therapy, and c) were fluent in Dutch. Patients were recruited between July 
2012 and February 2015. Medical ethics boards of the participating hospitals approved 
the study protocol.
Procedures and measures
The procedure was as follows: (1) consultations were audiotaped after obtaining 
informed consent from patients, (2) after each consultation oncologists completed a 
checklist, and (3) patients completed a survey, (4) after the recruitment ended oncolo-
gists completed a survey, and (5) additional tumor and treatment characteristics were 
collected from the medical charts, with patients’ consent. 
Half of the consultations were transcribed verbatim, the remaining were coded directly 
from audio. Due to time constraints, it proved impossible to transcribe all consultations. 
To ensure the reliability of coding directly from audio, each coder coded a sample of 
consultations (N=13-16) that had already been coded from transcript, minimally three 
months after the original coding. The agreement between coding from audio and tran-
scripts was high (81% and 83%, respectively; kappa for all items ≥0.6). Consultations 
were double-coded by 2 trained research assistants until an inter-rater kappa of mini-
mally 0.6 was reached for all items, then one research assistant performed final coding.
Below we describe per research question (RQ) in detail which data was collected in 
each of the steps described above.
RQ1: Frequency and mode of use of Adjuvant!
After each consultation, oncologists indicated whether Adjuvant! had been used during 
the consultation (no/yes), and if so, when (prior to/during the consultation/both prior 
and during). Further, if oncologists had used Adjuvant! during the consultation, we 
asked how they had used the model (only providing the prognostic information orally/
orally and visually (via the computer screen and/or a printout of Adjuvant!’s output)).
148
Chapter 6 












Average age in years (range) 59 (32-90) 58 (33-90) 59 (35-90)
Education level    
Low 44 (19.5) 27 (15.7) 31 (18.2)
Intermediate 114 (50.4) 92 (53.5) 83 (48.8)
High 68 (30.1) 53 (30.8) 56 (32.9)
Unknown 61 45 41
Numeracy level    
Low 51 (22.4) 35 (20.1) 39 (22.7)
Intermediate 59 (25.9) 45 (25.9) 45 (26.2)
High 118 (51.8) 94 (54.0) 88 (51.2)
Unknown 59 43 39
Tumor characteristics
TNM stage    
Stage I 127 (44.6)  96 (44.4)  92 (44.0)
Stage II 141 (49.5) 107 (49.5) 104 (49.8)
Stage III 17 (6.0) 13 (6.0)  13 (6.2)
Unknown 2 1 2
Consultation characteristics
Median duration in minutes (range) 27 (6-80) 26 (6-80) 28 (6-80)
Treatment discussed    
Chemotherapy only 35 (12.2) 24 (11.1) 28 (13.3)
Endocrine therapy only 35 (12.2) 23 (10.6) 23 (10.9)
Chemotherapy & endocrine therapy 217 (75.6) 170 (78.3) 160 (75.8)
Use of Adjuvant! during consultation    
Not used 96 (33.4) 57 (26.3)  92 (43.6)
Used 191 (66.6) 160 (73.7) 119 (56.4)
*In the determinants sample we only included consultations by oncologists who: a) had included at least 
five patients to the study population, and b) did not always or never use Adjuvant! during the consultation.
# In the information provision sample we included a random sample of all consultations consisting of 
approximately an equal number of consultations with and without Adjuvant!.
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Table 1 continued Characteristics of whole study population and subsets used in analyses (N (%))
Oncologist characteristics
Number of oncologists 30 24 28
Median number of patients included 6 (1-40) 5 (1-39) 4 (1-30)
Average age in years (range) 46 (30-66) 41 (30-66) 41 (30-66)
Gender    
Male 13 (43.3) 10 (41.7) 12 (42.9)
Female 17 (56.7) 14 (58.3) 16 (57.1)
Experience treating breast cancer    
Less than 5 years 11 (50.0) 9 (47.4) 10 (47.6)
Between 5-10 years 2 (9.1) 2 (10.5) 2 (9.5)
More than 10 years  9 (40.9) 8 (42.1) 9 (42.9)
Unknown 9 5 7
Type of hospital    
Academic 16 (53.3)  12 (50.0)  14 (50.0)
General teaching 14 (46.7)  12 (50.0)  14 (50.0)
*In the determinants sample we only included consultations by oncologists who: a) had included at least 
five patients to the study population, and b) did not always or never use Adjuvant! during the consultation.
# In the information provision sample we included a random sample of all consultations consisting of 
approximately an equal number of consultations with and without Adjuvant!.
If the checklist was missing, we used the audiotapes of the consultation to determine 
use of Adjuvant! (yes/no/unclear). Use of Adjuvant! was coded as ‘Yes’ if: a) prognos-
tic probabilities from Adjuvant! were discussed during the consultation irrespective 
of whether Adjuvant!’s output was shown to patients, or b) Adjuvant!’s output was 
used to graphically illustrate the potential treatment effect, irrespective of whether the 
oncologist mentioned the probabilities. 
RQ2: Determinants of Adjuvant! use
The potential determinants assessed were characteristics of a) the patient (age, educa-
tion level, numeracy, and preference to receive prognostic probabilities), b) the disease 
(TNM stage, grade, estrogen receptor (ER) status, triple negative disease and/or Her2 
status), and c) the oncologist (age, level of experience, type of hospital). If oncologists 
asked patients whether they wanted to receive prognostic probabilities, we coded 
patients’ response to this question (yes/no/patient did not respond). If only a companion 
indicated an opinion, this was taken as the patients’ opinion if she did not contradict it. 
After the consultation patients completed a survey covering, first, their education level 
(low (i.e., up to lower vocational education)/medium (i.e., up to secondary vocational 
education)/high (i.e., university of applied sciences and higher)). Secondly, their objec-
tive numeracy, i.e., their ability to understand and use numbers, was assessed using 
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the seven expanded numeracy items proposed by Lipkus et al.(18) Scores (range: 0-7) 
were divided into three categories (low numeracy= 0-2; intermediate numeracy= 3-5; 
high numeracy= 6-7). We assessed oncologists’ socio-demographic characteristics in 
a short survey disseminated after the patient recruitment period closed (age, number 
of years of experience with treating breast cancer patients (<5 years/6-10 years/ >10 
years) and type of hospital (general teaching/academic medical center)). Patient charts 
were examined to obtain tumor size (in cm), number of axillary lymph nodes, ER status 
and tumor grade. Tumor size and nodal status were used to determine TNM stage 
according to the American Joint Committee on Cancer definition, 7th edition (19).
RQ3: Communication of benefits and side-effects of treatment overall and by use of 
Adjuvant! 
From the consultations we extracted data on: a) which disease outcomes (mortality/
relapse probability reduction) were discussed, b) whether benefit discussion included 
explicit disclosure of probabilities (yes/no), c) whether side-effects were communicated 
(yes/no), d) which side-effects were communicated, and e) comprehensiveness of the 
description of the side-effects (side-effect only mentioned (basic)/side-effect mentioned 
including information on the course of the symptoms/side-effect mentioned including 
the probability of occurrence).
RQ4: Association between use of Adjuvant! and decision-making
From all consultations, we extracted data on whether a treatment decision was made 
(made/postponed/made for only one of the treatments discussed in case both chemo-
therapy and endocrine therapy had been discussed), and what was decided (forego/
undergo/treatment postponed).
Statistical analyses
The participation rate was 358 out of 500 (72%) patients. Patient consultations were 
excluded if the audiotaping had failed (N=71/358 (20%)). This resulted in a sample 
of 287 consultations for analysis (see Figure 1 for a flowchart). Descriptive analyses 
were performed and we assessed the prevalence of Adjuvant! use in the whole sample 
(N=287) (RQ1). To determine whether and which patient, oncologist and disease charac-
teristics influenced the use of Adjuvant! during consultations, we selected consultations 
by oncologists who had included minimally five patients into the study population and 
who did not always or never use Adjuvant! during the consultation (N=217) (RQ2). The 
association between the use of Adjuvant! and the determinants was assessed using 
χ² tests or Fisher’s Exact Test, as appropriate. 
The assessment of information provision about treatment benefits and side-effects 
(RQ3), and of whether a decision had been reached during the consultation (RQ4) 
required more extensive content analyses of the consultations. For reasons of feasibility 
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we used a random subset of approximately equal number of consultations with (N= 
92) and without (N= 119) Adjuvant!. Differences in information provision are depicted 
graphically. The association between use of Adjuvant! and decision-making was 
assessed using a χ² test or Fisher’s Exact Test as appropriate. Analyses were performed 
in SPSS 20. Significance testing was done two-sided at α=0.05. 




Thirty oncologists (mean age: 46 years (range: 30-66 years)) included a median of 6 
(range: 1-40) patients (Table 1). Patients (n= 287) were on average 59 years (range: 32-90 
years), and they mostly had stage I (45%) or stage II (50%) disease. In three-quarters 
of the consultations both chemotherapy and endocrine therapy were discussed. 
RQ1: Frequency and mode of use of Adjuvant!
Oncologists indicated in 70% of consultations that they had consulted Adjuvant! prior 
to the consultation. Oncologists with >10 years experience consulted Adjuvant! sig-
nificantly less often prior to the consultation than those with ≤10 years experience 
(53% vs. 96% (P<0.001)). Adjuvant! was used during 191 (67%) of the patient consul-
tations. In 74% of these 191 consultations, Adjuvant! was also reported to have been 
visually displayed either on the computer screen and/or using a printout of its output. 
If Adjuvant! was consulted prior to the consultation, it was subsequently used in 84% 
of those consultations.
RQ2: Determinants of Adjuvant! use during the consultation
Experienced oncologists used the model less frequently in the consultation than their 
less experienced counterparts (P= 0.03, (Table 2)). The higher the patient’s TNM stage, 
the less frequently Adjuvant! was used during the consultation (P= 0.002). No other 
patient, oncologist, or disease characteristics were associated with Adjuvant! use.
RQ3: Information provision about treatment benefits and side-effects of treatment 
by use of Adjuvant! and by treatment
Communication about benefits 
Figure 2 shows which benefits were presented during the consultations, by use of 
Adjuvant! and by treatment. In 183 of the 188 (97%) consultations in which chemotherapy 
was discussed, at least one benefit of chemotherapy was mentioned. In the remaining 
3% of chemotherapy consultations patients could only assume a treatment benefit. 
In 96% of chemotherapy consultations relapse probability reduction was presented, 
and in 26% mortality reduction was (also) presented. If Adjuvant! was used, mortality 
reduction was discussed more often than if Adjuvant! was not used (P<0.001).
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Age   
 0.10
younger than 50 years  17 (30)  29 (18)
50-70 years  29 (51)  105 (66)
older than 70  11 (19)  25 (16)
Education level   
 0.97
Low  7 (16) 20 (16)
Intermediate  25 (56) 67 (53)
High  13 (29) 40 (32)
Numeracy level   
 0.62
Low 11 (24) 24 (19)
Intermediate 12 (27) 33 (26)
High 22 (49) 72 (56)
Preference for hearing survival probabilities   
 <0.001does not want probabilities 20 (91)  4 (8)
wants probabilities 2 (9) 49 (93)
Disease characteristics
TNM stage   
 0.002Stage I 15 (26) 81 (51)
Stage II/III 42 (74) 78 (49)
Grade   
 0.97
Grade 1  6 (11) 17 (11)
Grade 2 30 (55) 83 (53)
Grade 3 19 (35) 57 (36)
ER status   
0.48 ER negative  5 (9)  22 (14)
ER positive 52 (91) 137 (86)
Triple negative   
 0.76Not triple negative 53 (95) 147 (93)
Triple negative  3 (5)  12 (8)
*Numbers do not always add up to column totals due to missing data.
#P-values from χ² tests or Fisher’s Exact Tests (as appropriate). 
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Her2neu status   
0.65Negative 46 (84) 138 (87)
Positive  9 (16)  21 (13)
Consultation characteristics
Treatment discussed   
0.11 
Chemotherapy only  4 (7) 20 (13)
Endocrine therapy only 10 (18) 13 (8)
Chemotherapy & endocrine therapy 43 (75) 127 (79)
Oncologist characteristics
Gender
0.13Male 23 (40) 84 (53)
Female  34 (60) 76 (48)
Experience treating breast cancer
0.03
Less than 5 years  12 (22) 58 (38)
5-10 years  2 (4) 13 (9)
More than 10 years  41 (75) 81 (53)
Type of hospital
0.60Academic 44 (77) 117 (73)
General teaching 13 (23)  43 (27)
*Numbers do not always add up to column totals due to missing data.
#P-values from χ² tests or Fisher’s Exact Tests (as appropriate). 
In 173 of the 183 (95%) endocrine therapy consultations, the treatment benefit was 
discussed. In the remaining 5% patients could only assume a treatment benefit. In 92% 
of consultations in which endocrine therapy was discussed, relapse reduction was 
mentioned, and in 26% mortality reduction was (also) mentioned. Mortality reduction 
was also discussed more often if Adjuvant! was used than if not (P<0.001). 
Probabilities regarding benefits were discussed in 189/191 (99%) consultations in 
which Adjuvant! was used and in 25/92 (27%) consultations in which Adjuvant! was 
not used. In two consultations Adjuvant! was only used as a ‘visual aid’ to indicate that 
relapse-free or breast cancer-specific survival improved with treatment. On average 
4.6 (range: 0-12) probabilities were discussed when Adjuvant! was used, compared to 
0.6 (range: 0-5) when Adjuvant! was not used. In 18% (39/214) of all consultations in 
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which probabilities were discussed (irrespective of Adjuvant! use) we were unable to 
classify the probabilities communicated. The oncologists’ explanation –or lack thereof– 
made it impossible to determine whether the probabilities mentioned were survival or 
disease-free survival estimates. 
Communication about treatment side-effects 
Overall, 59 different chemotherapy and 43 different endocrine therapy side-effects were 
communicated during the consultations. Of these side-effects 66% (chemotherapy) and 
79% (endocrine therapy) respectively were mentioned in fewer than five consultations. In 
Figures 3 and 4 we provide an overview of the side-effects that were communicated in 
at least ten consultations. There was no difference in the overall number of side-effects 
communicated by Adjuvant! use (Adjuvant! used, Md=6.0 (range: 1-13) vs. Adjuvant! 
not used, Md=6.5 (range: 1-15); P= 0.76). The overall number of side-effects communi-
cated depended mostly on which treatment was discussed. If only chemotherapy was 
discussed, a median of 7 (range: 1-13) side-effects were mentioned, if only endocrine 
therapy was discussed a median of 4 (range: 0-9) side-effects were mentioned. If both 
treatments were discussed, a median of 6 (range: 1-12) chemotherapy and 1 (range: 
0-9) endocrine therapy side-effects were discussed.
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Percentages if Adjuvant! was notused are based on N= 77 chemotherapy and N= 80 endocrine 
therapy consultations.
Percentages if Adjuvant! was used are based on N= 111 chemotherapy and N= 103 endocrine 
therapy consultations.
Figure 2 Frequency with which the various treatment benefits are discussed by Adjuvant! use
There also was a wide variation within and between oncologists in the number of 
side-effects they communicated (Figure 5). The frequency with which specific side-
effects were communicated differed by Adjuvant! use (Figures 3 and 4). There was 
no discernable pattern to the difference in which side-effects were communicated 
by Adjuvant! use. The comprehensiveness of the description of chemotherapy and 
endocrine therapy side-effects was basic in the majority of consultations, irrespective 
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of Adjuvant! use, and consisted only of mentioning the side effect. The probability of 
developing a side-effect was rarely discussed.
Percentages based on N=77 consultations without Adjuvant! and N=111 consultations with 
Adjuvant!. 
Only side-effects communicated in ≥10 consultations were incorporated in the figure.
Figure 3 Overview of chemotherapy side-effects communicated by Adjuvant! use
RQ4: Association between use of Adjuvant! and decision-making
A decision was made for all treatments discussed in 162 out of 211 (77%) consultations, 
the decision was postponed in 21 (10%) consultations, and in 26 (12%) consultations 
a decision was made concerning only one of the treatment options discussed. For two 
consultations, it was unclear whether or not a decision had been made. 
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When Adjuvant! was used, decisions were postponed more often (36/118 (31%); Adju-
vant! not used= 11/91 (12%); P= 0.005). For chemotherapy, overall the decision was 
postponed in 39/187 (21%) consultations, and in 30 out of those 39 (70%) consultations, 
Adjuvant! had been used (P<0.001). Also, in 48/187 (26%) consultations the decision 
was made to forego chemotherapy, and in 34 (71%) of those 48 consultations Adjuvant! 
had been used. For endocrine therapy, overall the decision was postponed in 21/178 
(12%) consultations, and in 17 (81%) of those 21 consultations Adjuvant! had been 
used (P= 0.01). Also, in 6/178 (3%) consultations the decision was made to forego 
endocrine therapy, and in 5 of those 6 consultations Adjuvant! was used. 
Percentages based on N=80 consultations without Adjuvant! and N=103 consultations with 
Adjuvant!. 
Only side-effects communicated in ≥10 consultations were incorporated in the figure.
Figure 4 Overview of endocrine therapy side-effects communicated by Adjuvant! use
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Discussion
In the current study we evaluated the frequency and determinants of use of Adjuvant!. 
We also assessed information provision about the benefits and side-effects of adjuvant 
systemic treatment, and whether information provision and the likelihood of reaching 
a decision during the consultation differed by the use of Adjuvant!. 
The oncologists in the current study consulted Adjuvant! prior to 7 out of 10 consulta-
tions, and Adjuvant!’s estimates were discussed during 2 out of 3 consultations. This is in 
line with findings from surveys amongst oncologists about how often they use Adjuvant! 
(8), and suggests that communicating survival probabilities during consultations with 
patients is becoming the norm. Less experienced oncologists were more likely to use 
Adjuvant! both prior to and during consultations. This is likely a generation effect, with 
younger oncologists being more computer-savvy, but also more open to discussing 
prognosis than older oncologists. Not surprisingly, the higher the disease stage, the less 
likely it was that Adjuvant! would be used during the consultation. Oncologists might 
be hesitant to cause anxiety in patients, to demotivate them for treatment, or cause 
them to lose hope by communicating modest survival probabilities. Communicating 
good survival, on the other hand, might be seen by oncologists as a way to comfort 
and reassure their patients that no matter what they choose to do, their prospects are 
good. In a recent survey, three out of four oncologists indicated that they used Adjuvant! 
to convince patients that chemotherapy is not necessary (8), especially so for patients 
with stage I disease. This could also partly explain why Adjuvant! is used more often 
when prognosis is better. We found that chemotherapy was waived more often than 
endocrine therapy, especially if Adjuvant! had been used.
Interestingly, we found that regardless of Adjuvant! use, the reduction in relapse proba-
bility was the treatment benefit that oncologists most often discussed (>90%); mortality 
probabilities were rarely discussed (<5%), although more so if Adjuvant! was used during 
the consultation. The high frequency of discussing reduction in relapse probability 
contradicts the findings of an earlier study showing that oncologists valued Adjuvant!’s 
mortality probabilities more, because they had concerns about the robustness of the 
relapse estimates (8). Indeed, Adjuvant!’s relapse estimates have been shown to be 
less sound than its mortality estimates (20-22). Perhaps our oncologists were not aware 
of this limitation of Adjuvant!, but it seems more likely that they chose to discuss the 
relapse probabilities because the effect of treatment on relapse is larger than that on 
mortality. If treatment is an obvious ‘best’ choice from a medical perspective, such 
implicit persuasion need not be harmful. However, given that for the majority (>90%) 
of patients in this study there is no ‘best’ option, such steering could have unwanted 
effects (17). Remarkable was that in about one in five consultations we were unable to 
determine whether the probabilities communicated were overall or disease-free sur-
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vival probabilities. Unclear risk communication undermines oncologists’ intent to help 
patients to better understand their prognosis (8). These are disconcerting findings that 
require further in-depth investigation. If confirmed, it underlines the need for increased 
attention for risk communication in pre- and post-graduate curricula to provide clinicians 
with the tools to better convey prognosis to their patients.
Figure 5 Frequency with which the various treatment benefits are discussed by Adjuvant! use
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The use of Adjuvant! does not seem to drive the overall number of side-effects communi-
cated during consultations, but we did find that the specific side-effects communicated 
varied by Adjuvant! use. One could perhaps think that if Adjuvant! is used to convince 
patients not to undergo chemotherapy, oncologists might be more inclined to communi-
cate the more severe treatment side-effects, and if the aim is to convince patients about 
the merits of treatment the more severe side-effects would be omitted. However, such 
pattern was not identified. No single side-effect of either chemotherapy or endocrine 
therapy was communicated in all consultations. Apparently, there is no consensus with 
regards to which side-effects minimally need to be communicated to patients. Indeed, 
current clinical guidelines do not provide guidance about which side-effects must be 
communicated (5-7). Moreover, oncologists mostly only mentioned the side-effect, 
without further information on the probability of experiencing the side-effect, its impli-
cations for daily life, or its course over time. These findings are worrying, as patients 
also need to be appropriately informed about what the side-effects of treatment entail to 
be able to decide whether or not the benefits outweigh the side-effects. In our sample, 
oncologists regularly indicated that the breast cancer nurse or nurse practitioner would 
elaborate further on the side-effects (data not shown). This is not a mitigating factor, 
since in three out of four consultations the treatment decision was made during the 
consultation. Patients should be informed at that point in time about both the benefits 
and the side-effects of treatment. Remarkably, in five chemotherapy and nine endo-
crine therapy consultations, no treatment benefit was explicitly communicated, it had 
to be inferred. Nonetheless, in all but two of these 14 consultations, it was decided to 
initiate therapy. If patients are ill-informed about the potential benefits and side-effects 
their expectations might be unrealistic, which can lead to decisional regret and greater 
treatment discontinuation rates. For endocrine therapy, high discontinuation rates have 
been reported (23). Also, patients may receive treatment they might not have chosen 
had they been able to appropriately weigh side-effects and benefits, in a process of 
shared decision making. 
Interestingly, decision-making was postponed more often when Adjuvant! was used, 
particularly in patients with stage I disease (data not shown). Perhaps hearing the 
survival probabilities from Adjuvant! makes patients realize that the treatment benefits 
are only modest. Patients might therefore need more time to consider whether they 
feel the benefits outweigh the side-effects. 
A limitation of our study is its descriptive nature. Oncologists were not randomized to 
the use of Adjuvant! and therefore results may have been confounded by specifics of 
the oncologists or the particular patient. It is important to keep in mind that although 
we explicitly instructed oncologists to conduct their consultations as they normally 
would, the study might have influenced their use of Adjuvant!. We therefore asked 
oncologists in the post-study survey whether their use of Adjuvant! had changed during 
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the study period. Only two oncologists indicated to have used Adjuvant! more often 
than before our study.
This is the first study to assess the use of Adjuvant! during real-time patient consultations, 
its influence on information provision about the benefits and side-effects of treatment, 
and decision-making. Although Adjuvant! is currently offline due to updates and it is 
unclear when it will become available again, this study serves as a model for clinical 
usage of other prediction tools in oncology (e.g., PREDICT(24) or CancerMath(25)). Our 
findings underscore the importance of obtaining more insights into the use of these tools 
in clinical practice. Their use during consultations seems to have become commonplace, 
yet, there is limited knowledge of how well their estimates are communicated, whether 
patients understand this information, and whether this type of information influences 
decision-making (26). The findings from this study suggest that there is room for 
improvement in how probabilities are communicated, as well as in which information 
about the side-effects of treatment are communicated and how. Adequate information 
provision is key if oncologists want to enable their patients to participate in decision-
making.
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Treatment decision-making is often guided by evidence-based probabilities, which 
may be presented to patients during consultations. These probabilities are intrinsically 
imperfect, and embody two types of uncertainties: aleatory uncertainty arising from the 
unpredictability of future events, and epistemic uncertainty arising from limitations in 
the reliability and accuracy of probability estimates. Risk communication experts have 
recommended disclosing uncertainty. We examined whether uncertainty was discussed 
during cancer consultations, and whether and how patients perceived uncertainty.
Methods
Consecutive patient consultations with medical oncologists discussing adjuvant treat-
ment in early-stage breast cancer were audiotaped, transcribed, and coded. Patients 
were interviewed after the consultation to gain insight into their perceptions of uncer-
tainty. 
Results
In total 198 patients were included by 27 oncologists. Uncertainty was disclosed in 
49% (97/197) of consultations. In those 97 consultations, 23 allusions to epistemic 
uncertainty were made and 84 allusions to aleatory uncertainty. Overall, the allusions 
to the precision of the probabilities were somewhat ambiguous. Interviewed patients 
mainly referred to aleatory uncertainty if not prompted about epistemic uncertainty. Even 
when specifically asked about epistemic uncertainty, one in four utterances referred 
to aleatory uncertainty. When talking about epistemic uncertainty many patients con-
tradicted themselves. In addition, one in ten patients seemed not to realize that the 
probabilities communicated during the consultation are imperfect. 
Conclusions
Uncertainty is conveyed in only half of patient consultations. When uncertainty is 
communicated, oncologists mainly refer to aleatory uncertainty. This is also the type of 
uncertainty that most patients perceive and seem comfortable discussing. Given that it is 
increasingly common for clinicians to discuss outcome probabilities with their patients, 
guidance on whether and how to best communicate uncertainty is urgently needed. 
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Introduction
Medical decision-making, whether relating to diagnostic procedures or treatment, 
should ideally be guided by evidence-based probabilities. Numerous prediction models 
have been developed to promote this goal. The individualized prognostic estimates 
these models provide facilitate better conceptualization of the trade-offs between 
benefit and harm of different treatment options. However, even evidence-based prob-
ability estimates are intrinsically imperfect. They are based on past observations and 
unavoidably limited evidence, resulting in two major types of uncertainty. First-order, 
or aleatory uncertainty, arises from the unpredictability of single events arising from the 
fundamental indeterminacy or randomness of future outcomes. Aleatory uncertainty 
is inherent to the concept of probability (we seldom speak of a probability of 1 or of 
0). Second-order, or epistemic uncertainty, arises from deficits in knowledge, due to 
limitations in a) the precision of the risk estimates or b) their applicability to a specific 
patient (1, 2). 
Risk communication experts have argued, mainly from an ethical perspective, that 
patients should be fully informed, and thus also be informed about these uncertainties 
(3). Failure to explicitly address epistemic and aleatory uncertainties may create mis-
conceptions about the level of precision and individualization of probabilities presented 
during consultations. In the absence of adequate communication of such uncertainty, 
patients may have excessive confidence in probabilities, thus (potentially) resulting in 
pseudo-certainty. 
Currently, no literature is available on the extent to which physicians communicate the 
epistemic uncertainty of prognostic estimates and the inability to predict individual 
disease outcomes. In addition, it is unknown to which extent patients understand these 
uncertainties and how these uncertainties are best communicated (3, 4). Clinicians may 
be hesitant to communicate uncertainty, fearing that such communication would make 
the information (even) more difficult for patients to comprehend, for we know that most 
people struggle to understand probabilities, irrespective of their education level (1, 5). 
For clinicians it is a challenge to find a balance between ´fully´ informing their patient, 
whilst not overwhelming them by providing too much information. 
In the current study, we investigated the communication of uncertainty in the context 
of decision-making about adjuvant systemic treatment for early-stage breast cancer. 
Stage I-III breast cancer patients undergoing adjuvant systemic treatment may expe-
rience improvement in both disease-free and cancer-specific survival (6-10). Using 
known clinical prognosticators (e.g., tumor size, nodal status and differentiation grade) 
and/or bio-molecular profiles, the likelihood of beneficial treatment outcomes can be 
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calculated, for instance using the Adjuvant! prediction model (11). The likelihoods from 
Adjuvant! are frequently discussed during consultations in the adjuvant setting (12, 13). 
In combination with estimates of treatment effect, these likelihoods improve insight on 
the balance between the potential benefits and side-effects of treatment (10, 14, 15). 
We assessed a) whether and which type of uncertainty oncologists disclosed: i.e., the 
limitations in the precision of risk estimates/their applicability to an individual patient 
and/or unpredictability of single events, and b) patients’ perceptions of the uncertainty 
associated with probabilities discussed during the consultation. 
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The current study was nested in a large multicenter observational study with a partici-
pation rate of 358/500 (72%), which assessed the communication of survival probability 
estimates calculated by the Adjuvant! prediction model (11) during consultations of 
stage I-III invasive breast cancer patients by medical oncologists. Consecutive outpa-
tient female breast cancer patients, eligible to receive chemotherapy and/or endocrine 
therapy, who were fluent in the Dutch language, were invited to participate in the cur-
rent study. We included patients if survival probabilities from the Adjuvant! prediction 
model had been discussed during the consultation (Figure 1). This was determined 
following analysis of the content of the consultations. The medical ethics boards of 
the participating hospitals approved the study.
Adjuvant! prediction model
Adjuvant! (11) is a freely available online prognostication tool that provides estimates 
of 10-year a) overall, b) breast cancer-specific, and c) disease-free mortality and d) 
benefit of adjuvant systemic treatment. The information is presented as bar charts. 
Adjuvant!’s prognostic estimates are based on patient and tumor characteristics (i.e., 
age, patient’s general health, tumor size, nodal status, estrogen receptor status and 
histological tumor grade) and type of systemic treatment. Oncologists may print the 
page to hand to the patient, or show the results on a computer screen.
Procedures 
Consultations
Prior to their consultation, patients were informed that the study aimed to investigate 
information provision during consultations concerning adjuvant systemic therapy. The 
concept of uncertainty was not introduced. Oncologists were instructed to conduct 
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Patient interviews 
Uncertainty was addressed in two types of interviews, 1) ‘Standard’ and 2) ‘In-depth’ 
interviews. The standard interview was a component of the main study. Patients were 
interviewed by telephone within seven days of their consultation (mean=3.4 days). The 
interviewer had no knowledge of what had been discussed during the consultation prior 
to this interview. Given the extensive character of the interview of the main study, we 
chose to only probe about epistemic uncertainty, since this is particularly relevant in 
the context of risk communication using probabilities from prediction models. To begin 
with, we asked patients whether the oncologist had discussed probabilities during the 
consultation. If patients indicated that this was the case, we asked them to list the 
probabilities discussed. Next, we posed two probes on uncertainty. First, we posed an 
‘Open probe’: “What do the probabilities [repeat probabilities the patient has already 
mentioned] mean to you?”. Second, we posed a ‘Precision probe’: “In your opinion, 
are the probabilities you were provided with during the consultation [repeat probabilities 
the patient has already mentioned] exact survival probabilities… [pause] or could they 
be higher or lower for example”. 
As probing turned out to be a challenge, not only practically but also ethically, with 
limited time, we could not elaborate on uncertainty during the standard interviews. 
Therefore, we decided to conduct additional in-depth interviews solely dedicated 
to uncertainty in a subset of patients not previously interviewed. Thus, we hoped to 
achieve a more comprehensive exploration of the patients’ awareness of and views on 
epistemic uncertainty (consisting of the imprecision of risk estimates and their appli-
cability to an individual patient), and the unpredictability of single events (i.e. aleatory 
uncertainty). We extended the inclusion period of the main study to recruit patients for 
these latter interviews. Expecting to need at least 15 interviews to reach saturation, we 
approached 15 consecutive patients not previously interviewed with whom probabilities 
had been discussed during the consultation. We conducted the in-depth interview only 
if patients indicated that probabilities had been discussed, irrespective of whether this 
had indeed been the case (according to the audiotapes). After 12 in-depth interviews, 
no new themes had emerged. Consequently, we ended inclusion and completed three 
already scheduled interviews.
On average, in-depth interviews took place within four days of the consultation (range: 
0-12 days), either in person (N=10) or, by telephone if preferred (N=5). We recruited 
and informed patients in the same way about the study as the patients of the standard 
interviews. First, we used an ‘Open probe’ not introducing the concept of uncertainty, 
to assess whether patients spontaneously referred to the uncertainty associated with 
the probabilities. Thereafter, we probed patients’ perception of the uncertainty asso-
ciated with the survival probabilities discussed during the consultation. We also asked 
patients whether - to the best of their recollection - uncertainty had been discussed 
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during the consultation and whether they thought it important to hear about such 
uncertainty during the consultation (see Appendix A for the probes on uncertainty used 
in the in-depth interviews). 
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* For one patient with whom we conducted an in-depth interview, audiotaping of the consultation failed.
Patient and oncologist questionnaire
Patients completed a written survey after having been interviewed assessing age 
and education level (defined using the highest level of schooling/vocational training 
completed) as well as objective numeracy, i.e., their ability to understand and use 
numbers. We used the seven expanded numeracy items proposed by Lipkus et al. (5). 
Scores (range: 0-7) were divided into three categories (low numeracy= 0-2; intermediate 
numeracy= 3-5; high numeracy= 6-7). 
After patient recruitment was closed, we asked oncologists to fill out a survey to obtain 
their age, gender, and number of years of experience with the systemic treatment of 
breast cancer. They were also asked to indicate their reluctance to disclose uncertainty 
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to patients on the relevant subscale of the Physicians’ Reactions to Uncertainty Scale 
(example of items: “When physicians are uncertain of a diagnosis, they should share this 
information with their patients”, and “If I shared all of my uncertainties with my patients, 
they would lose confidence in me”) (16) (scored on a six-point Likert scale, range 
between 5-30, with higher scores indicating greater reluctance towards disclosure).
Finally, we asked oncologists to indicate the frequency with which during consultations 
they discussed epistemic and aleatory uncertainty with patients on five-point Likert 
scales (categories: never, seldom, sometimes, often, and always). 
Coding and analyses 
Consultations 
Two trained researchers analyzed the content of the consultations to ascertain which 
treatment had been discussed (chemotherapy, endocrine therapy or both) and identify 
references to epistemic (yes/no) and aleatory uncertainty (yes/no). 
Due to time constraints, it proved impossible to transcribe all consultations. Therefore, 
consultations were analyzed either directly from a verbatim transcription (N=94/197 
(48%)) or from audio (N=103/197 (52%)). The coders first coded ten transcripts inde-
pendently. Inter-rater agreement was 100%. To also ensure the reliability of coding 
directly from audio, each coder coded a sample of consultations (N=13-16) that had 
already been coded from transcript minimally three months after the original coding. 
The agreement between coding from audio and transcripts was again high (81% and 
83%, respectively). As the agreement between coders was good, one researcher 
performed final coding.
Patient interviews
Patients’ answers to the uncertainty probes in the Standard Interviews were transcribed. 
To categorize emerging themes, the research team developed an initial codebook based 
on the literature and open coding by two researchers of a subset of five consultations, 
thereafter it was refined and applied. This process was repeated several times, and 
the categories in the codebook are based on the coding of a subset of 30 interviews. 
The content of all standard interviews was double-coded by two trained researchers 
independently, and discrepancies were resolved in consensus meetings.
All 15 in-depth interviews were transcribed verbatim and coded independently by the 
two trained researchers, using the same categories used to code the standard inter-
views as a starting point. New categories were added as encountered. Discrepancies 
were resolved in consensus meetings.
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Table 2 Oncologist characteristics (N=18)
N (%)




Gender (male) 12 (44)













Self-reported frequency of disclosure of uncertainty (% often and always)
Aleatory uncertainty (i.e., the unpredictability of single events)
15 (79)
Epistemic uncertainty, specifically:
precision of prognostic estimates




* Five-item reluctance to disclose uncertainty to patients subscale of the Physicians’ Reactions to 
Uncertainty Scale (16), scored on a six-point Likert scale; the higher the score, the greater the reluctance 
towards disclosing uncertainty to patients (score range: 5-30).
Finally, the two coders independently grouped the 40 categories (i.e., themes) identi-
fied during the coding of both the standard and in-depth interviews into overarching 
domains for presentation purposes. The definitive grouping was established through 
further discussion and consensus among members of the research team (see Table 3 
for the Standard Interview themes and Figure 2 for the In-depth Interview domains).
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Results
We included 198 patients (Mdn age =59 years; range: 32-90). Overall, 74% of patients 
were recruited at general teaching hospitals, 29% were highly educated, and 53% were 
highly numerate (Table 1). The median duration of the consultations was 28 minutes 
(range: 5-80). Audiotaping of the consultation was successful for all patients except 
one. In 79% of consultations Adjuvant!’s prognostic estimates were presented orally 
and its output was displayed visually on the computer screen and/or on a printout of 
the output. The standard interview was conducted with 170 of the 198 patients, the 
in-depth interview was conducted with 15 patients, and no interview was conducted 
with 13 patients (nine patients could not be reached by telephone within 1 week after 
the consultation, and four declined to be interviewed).
Twenty-seven medical oncologists (Mdn age = 42 years; range: 30-66) recruited patients 
(Mdn=7 patients per oncologist; range: 1-33) (Table 2). Twenty oncologists (partially) 
completed the survey (74%), of whom 12 had more than 10 years of experience in this 
setting. Oncologists showed low to moderate reluctance towards disclosing uncertainty 
to patients (Mdn=12 out of a maximum of 30 points; range: 5-17). Nine of the 19 
oncologists said they often or always discuss epistemic uncertainty (i.e. the imprecision 
of risk estimates and/or their applicability to a specific patient) during consultations, 
and 15/19 said they often or always discuss the unpredictability of single events.
Consultations
Disclosure of uncertainty during consultations
In about half (N=97/197 (49%)) of the consultations some type of uncertainty was dis-
closed. During these consultations, 107 references to uncertainty were made, of which 
84 (79%) allusions to the unpredictability of single events (aleatory uncertainty). For 
example, one oncologist said: “… [there are] no guarantees. It remains … I always say 
that in reality if you look at an individual it is 100% or 0%. So you either get the disease 
back or you don’t, right. But if you have 100 women, then you have 30 women in whom 
during the course of 10 years, metastases will manifest... And I can’t tell just by looking 
at you whether you are one of the 70 lucky ones or one of the 30 unlucky ones”. The 
remaining 23 (21%) references to uncertainty were allusions to the imprecision of the 
risk estimates and/or their applicability to a specific patient (epistemic uncertainty). 
Allusions to the imprecision of the risk estimates were generally somewhat vague, for 
example: “Of course there always is a margin associated with such statistics”. Utterances 
about the applicability of the probabilities to specific (subgroups of) patients were more 
tangible, for example: “… look these are averages … yes. It’s a large database, and we 
can’t comment on the individual ... the only thing we can do is look at averages. And 
of course, there are always exceptions on both sides”, or “… these probabilities will 
be somewhat different for you … your relapse risk will be higher, because the model 
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[Adjuvant!] does not take the Her2 [Her2neu receptor status] into account”. 
Standard interviews
Patients’ perception of the various types of uncertainty
One hundred forty-four (85%) patients indicated that probabilities had been discussed 
during the consultation. We posed the open probe to them. Of those 144 patients, 97 
(67%) did not make a reference to uncertainty and 47 did. The response to the open 
probe of 12 of these 47 patients contained allusions to more than one aspect of uncer-
tainty, resulting in 62 allusions. Overall, 37/62 allusions were about the unpredictability 
of single events, and 10/62 allusions were about the imprecision of the risk estimates 
or their applicability to a specific patient. The remaining 15/62 allusions were general 
statements without further clarification as to what the patient was aiming at (e.g., “It’s 
just statistics …” or “… it’s statistically a substantial reduction of my recurrence risk”) 
or statements about the patients’ struggle to cope with uncertainty. Table 3 presents 
patients’ utterances about uncertainty during the standard interview. 
Understanding of imprecision 
The imprecision probe was posed to 80% (115/144) of patients who indicated prob-
abilities had been communicated. This probe was not posed to 29 patients as the 
interviewer felt they were too emotional and/or had too limited understanding of the 
probabilities to allow probing. We found that patients generally seemed to struggle 
with what we were asking them. Patients seemed to think that we were asking them 
whether the probabilities they had heard during the consultation were correct, e.g., “I 
think they calculated that [the probabilities] correctly. Yes, I’m confident about that”. 
Fifteen out of the 115 patients (13%) indicated they were unable to provide an answer. 
The 100 patients that did provide an answer made 178 allusions to uncertainty (Table 
3). We were asking patients about the imprecision of the risk estimates, yet only 35% 
(63/178) of utterances referred to imprecision.
One out of three patients who alluded to imprecision (20/63) indicated that the proba-
bilities were exact, i.e., they reported no uncertainty about the probability. About one 
out of four (41/178) utterances were an allusion to the inapplicability of probabilities to 
an individual, and 23% (41/178) of utterances were an allusion to the unpredictability 
of single events. The remaining 26 of the 178 (15%) remarks were statements about 
patients’ struggle to cope with uncertainty or vague allusions to uncertainty (e.g., “… 
it’s just statistics”).
In-depth interviews
Figure 1 provides an overview of the themes identified in the 15 in-depth interviews 
(see Table 1 for patients’ socio-demographic characteristics). When we posed the open 
probe, 26 unique references to uncertainty were made, whereas 66 unique references 
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were made after we posed the probes about the unpredictability of single events 
(aleatory uncertainty), and the imprecision of the risk estimates, their applicability to a 
specific patient (epistemic uncertainty). Fourteen of the 26 references to uncertainty 
following the open probe alluded to the unpredictability of single events, four alluded 
to the imprecision of the risk estimates, one alluded to the applicability of the proba-
bilities to a specific patient, and seven were vague allusions to uncertainty or patients’ 
struggle to cope with uncertainty.
Again patients seemed to have difficulty understanding what we were asking them 
when we probed specific elements of uncertainty. Patients mainly struggled with probes 
about the imprecision of the risk estimates and their applicability to a specific patient. 
Box 1 provides excerpts from an interview as an illustration of the struggle to formu-
late answers and inconsistencies between a patient’s utterances. Of the six patients 
who indicated that there was no uncertainty with regard to the precision of prognostic 
estimates, four were highly numerate. Utterances about the imprecision of the risk 
estimates and their applicability to a specific patient frequently contained (logical) 
inconsistencies. An overview of inconsistent utterances within patients is provided in 
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Discussion
We investigated whether and which type of uncertainty oncologists disclose during 
consultations and explored patients’ perceptions of the uncertainty associated with the 
probabilities discussed during their consultation. Additionally, we queried oncologists 
about their willingness to discuss uncertainty, and their practice in this regard. We 
found that communication of uncertainty is limited. First, oncologists talked about 
uncertainty in only half of the consultations. Second, if they did discuss uncertainty, 
oncologists infrequently discussed the imprecision of the risk estimates (epistemic or 
2nd-order uncertainty), despite its potential relevance in the context of risk estimates 
produced by prediction models. Furthermore, the discussions that did occur most often 
consisted of vague allusions to imprecision. If oncologists referred to uncertainty, it 
was mostly (4 out of 5) an allusion to the unpredictability of single events (aleatory or 
1st-order uncertainty). 
The focus on disclosure of the unpredictability of single events may not be surprising 
as this type of uncertainty (‘aleatory uncertainty’) is relatively straightforward to discuss 
and comprehend. People are generally aware of the unpredictability of future events. 
Conversely, comprehending epistemic uncertainty (i.e. uncertainty about the precision 
of the risk estimates and their applicability to a specific patient) requires insight into the 
nature of probability and the origin of probability estimates. Clinicians may be hesitant 
to further complicate matters by bringing up a complex construct such as epistemic 
uncertainty bearing in mind that many people, even those highly educated, struggle 
to understand probabilistic information (1, 5). Moreover, the goal of discussing survival 
probabilities during consultations is to inform patients about their prognosis with and 
without adjuvant systemic treatment, and ultimately to help patients pass judgment 
about whether or not undergoing treatment is worthwhile (13). Clinicians may not want 
to undermine patients’ confidence in probabilities by highlighting the limitations in their 
reliability or accuracy. Additionally, even if oncologists wish to discuss the imprecision 
of probabilities, this intent might be subverted by the fact that Adjuvant!, like other 
prediction models, does not provide such information. Perhaps due to the absence 
of information about precision, allusions to (im)precision were often somewhat vague. 
Our study also shows that eliciting patients’ perceptions of uncertainty is methodologi-
cally difficult. This may be due to the abstract nature of uncertainty. In addition, people 
may generally not give much thought to such uncertainty, possibly also for reasons 
of coping. As we interviewed patients shortly (within one week) after the consultation 
with their medical oncologist, it may have been difficult for them to delve too deeply 
into this topic. At the time of the consultation, they were still recuperating from sur-
gery or undergoing radiotherapy. They may not have had the time to process all that 
happened to them recently and put it into perspective. Our questions may also have 
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caused anxiety by making patients aware of the fallibility of the probabilities guiding 
their treatment decisions. This posed a moral dilemma for the interviewers; they found 
themselves trying to find a balance between obtaining an answer to the research 
question and not distressing patients.
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They dealt with this problem by dropping the probe if they perceived signs of appre-
hension in patients and then did not push the subject any further, even without having 
gotten a clear answer. This strategy limited the amount of information gained from 
the standard interviews and the potential inferences we can draw about patients’ 
understanding of uncertainty. A deeper understanding requires probing much further 
in spite of patients’ (perceived) apprehension. The face-to-face in-depth interviews 
were easier in this respect, but in those, we still ran into substantial incomprehension, 
perhaps mixed in with some apprehension and/or denial.
Patient A (61 years, highly numerate with stage II disease), her views on:
- the certainty of the survival probabilities: 
“I cling to it [survival probability], whilst I secretly think, everyone is unique, so you never know. Yet, I 
still put a lot of… have a lot of faith in them [probabilities]”
- the precision of the survival probabilities: 
“… uhm I’ve never thought about it [precision of probabilities]. But now I do think about it, I think it 
[the probability] does fluctuate a little. Yes, so not exactly 10, it could also be 11.”
“… but I think it’s more… what is precise? I don’t know whether they [oncologists] can say it [survival 
probability] so precisely, that it’s [survival probability] not greater than 10%. But I do think that if it 
had been 11% she would’ve told me. Yes… I’m confident about that, so it [survival probability] is 
exact.”
 “… on average it [survival probability] could also be higher. If you are in a group [with specific 
prognostic characteristics], you’re in that group… and if you say that on average you have 10% 
chance of getting it [cancer] again… I’m not so good at this.... I don’t think in terms of averages, 
because then it [10-year recurrence risk] could also be 5 or 15. I want to think about the 10% 
[recurrence risk after adjuvant treatment discussed during the consultation].”
- whether her oncologist can predict her prognosis and to what extent available survival 
probabilities apply her personally: 
“I think so [it is possible to predict prognosis for an individual], but she [the oncologist] did not do it. 
She explained that I was in a certain group, but not everyone in that group is exactly the same… but 
an individual risk [estimate] might be possible. No no no, she based it [probabilities] on the group…” 
“I do think she could have been more specific, but whether that would’ve been useful, a single 
percent [higher or lower on an individual level]. If you got your own percentage [survival probability] it 
could deviate from 10… a little bit. It wouldn’t be far off.”
Box 1 Example of answers during an in-depth interview
Patients seemed to struggle with information about uncertainty. This was most true 
for the imprecision in probability estimates (epistemic uncertainty), and least with the 
fundamental inability to predict individual futures (aleatory uncertainty). We observed 
many logical contradictions in patients’ answers. In addition, if not specifically asked 
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about uncertainty, only about one in four referred to uncertainty, and three out of five 
of those utterances were allusions to the unpredictability of single events. Even when 
we specifically asked about the imprecision of risk estimates and their applicability to 
a specific patient, almost one in four utterances were allusions to the unpredictability 
of single events. It is unclear whether patients do not perceive epistemic uncertainty, 
or whether they did not understand what we were asking them. For example, when 
asked about imprecision, patients seemed to think that we were asking whether the 
probabilities were true – i.e., whether their oncologist had got them right or whether he/
she had been truthful with them. They seemed unable to reconcile the thought that a 
probability can be correct and at the same time not be exact. These seemingly incom-
patible realities may account for some of the inconsistencies in patients’ perceptions 
of uncertainty. Previous reviews have also identified a struggle to reconcile seemingly 
incompatible realities; in those cases, patients tried to reconcile the need to be fully 
informed about prognosis with not being overwhelmed with complex medical informa-
tion (17, 18). Patients seem to use ‘positive thinking’, or even an element of denial in 
their recall of prognostic information (19, 20). Perhaps such coping strategies also play 
a role here, which may at least partly explain the logical inconsistencies we observed. 
Most patients seem to realize that the unpredictability of single events is inherent 
to probabilities, but across education and numeracy levels they do place value on 
probability information. These probabilities seem to satisfy patients’ need to have some 
sense of certainty to cling to (e.g., “I attach a lot of value [to the probabilities] ... in truth, 
I cling to them [probabilities], even though I think to myself, everyone is unique…”). 
Patients seem to perceive the unpredictability of single events as an inevitable part of 
life (e.g., “…there are no guarantees in life, not with this [cancer]… not with anything.”), 
but uncertainty about the precision of the risk estimates and their applicability may be 
more challenging to cope with. Acknowledging this type of uncertainty may undermine 
the sense of security some patients seem to derive from the probabilities communicated 
during the consultation (e.g., “I don’t think in terms of averages, because then it [10-year 
recurrence risk] could also be 5 or 15. I want to think about the 10% recurrence risk 
after adjuvant treatment discussed during the consultation”). Conversely, it has been 
suggested that if explicit prognostic information, including its associated uncertainty, 
is coupled with appropriate emotional support it could be a way of decreasing anxiety, 
generating greater self-efficacy and ultimately achieving a better quality of life (21). 
Research is needed to investigate whether this approach is effective in the curative 
setting. 
This is the first study to investigate disclosure of uncertainty during real-time consulta-
tions, and to explore perceptions of uncertainty in a large sample of patients. Currently, 
it is increasingly common for clinicians to discuss probabilities during consultations with 
patients. Whether disclosure of uncertainty should be part of risk communication or 
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not, however, is a matter of debate. This debate has so far been based on ethical and/
or practical concerns. The available evidence is limited and most work in this area has 
been experimental or focused on healthy subjects’ perceptions of uncertainty (e.g., (2)).
Therefore, although informative, the currently available evidence might not be the best 
indication of how actual patients, especially those facing a potentially life-threatening 
illness, perceive and understand information about uncertainty. 
We did not assess whether uncertainty was communicated during consultations in 
which prognostic estimates were not communicated. The current debate revolves 
around whether the uncertainty surrounding risk estimates (e.g., survival estimates) 
should be communicated whenever these risk estimates are communicated to patients. 
Therefore, we opted to focus on consultations in which prognostic estimates had 
been discussed. Further, in the consultations in which no prognostic estimates were 
discussed, oncologists can only have discussed aleatory uncertainty. 
Our study showed that there is wide variability in the communication of uncertainty, 
and that clarity is often lacking. Oncologists infrequently fully inform their patients 
about uncertainty around the probabilities given. This is especially true for the uncer-
tainty concerning precision and applicability to individuals. When communicated, such 
information turns out to be difficult to understand. If clinicians wish patients to become 
aware of this type of uncertainty, its inherent complexity makes it imperative that such 
information be presented in a clear manner. Otherwise, the meaning behind clinicians’ 
statements is likely to be lost on most patients. Witteman et al. developed pictographs 
with animated random dispersal of risk events, and the effect of such pictographs has 
been evaluated in healthy subjects (22, 23). Such visual display formats could facili-
tate communication about uncertainty, and increase patient awareness of the random 
nature of probabilities. However, no clear guidance exists today on how best to inform 
patients about uncertainty, more research is needed. In the meantime, it is clear that it 
is important to raise awareness in communication skills training about the importance 
of clearly formulating information about uncertainty if oncologists choose to discuss it 
with patients. For now it seems that patients can grasp aleatory uncertainty, but have 
difficulty with epistemic uncertainty.
It was not our aim to assess whether or not there is a discrepancy between oncologists’ 
perception about the frequency with which they disclose uncertainty and their actual 
disclosure. To answer this question, oncologists should be asked after each consultation 
whether or not they communicated uncertainty. Such a question could have predisposed 
oncologists to discuss uncertainty more often than they normally would have, hindering 
our aim, i.e., to observe what currently happened in clinical practice. It may be of value 
for future research to explore whether or not oncologists’ perception about how often 
they disclose uncertainty is congruent with observed disclosure during consultations. 
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Oncologists might feel they communicated uncertainty, but for example the way they 
formulate this information is not clear or explicit enough. Indeed in the current study 
we found that especially communication about epistemic uncertainty was somewhat 
vague. Results of such studies may help shape communication training. 
Interestingly, the moral dilemma we encountered while probing patients during the 
interviews is comparable to the difficulty oncologists face, trying to balance com-
plete information provision and not causing unnecessary confusion and/or distress 
in patients, and not overwhelming them with too much information. If the problems 
we encountered during the interviews mainly arise from a lack of understanding, the 
focus of future research should be on how clinicians can best inform their patients 
about uncertainty. Alternatively, perhaps the most urgent question currently is whether 
uncertainty should be communicated at all. If indeed not paying attention to uncertainty 
may help patients to better cope with their disease, the imperative of autonomy and 
full disclosure may contradict that of well-being (24, 25). Our findings suggest that the 
question how to communicate the uncertainty of risk estimates may be secondary to 
the question whether patients benefit from such information. This dilemma deserves 
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Appendix A Interview protocol to explore patient awareness and perceptions about 
uncertainty
1. Open probe assessing patients’ awareness of the uncertain nature of the 
prognostics estimates discussed if this is not brought up by the interviewer (= 
open probe without priming): 
Open probe assessing patients’ awareness of uncertainty associated with the survival 
estimates, without introducing the concept of uncertainty: What did you think about 
when you first heard these probabilities?
Then the interviewer explicitly stated that some of the questions that would next be 
posed might be a bit abstract and difficult. We made clear that we were in no way 
implying that she did not understand the information correctly or that her oncologist 
withheld information or provided her with incorrect information. We explained that we 
only wanted to know if she has ever thought about the following concepts and what 
her views are.
2. Probes for specific elements of uncertainty:
a. Open probe assessing patients’ views on the certainty of the survival estimates, after 
introducing the concept of uncertainty (= certainty probe): We have just talked about 
the probabilities from ...[name source].. you had talked about with dr…. In your opinion, 
how certain are the risk estimates your doctor gave you? How much confidence or 
faith do you have in those probabilities?
b. Probe assessing patients’ views on the precision of the risk estimates (= precision 
probe): How precise or exact do your risk estimates seem? [pause, allowing the patient 
room to respond] For example, do you think it’s possible that your actual risk is higher 
or lower?
c. Probe assessing patients’ views on their oncologist’s ability to predict single events 
(= predicting future/applicability to individual probe): 
• In your opinion, to what extent do you think your oncologist is able to predict your 
prognosis, for you as an individual?
• To what extent do you feel the risk estimates you discussed with your oncologist 
apply to you personally?
3. Probe to assess whether patients felt they had been informed about uncertainty:
a. We have talked at length about your views on how exact the probabilities you dis-
cussed with dr. … are and whether you think they apply to you personally. We were 
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keen to find out whether you had ever given it any thought and what your thoughts 
are on this subject. We would also like to know, did you discuss any of these issues 
with your oncologist?
b. If patient answers yes:
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Shared decision-making (SDM) is widely advocated, especially for preference-sensitive 
decisions like those on adjuvant treatment for early-stage cancer. Here decision-
making involves a subjective trade-off between benefits and side-effects, and therefore 
patients’ informed preferences should be taken into account. If clinicians consciously 
or unconsciously steer patients towards the option they think is in their patients’ best 
interest (i.e., implicit persuasion), they may be unwittingly subverting their own efforts 
to implement SDM. We assessed the frequency of use of implicit persuasion during 
consultations, and whether the use of implicit persuasion was associated with expected 
treatment benefit, and/or decision-making.
Methods
Observational study design in which consecutive consultations about adjuvant systemic 
therapy with stage I-II breast cancer patients treated at oncology outpatient clinics of 
general teaching hospitals and university medical centers were audiotaped, transcribed 
and coded by two researchers independently.
Results
In total 105 patients (median age=59; range: 35-87 years) were included. A median of 
five (range: 2-10) implicitly persuasive behaviors were employed per consultation. The 
number of behaviors used did not differ by disease stage (P=0.07), but did differ by 
treatment option presented (P=0.002) and nodal status (P=0.01). About 50% of patients 
with stage I or node-negative disease were steered towards undergoing chemotherapy, 
whereas 96% of patients were steered towards undergoing endocrine therapy, irre-
spective of expected treatment benefit. Decisions were less often postponed if more 
implicit persuasion was used (P=0.03).
Interpretation
Oncologists frequently use implicit persuasion, steering patients towards the treatment 
option that they think is in their patients’ best interest. Expected treatment benefit does 
not always seem to be the driving force behind implicit persuasion. Awareness of one’s 
use of these steering behaviors during decision-making is a first step to help overcome 
the performance gap between advocating and implementing SDM.
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Introduction
Shared decision-making (SDM) is broadly advocated as an ideal for clinical practice. It 
is especially relevant for so-called preference-sensitive decisions (1), for which there is 
no obvious ‘best’ treatment. Treatment choice then depends on a necessarily subjective 
trade-off between the benefits and side-effects of treatment alternatives. Therefore, 
patients’ informed values and preferences should drive decision-making. The SDM 
process can be disrupted if the presentation of treatment options contains implicit value 
judgments, driven by clinicians’ own assessment of whether the benefits outweigh the 
side-effects. When the presentation of evidence implicitly steers patients towards a 
particular choice, patients may get the erroneous impression that this is the only or 
‘best’ option (i.e. implicit persuasion). Ziebland et al. showed such behaviors to be 
barriers to SDM, albeit without framing them as such (2). Karnieli-Miller and Eisikovits 
are, to the best of our knowledge, the only researchers who systematically analyzed 
the use of implicitly persuasive behaviors (3). 
The current study describes a systematic assessment of the use of implicit persuasion 
in adjuvant systemic treatment in oncology. Chemotherapy and endocrine therapy for 
stage I-II breast cancer reduce the probability of disease recurrence, but the size of the 
benefit varies widely (generally between ~3-10% benefit in terms of 10-year survival), 
depending on patient and tumor characteristics (e.g., tumor size, nodal status and 
Her2neu status). Yet, these treatments are associated with important short- and long-
term side-effects, making the decision preference-sensitive (4-7). As it is impossible to 
predict which patients will benefit from undergoing treatment, international guidelines 
suggest to discuss adjuvant systemic treatment with patients if treatment minimally 
yields 3-5% absolute benefit in terms of overall mortality (8-12). This however also 
implies 95-97% overtreatment. 
We investigated 1) whether and which implicitly persuasive behaviors oncologists use 
when discussing adjuvant systemic treatment for breast cancer overall and by treat-
ment, 2) whether the frequency and/or direction of implicit steering is associated with 
expected treatment benefit, and 3) whether the use of implicitly persuasive behaviors 





The current study was embedded in a larger multicenter observational study assessing 
communication about adjuvant treatment. Consecutive female patients with stage I-III 
breast cancer, eligible to receive chemotherapy and/or endocrine therapy and fluent in 
Dutch, were invited to participate (72% response). All oncologists treating breast cancer 
patients at four participating general teaching and academic hospitals consented to 
participate in the main study. 
For the current study, we selected a random sample of 105 consultations with stage I-II 
breast cancer patients available by February 2014. The study protocol was approved 
by the medical ethics boards of the participating hospitals.
Procedures and measures
After patients had provided written informed consent, the first consultation with their 
medical oncologist, in which chemotherapy and/or endocrine therapy was discussed, 
was audiotaped. All consultations were transcribed verbatim. Next, a coding scheme 
to code the use and direction of implicit steering was developed using the behaviors 
described by Karnieli-Miller and Eisikovits (3) as a starting point. All consultations were 
independently coded by two coders (EGE and AvdH), and discrepancies resolved 
through consensus (Appendix A describes the development of the coding scheme 
and coding procedures). We classified the implicitly persuasive behaviors into four 
overarching themes, namely, 1) unbalanced presentation of benefits and side-effects, 2) 
presenting treatment recommendations as authorized decisions, 3) creating the illusion 
of decisional control, and 4) persuading patients using (clinical) experience (Appendix 
Table 1 describes the behaviors coded). 
Information on patients’ education level and oncologists’ age were collected using 
self-report questionnaires. Information on consultation characteristics were extracted 
from the transcripts of the consultations, namely: a) adjuvant treatment discussed, b) 
number of side-effects communicated, c) timing of decision-making (prior to, during 
the consultation, or postponed) and d) treatment choice. If the treatment decision 
was postponed, medical charts were consulted to determine treatment choice. Tumor 
characteristics (size, histological grade, nodal status, estrogen and Her2neu receptor 
status) were collected from medical records. Stage (based on Tumor Node Metastasis 
(TNM)) was based on the American Joint Committee on Cancer definition, 7th edition 
(13). 
Statistical analysis
Descriptive analyses were performed. We report the frequency of use of the behaviors 
203
Use of implicit persuasion in decision-making about adjuvant systemic therapy
8
per theme, overall and for chemotherapy and endocrine therapy separately. Fisher’s 
Exact Tests for categorical variables were used to compare: a) the use of each implicitly 
persuasive behavior by treatment discussed, and b) the direction of the implicit steering 
by patient and tumor characteristics. When appropriate, Mann-Whitney and Kruskal-
Wallis tests were used to make comparisons between the frequency with which implicitly 
persuasive behaviors were exhibited and a) TNM stage, b) nodal status and c) whether 
or not a decision was reached during the consultation. The congruence between 
the direction of implicit steering by oncologists (forego or undergo (neutral category 
excluded)) and treatment choice (forego or undergo) was computed for chemotherapy 
and endocrine therapy separately using Cohen’s kappa (κ). Significance testing was 





Eighteen oncologists (56% male; mean age 51 years (range:34-66)) included 105 
patients (see Table 1). Patients were on average 59 years (range:35-87) and 53% 
had stage I disease. In 71% of the consultations, both chemotherapy and endocrine 
therapy were discussed. 
RQ1: use of specific implicitly persuasive behaviors, overall and by treatment
Overall, a median of five (range:2-10) implicitly persuasive behaviors were observed, 
and the number of behaviors used greatly varied between and within oncologists 
(Figure 1). More implicitly persuasive behaviors were used in consultations in which 
both chemotherapy and endocrine therapy (Md.=6.0) were discussed than in those 
where chemotherapy (Md.=4.0) or endocrine therapy (Md.=4.0) alone were discussed 
(P=0.001). There was variation in the overall use of implicitly persuasive behaviors as 
well as in which specific behaviors were used by the treatment under discussion (see 
Table 2). Below we report the frequency of use of the implicitly persuasive behaviors 
by theme, overall and for chemotherapy and endocrine therapy separately.
Theme 1: Unbalanced presentation of benefits and side-effects 
In 81% (85/105) of consultations side-effects were underreported (fewer than five, see 
Appendix A for coding) (see Table 2). This was significantly more often the case for 
endocrine therapy (65/90 (72%)) than chemotherapy (47/90 (52%)) (P=0.009), irrespec-
tive of whether only endocrine therapy or endocrine therapy alongside chemotherapy 
was discussed (P=0.75). On average 2.6 (range: 0-9) endocrine therapy side-effects 
and 4.2 (range:0-13) chemotherapy side-effects were communicated. 
Overall, side-effects were presented after the treatment decision was made in 67% 
(70/105) of consultations, more often in the case of endocrine therapy (59/90 (66%)) than 
in that of chemotherapy (32/90 (36%) P<0.001). In the consultations where side-effects 
were communicated after the decision was made, decisions seemed to have been 
made prior to the consultation by the oncologist (and/or the multidisciplinary team) 
(chemotherapy=59% (19/32) and endocrine therapy=81% (48/59)), or the decision was 
made during the consultation after only discussing the expected benefits (chemother-
apy=41% (13/32) and endocrine therapy=19% (11/59)).
In 51% (53/105) of consultations, oncologists emphasized patients’ ability to minimize 
discomfort caused by the side-effects, especially for chemotherapy-related side-effects. 
The improvements in the ability to prevent/control chemotherapy-induced nausea were 
particularly stressed, as was the reversibility of severe side-effects (e.g., trastuzumab-
induced cardiac failure, or chemotherapy-associated peripheral neuropathy). 
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Table 1 Patient, disease, oncologist and consultation characteristics
N (%)
Patient’ characteristics (N=105)











Mean age in years (range) 51 (34-66)
























Decision made during consultation
Decision postponed





a When both chemotherapy and endocrine therapy had been discussed, a decision was made for only one 
of them; TNM= Tumor size – Nodal status – (presence of distant) Metastasis.
Additionally, in 43% (45/105) of consultations the impact of treatment on patients’ quality 
of life was minimized – more often for endocrine therapy (38 of 90 (42%)) than chemo-
therapy (8 of 90 (9%)) (P<0.001). Phrases used when talking about endocrine therapy 
were, e.g., “It’s just a little pill a day” or “Well, aspirin has side-effects too”. Oncologists 
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In 39% (41/105) of consultations either the benefits or harms of treatment were empha-
sized irrespective of which treatment was discussed, by repeatedly making statements 
such as: “The benefits are truly substantial”, “You cannot say that with treatment the 
disease will not return, but the probability it will, gets much, much smaller” or “Under-
going chemotherapy is serious overkill for such small benefits” or “Luckily you don’t 
need chemotherapy, that’s the good news… only endocrine therapy suffices”. 
Theme 2: Presenting treatment recommendations as authorized decisions
In 83% (87/105) of consultations oncologists presented treatment as an authorized ‘we’ 
decision, common wordings being: “You would not be here, if we as a professional group, 
did not think that it [the treatment] is at least worth considering…”, “In the Netherlands, 
we [medical oncologists] agree that…”. Overall, 35 explicit references to the guideline 
were made. No differences were seen between endocrine treatment and chemotherapy.
Theme 3: Creating the illusion of decisional control 
The most important decision that needs to be made during these consultations is 
whether or not to start treatment. Yet in 50% (52/105) of consultations, the oncologist 
and/or the multidisciplinary team seemed to have unilaterally made the main treatment 
decision.
Patients were given the power to decide about secondary decisions, namely when to 
start or whether or not to (dis)continue endocrine therapy (49% (44/90) or chemother-
apy (17% (15/90); (P<0.001)). For example: “About the hormone tablets we often say 
to patients, just try it. The side-effects are really not so severe that you cannot handle 
them. And if you find that the hot flashes are really awful… then you can always stop 
and they will go away…”. Overall, in 33% (30/90) of chemotherapy and 57% (51/90) of 
endocrine therapy consultations, decision-making seemed to have taken place prior 
to the consultation, and the aim of the consultation seemed to be to notify the patient 
of the treatment plan and not to decide about treatment, e.g.: “You are here to talk 
about whether or not it is worthwhile to undergo chemotherapy, endocrine treatment 
we’ll do anyway ”. 
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Table 3 Direction of implicit steering per treatment discussed by patient and tumor characteristics
















Patient and tumor characteristics (N(row%))
Age in years
Younger than 50

































































































































Ncol= total number of patients in the column.; row%= row percentage; Missing category was excluded 
from pertinent analysis; Stage= TNM stage (13); Grade = Bloom-Richardson grading system; # Neutral 
means that if a technique was used, it did not clearly steer either towards foregoing or undergoing 
treatment (e.g., a consultation in which only a reference to the guideline was made); * P-values for Fisher’s 
exact test.
In 31% (28/90) of consultations endocrine therapy implicitly tagged along with chemo-
therapy, with patients agreeing to both treatments while only chemotherapy had been 
discussed. Also, in 18% of consultations (19/105) it was emphasized that the proposed 
treatment is milder than the ‘standard’ treatment. For example, “…given that you are 
older, we would not go for the toughest regimen, the six courses. We would give you 
four courses [of chemotherapy] instead…”. 
Theme 4: Persuading patients using (clinical) experience
Behaviors in this category were observed in ≤10% of consultations. The most frequently 
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observed behaviors were a) deterring vs. encouraging: using others as examples (10/105 
(10%)) (e.g., “In my experience most patients get through the chemotherapy quite well 
nowadays, it’s not like shown in movies, people spending the whole day hunched over 
the toilet…”), and b) giving the impression that undergoing or foregoing treatment 
is quite unusual (e.g., “It’s unheard for patients with these disease characteristics to 
forego treatment…”). 
RQ2: association of frequency and direction of implicit persuasion with expected 
treatment benefit 
We did not find a significant difference in the number of of implicitly persuasive behav-
iors used between patients with stage I (Md.=5.0; range: 2-10) vs. those with stage II 
disease (Md.=5.5; range: 2-10) (P=0.07). Nodal status was significantly associated with 
the number of implicitly persuasive behaviors observed (N+ Md.=6.0 (range: 2-10) vs. 
N0 Md.=5.0 (range: 2-10); P=0.01). 
For chemotherapy more patients with stage II (76% (31/41)) or node-positive (86% 
(25/29)) disease were steered towards undergoing treatment than those with stage I 
(49% (23/47)) or node-negative (50% (30/60)) disease (Table 3). For endocrine therapy, 
96% (86/90) of patients were steered towards undergoing treatment, irrespective of 
prognostic factors.
RQ3: association of implicit persuasion with decision-making
More implicitly persuasive behaviors were observed if the treatment decision was made 
(Md.=5.0; range: 2-10) or partly made (Md.=6.5; range: 3-10), than if the decision was 
postponed (Md.=3.5; range: 2-9) (P=0.03). There was congruence between the direction 
of implicit steering and the final treatment choice (chemotherapy κ=0.7 (95%-CI: 0.5-
0.9) and endocrine therapy κ=0.8 (95%-CI: 0.7-0.9)). Overall, 89% (50/56) of patients 
steered towards undergoing chemotherapy consented to undergoing chemotherapy, 
and, 84% (16/19) of patients who were steered towards foregoing chemotherapy, 
consented to foregoing treatment. Similarly, 95% (82/86) of patients steered towards 




We investigated whether and how often oncologists exhibit implicitly persuasive behav-
iors overall and by treatment discussed, and whether the use of these behaviors was 
associated with expected treatment benefit, and reaching a decision during the con-
sultation. Oncologists exhibited implicitly persuasive behaviors in all 105 consultations 
analyzed. These behaviors seemed aimed at steering patients towards the treatment 
option the clinician favored. This is noteworthy, as we focused on decisions where there 
is no clear-cut ‘best’ option, thus decision-making should be guided by the patient’s 
informed preferences. Yet, for patients to develop informed preferences, the presenta-
tion of the treatment options has to be free of implicit value judgments. 
How many and which behaviors are used depended on the treatment discussed. 
Behaviors used when discussing chemotherapy entailed an unbalance presentation 
of benefits and side-effects. Chemotherapy is well-known to patients and its impact is 
generally feared. The tendency to stress the benefits and/or emphasize that patients 
are well-capable of controlling the side-effects may be an understandable attempt to 
correct potential misconceptions and balance patients’ perceptions about treatment. 
However, if overdone this may cause patients to make a decision based on unrealistic 
expectations, or it may create the erroneous perception of a ‘best’ or only choice. 
Endocrine therapy was consistently presented as a standard treatment for hormone-
sensitive tumors, implying that there is no choice. However, given that 53% of the 
patients in this population had stage I disease and 69% had node-negative disease, 
foregoing treatment would often have been a viable option to present. Endocrine 
therapy was also consistently framed as a ‘walk in the park’, especially compared to 
chemotherapy. In four out of ten consultations the impact of endocrine therapy was 
minimized, potentially causing patients to underestimate the impact of treatment. 
Consequently, patients might opt to discontinue treatment sooner if the side-effects 
are more severe than they expected. Although endocrine therapy side-effects may be 
relatively mild, a substantial number of women find them burdensome.(14) Coping with 
those ‘mild’ side-effects may constitute an unsustainable long-term burden. Indeed, 
~40-50% discontinuation rates of endocrine therapy are reported (15-18). The reported 
discontinuation rates for chemotherapy are lower (~12%) (19).
A worrisome finding is that in two-thirds of all consultations, a treatment decision was 
made before the patient received information on the side-effects, thus without the 
patient being afforded the opportunity to weigh the benefits against the side-effects. It 
appears that the final decision was driven mainly, if not solely, by the expected benefits 
of treatment. Hence, in a large proportion of consultations an essential premise of SDM 
was not met. Interestingly, a large proportion of treatment decisions seemed to have 
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been made unilaterally by clinicians prior to the consultation. This is a puzzling obser-
vation, given that three out of four patients wanted to be involved in decision-making 
and seven out of ten oncologists indicated that they favored involving their patients in 
decision-making (data not shown). Perhaps SDM took place during the post-operative 
consultation with the surgeon. However, this seems unlikely, as adjuvant systemic 
treatment decisions are the domain of medical oncologists. From our own and others’ 
research we know that in the field of surgery, little patient involvement is seen (20, 21). 
More likely, the recommendation of the multidisciplinary team meeting was presented 
to the patient as a decision (22).
Bars show the range of implicitly persuasive behaviors used by individual oncologists, and the 
median number of implicitly persuasive behaviors used is indicated. 
Between brackets on the x-axis the number of patients each oncologist contributed to these analysis 
is indicated.
Figure 1 Use of implicit persuasion behaviors within and between oncologists
We did not find a strong association between expected benefit and the use of implicitly 
persuasive behaviors. For chemotherapy there was more steering towards undergoing 
treatment in patients with a worse prognosis, but still half of the stage I and node-
negative patients were steered towards undergoing treatment. For endocrine therapy 
steering was always towards undergoing treatment. These findings are surprising, as 
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in a survey Dutch medical oncologists indicated that between 6-10% absolute survival 
gain is the minimal percentage benefit that offsets the potential side-effects of systemic 
therapy (23). Yet, oncologists still steered patients for whom the potential absolute 
survival gain was <6% towards undergoing treatment.
More implicitly persuasive behaviors were observed in consultations were a decision 
was made, than in those in which decision-making was postponed. The direction of 
steering was also congruent with the treatment decision in over 80% of consultations. 
It can be argued that implicit persuasion need not impede patients’ choosing the option 
that best suits them, however, this argument relies on the assumption that patients’ 
preferences are known. Yet, oncologists’ only explored patients’ endocrine therapy 
preferences in a quarter of consultations, and chemotherapy preferences were explored 
with four in ten patients considering treatment (data not shown). Similar findings have 
been reported in the literature (21, 24).
This study is the first to systematically investigate the use of implicit persuasion during 
consultations about adjuvant systemic treatment in cancer. In a similar vein in pancreatic 
cancer, oncologists impeded patients from foregoing treatment by presenting investi-
gations into the feasibility of surgery as an assessment of whether patients ‘qualified 
for surgery’, instead of presenting surgery as an option to be considered (2). Patients 
who ‘qualified’ for surgery subsequently failed to realize that they had a choice, as 
surgery was presented as ‘a win’ (2). Note that our study has some limitations. We 
audiotaped the consultations, and therefore, could not explore non-verbal cues. Also, 
in some subgroups the number of patients was small.
It is perhaps not surprising, that implicitly persuasive behaviors are frequently exhibited 
during consultations in the current setting, given that these decisions involve a diffi-
cult trade-off between the chances of preventing metastasis and death and those of 
side-effects associated with treatment. Adding to the difficulty is the timing. Patients 
barely have had time to process the diagnosis and recuperate from surgery, when they 
have to decide about the next step in the treatment process. It is thus understandable 
that some patients feel overwhelmed and incapable of making a treatment decision. 
Oncologists’ desire to help their patients by consciously or unconsciously steering them 
towards the option they believe is in their patients’ best interest is understandable and 
even commendable. Indeed, the utterances made by oncologists were often attempts 
to comfort and reassure patients or assuage any perceived decisional conflict. However, 
if oncologists wish to stimulate patient participation in decision-making and decisions 
to be the result of a shared process, employing these behaviors undermines this intent. 
In order to truly make strides in the implementation of SDM in clinical practice, the 
regular use of implicit persuasion deserves careful consideration in further research. 
Additionally, clinical education programs (at both pre- and postgraduate level) need 
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to address this issue to create awareness, and provide clinicians with tools to help 
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Appendix A Additional information on the methods applied
Development of coding scheme
For the current study we used the list of implicitly persuasive behaviors coined by 
Karnieli-Miller and Eisikovits(3) as a starting point. As Karnieli-Miller and Eisikovits 
had analyzed diagnostic disclosure consultations by pediatric gastroenterologists, we 
used our first 35 consultations to translate the original behaviors to the oncological 
setting and to identify additional behaviors. We (EGE, AvdH, AHP and AMS) identified 
new implicitly persuasive behaviors, namely: 1) selectively presenting the side-effects 
of treatment, 2) giving the impression that undergoing or refusing treatment is quite 
unusual, 3) having one treatment implicitly tag along with another, 4) presenting the side 
effects after the final treatment decision had been made, 5) minimizing the treatment’s 
impact, 6) making assertions about the patients’ personality, and 7) presenting treatment 
as an authorized decision based on ‘the guideline’. Additionally, we adapted one of 
the behaviors described by Karnieli-Miller and Eisikovits. We felt that ‘emphasizing 
the benefits of treatment and frightening patients about non-compliance’ were two 
separate behaviors and thus coded them separately. We also extended ‘emphasizing the 
benefits of treatment’ to incorporate steering by placing emphasis on the side-effects 
of treatment. One behavior described by Karnieli-Miller and Eisikovits was not coded, 
namely ‘Trying to avoid offering other treatment alternatives’. This could have been 
relevant for elderly (70 years and older) patients, for whom chemotherapy (in a lighter 
form, 4 instead of 6 courses for example) may be a realistic alternative to 5-years of 
endocrine treatment, if the patient is physically able to cope with the chemotherapy. 
However, this option was never discussed with patients unless endocrine treatment 
was not an option (ER-negative disease), which is in line with current guidelines. 
Descriptions of the 15 behaviors included in the final coding scheme can be found in 
Appendix Table 1. 
 
Coding procedures
Coding implicitly steering behaviors
Two coders independently coded transcripts of all included consultations. If after coding 
we found discrepancies in coding, the coders reviewed the transcript together and 
resolved the discrepancies through consensus. After coding the first 35 consultations, 
the agreement between coders varied for the various behaviors between 43-97%, with 
the most disagreements about the behavior emphasizing the benefits or side-effects 
of treatment (43% agreement). For all other behaviors agreement was more than 70%. 
After coding the first 35 consultations we did not identify new implicitly persuasive 
behaviors. However, we did encounter new examples of behaviors already included in 
the coding scheme. After consensus we included these examples into our definition 
and all the consultations that had been coded up to that point were analyzed again 
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to see if we previously had not missed the newly identified example of a behavior in 
the coding scheme.
Categorization of implicitly persuasive behaviors
After all the consultations had been coded (as at that point no new behaviors could 
be identified) the implicitly persuasive behaviors were grouped into categories for 
presentation purposes, namely: a) unbalanced presentation of benefits and side-effects, 
b) presenting treatment recommendations as authorized decisions, c) creating the 
illusion of decisional control and d) persuading patients using (clinical) experience. 
As both chemotherapy and endocrine therapy have numerous side-effects that 
can significantly impact patients’ quality of life, we chose an arbitrary cut-off of five 
side-effects as a proxy for balanced communication about side-effects. Two coders 
independently devised categories to divide the 15 behaviors in the final coding scheme 
into. Afterwards they compared the categories they had created and decided on the 
final categorization through consensus. 
Coding direction of steering
We also assessed the direction of the steering observed during consultations, i.e., 
whether the oncologist was steering the patient towards undergoing or foregoing treat-
ment. We coded this after we had achieved consensus about which implicitly steering 
behavior had been used and had finalized the coding of these behaviors. Coding of the 
direction of steering is based on the coders’ impression after analyzing the consultations 
for use of implicit steering. We coded the direction of steering as ‘neutral’ when the 
technique(s) used did not clearly steer either towards foregoing or undergoing treatment 
(e.g., a consultation in which only a reference to the guideline was made). Two coders 
coded the direction of steering for 20/105 consultations, afterwards the congruence in 
coding between the coders was computed for chemotherapy and endocrine therapy 
decisions separately, using Cohen’s kappa (κ). This resulted for chemotherapy decision 
in κ=0.80 and for endocrine therapy decisions in κ=0.85. As congruence was good, 
from that point on one coder coded the direction of steering. If the coder was in doubt 
about the direction of steering, she asked the other coder to independently review the 
transcript and direction of steering was determined through consensus. 
Appendix Table 1 Coding scheme implicit persuasion behaviors





























Fewer than five side-effects were communicated 
about chemotherapy and endocrine therapy 
respectively. Often if the oncologist only focuses 
on the most common and least threatening side-
effects.
□ No
□Yes, and alluded to:
 □ Chemotherapy
 □ Endocrine therapy
Emphasizing 
the benefits or 
side-effects of 
treatment+
The oncologist either emphasizes the magnitude of 
the treatment effect and minimizes the side-effects 
or vice versa.
□ No
□ Yes, and alluded to:
 □ Chemotherapy




The oncologist downplays the impact of treatment, 
for example: “Endocrine therapy is a relatively 
innocuous treatment, you just have to take a little 
tablet everyday… besides even aspirin has side-
effects”.
□ No
□ Yes, and alluded to:
 □ Chemotherapy
 □ Herceptin 
 □ Endocrine therapy
Emphasizing 




The oncologist emphasizes that he/she and/
or the patient is able to control and oversee the 
side-effects of treatment. In order to combat 
chemotherapy-induced nausea, for example all the 
patient needs to do is ask and the dosage of anti-
emetics can be increased or other anti-emetics 
could be tried.
□ No
□ Yes, and alluded to:
 □ Chemotherapy
 □ Endocrine therapy
Presenting the 
side-effects 




The oncologist presents the side-effects of 
treatment after a decision on whether to start 
treatment or not was made.
□ No
□ Yes, and alluded to:
 □ Chemotherapy

































based on ‘the 
guideline’
The oncologist presents the treatment as 
an authorized decision based on guideline 
recommendation for patients with her personal 
(e.g., age) and/or disease characteristics (e.g. 
tumor size or nodal status).
□ No
□ Yes, and alluded to:
 □ Chemotherapy





The oncologist presents the treatment as an 
authorized decision based on consensus amongst 
experts, “We are in favor of…”.
□ No
□ Yes, and alluded to:
 □ Chemotherapy
 □ Endocrine therapy
 □ Treatment in general
+ Persuasive behavior adapted from or added to the list originally coined by Karnieli-Miller et al. (3)
Appendix Table 1 continued Coding scheme implicit persuasion behaviors




















l From mild 
to serious 
treatment 
- a gradual 
decision+
The oncologist presents the various treatment strategies in such a way 
that the proposed course of treatment seems to be the least aggressive 
or invasive and consequently more appealing. For example: “In your 
case we propose a four-course chemotherapy regime instead of the 
standard six-course regime, which only yields slightly less disease-free 
survival gain but is easier pull through”.
□ No
□ Yes, and alluded to:
 □ Chemotherapy






The oncologist presents the combination of chemotherapy and 
endocrine therapy as a “package deal”. He/she focusses on 
chemotherapy during the consultation and implicitly assumes that by 
agreeing to start chemotherapy, the patient is agreeing to undergo 
the whole treatment package, although endocrine therapy was not 
(extensively) discussed.
□ No
□ Yes, and alluded to:
 □ Chemotherapy




The oncologist for example decides that endocrine therapy will be 
started, which is the main treatment decision that needed to be made. 
However, the patient is told that she could always decide to terminate 
treatment if the side-effects become too much to bare. Thus the actual 
decision – to start treatment or not – is made by the oncologist, and by 
leaving the decision on when and whether or not to terminate treatment 
in the patients’ hands, the illusion is created that treatment decision-
making was shared or even patient-driven.
□ No
□ Yes, and alluded to:
 □ Chemotherapy

























The oncologist emphasizes the seriousness of the diagnosis and the 
potential negative implications of the disease, especially if the patient 
foregoes adjuvant treatment, before presenting the treatment options. 
□ No
□ Yes, and alluded to:
 □ Chemotherapy
 □ Endocrine therapy





The oncologist stresses what could go wrong if the patient does not 
comply with the recommended course of treatment, i.e. foregoes 
treatment against medical advice or does not take the treatment in the 
dosage and intervals prescribed.
□ No
□ Yes, and alluded to:
 □ Chemotherapy






The oncologist makes assertions about what the patient could or could 
not handle, her ability to persevere and priorities in life, to steer her 
towards undergoing or foregoing treatment. 
□ No
□ Yes, and alluded to:
 □ Chemotherapy





The oncologist uses other patients’ frightening or hopeful stories as 
examples to convince patients to choose the course of treatment 
favored by the oncologist.
□ No
□ Yes, and alluded to:
 □ Chemotherapy









The oncologist emphasizes that it is very unusual for patients like 
yourself to undergo or forego treatment, e.g.: “It is unheard of for 
patients with HER2-positive disease like you to forego chemotherapy 
and trastuzumab”
□ No
□ Yes, and alluded to:
 □ Chemotherapy
 □ Endocrine therapy






Summary and discussion 
This thesis contains studies that provide new insights in how breast cancer patients 
are informed about the benefits and side-effects of adjuvant systemic treatment, with a 
particular emphasis on the use of prediction tools in the information provision process. 
Of available prediction tools, Adjuvant! is arguably the best known worldwide. Its use 
is recommended by several (inter)national guidelines (e.g., British NICE (1), American 
National Comprehensive Cancer Network (2) and the Dutch national treatment guide-
lines (3)). Therefore, in this project Adjuvant! (4) is the common thread between the 
various studies. 
From the work contained in this thesis, seven key findings can be distilled, namely:
I. Many prediction tools are available to aid adjuvant sys-
temic treatment decision-making, however, they require 
either further calibration and/or broad validation
(Chapter 2 and 3)
II. Medical oncologists set higher thresholds for considering 
adjuvant systemic treatment worthwhile compared to the 
thresholds used in clinical guidelines
(Chapter 4)
III. Adjuvant! is regularly used by medical oncologists to 
inform patients about their prognosis and the potential 
treatment benefit
(Chapter 5 and 6)
IV. In spite of reservations about the robustness of Adju-
vant!’s relapse estimates, medical oncologists usually 
only communicate the relapse probabilities to patients
(Chapter 6)
V. The uncertainty associated with Adjuvant!’s estimates 
is not always communicated, and patients struggle with 
the concept of epistemic uncertainty
(Chapter 5 and 7)
VI. The suboptimal information provision about treatment 
side-effects during consultations suggests that adjuvant 






VII. In spite of the lack of a ‘best’ treatment option, medi-
cal oncologists use implicit persuasion to steer patients 
towards the treatment option they deem in their patients’ 
best interest
(Chapter 8)
Below these seven key findings are discussed. The buildup of the discussion for each 
key finding is as follows: first, the key finding is described; thereafter follows a reflection 
on the significance of our finding in the context of available literature and/or clinical 
practice and our thoughts on future directions. 
I. Many prediction tools are available to aid adjuvant systemic treatment decision-
making; however, they require either further calibration and/or broad validation 
(Chapter 2 and 3)
Summary
We conducted a systematic review of published prediction tools to help decision-
making about adjuvant systemic treatment for early-stage breast cancer (Chapter 
2). We identified 20 prediction tools developed to primarily aid medical oncologists’ 
clinical decision-making. Even though the development study of many of these tools 
reported that their discriminatory accuracy was good, many have not undergone broad 
external validations and recalibration if needed, or widespread implementation in clinical 
practice. Exceptions are Adjuvant! (4), PREDICT (5), Nottingham Prognostic Index 
(6), and tools based on bio-molecular profiles, most notably Oncotype Dx (7) and 
MammaPrint (8). Our review suggests that Oncotype Dx and MammaPrint are able to 
accurately discriminate between patients with high vs. low risk of recurrences. Generally, 
in validation studies, Adjuvant!’s estimates seem reasonably sound in the whole study 
population. However, review of the studies reporting validations of Adjuvant! shows that 
its relapse probabilities are less reliable than its mortality estimates, and shortcomings 
in the model’s discriminative ability and calibration in young (<40 years) and elderly 
patients (>70 years) were reported.
Further, Adjuvant! and MammaPrint can be used all over the world, but they have 
mainly been validated in North American and European patient populations (Chapter 
2). The validation studies we reviewed in Chapter 2 suggest that Adjuvant!’s estimates 
and MammaPrint’s classification of patients into risk categories might be less accu-
rate in Asian populations. Evidence on the performance of other tools in non-western 
populations is limited.
Also, none of the tools we identified in Chapter 2 provide insights in both the benefits 
and harms of treatment. All of them solely focused on disease-free, all-cause and/
or breast cancer specific survival. We also assessed the readability of the output of 
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available prediction tools (Chapter 2). We found that the output regularly contained 
complex bio-medical jargon that was not explained in laymen terms. 
In Chapter 3 we assessed the discriminative ability and calibration of Adjuvant! and 
PREDICT’s all-cause mortality estimates for patients younger than 50 years at diagnosis. 
We found that the discriminatory accuracy of both tools was poor to moderate, and 
calibration was poor in the extremes (i.e., for patients with the best and those with the 
poorest prognosis). The magnitude of Adjuvant!’s and PREDICT’s underestimations 
of all-cause mortality was smaller than what had been reported in previous studies 
(differences of up to 35% between observed and predicted mortality), but both tools 
tended to underestimate all-cause mortality for patients younger than 40 years (range 
underestimation: 6.0 to 6.6%). 
In conclusion, many prediction tools have been developed to predict survival with/
without adjuvant systemic therapy for early-stage breast cancer. However, most have 
not undergone broad validation. Those for which there is more evidence on their per-
formance, need to be recalibrated to improve their performance in multiple populations, 
e.g., patients younger than 50 years and those older than 70 years at diagnosis, and 
patients in Asian populations.
Reflections and Future Directions
Numerous prediction tools are available to aid decision-making about adjuvant systemic 
therapy for breast cancer. These tools only focus on one side of the trade-off between 
benefits and harms involved in decision-making about adjuvant systemic therapy, 
namely survival probabilities. Thus, if medical oncologists do not provide patients with 
balanced information about the side-effects, decision-making will be mainly driven by 
the treatment benefits. 
An important element that is often missing, even for tools that have been validated 
more extensively and have seemingly found their way into clinical practice, is an impact 
analysis. As described by Reilly et al. (9), an impact analysis consists of four assess-
ments, namely: 1) did the decision rule lead to the intended effect on patient care (e.g., 
reduce chemotherapy uptake); 2) was the observed impact greater or less than the 
expected impact; 3) was the accuracy of the tool preserved; and 4) did modification of 
the tool itself or its target population impact its accuracy (9). Adopting these steps could 
elevate the development of prediction tools to more than merely scientific endeavors. 
Recently published prospective studies (i.e., TAILORx (10) and MINDACT (11)) reported 
that for specific patient populations Oncotype Dx and MammaPrint can be used to 
safely select patients that can forego adjuvant chemotherapy. Prospective studies are 
rare, as they are difficult to carry out in clinical practice. Additionally, Oncotype Dx and 




gone. However, for tools such as Adjuvant! and PREDICT it is difficult to provide such 
advice. Additionally, they arguably do not aim to provide strong directives on whether 
or not to undergo treatment, but to inform clinicians and patients, and thereby help 
them decide whether they feel the treatment benefits are worthwhile. A randomized 
controlled trial showed that patients receiving Adjuvant! estimates did decide to forego 
treatment more often than those who did not (12). Such work suggests that Adjuvant! 
does influence the treatment preferences and final treatment decisions. 
When we zoomed in on Adjuvant!’s calibration and discriminative ability, we found 
that Adjuvant!’s relapse probabilities are less accurate than its mortality estimates 
(as discussed in Chapter 2) (13,14). This can in part be attributed to the fact that the 
model does not distinguish between loco-regional and distant metastases. Until these 
estimates are updated and there is evidence that they are accurate, clinicians need to be 
careful if they decide to use them. A factor complicating clinicians’ ability to somewhat 
gauge the precision of these estimates is Adjuvant! (like many other prediction tools) 
does not provide the confidence interval around its estimates. Given the limitations 
identified, it could be argued that perhaps clinicians should refrain from communicating 
the relapse probabilities to patients, in any case to the subgroups of patients where the 
largest over- and/or underestimations have been reported (e.g., patients < 50 years and 
those > 70 years at diagnosis). Further, Adjuvant! and PREDICT’s breast cancer specific 
and/or all-cause mortality estimates are not optimally accurate in young patients (as 
discussed in Chapter 2 and 3, and reported in recent studies such as Maishman et al. 
(15) and Lambertini et al. (14)). Adjuvant! also does not perform well in elderly patients 
(aged 70 years and older) (as discussed in Chapter 2). Prediction tools to help medical 
oncologists and patients better weigh the pros and cons of options are particularly useful 
in this patient population, as there is a fine line between “doing too little” and “doing 
too much” (16,17). A validation study in a large population of elderly patients found that 
Adjuvant!’s discriminatory accuracy was moderate for mortality, but poor for recurrence 
(13). Calibration was poor for both Adjuvant!’s mortality and recurrence estimates. An 
analysis of PREDICT’s estimates showed that its 5-year overall survival estimates were 
reliable for elderly patients, whilst its 10-year overall survival estimates were not (18). 
Currently, both Adjuvant! and PREDICT are undergoing extensive updating, which 
could improve their performance in young and elderly patients, but this needs to be 
assessed when the new versions become available.
One characteristic of Adjuvant! that is deemed as an advantage (e.g., in the Dutch 
national breast cancer guidelines (3)) over other tools, is the fact that it is the only tool 
that takes comorbidity into account. This is especially relevant when predicting (disease-
free) survival for elderly patients as there is large heterogeneity in terms of comorbidity 
in this patient subgroup, i.e., potentially competing causes of death. The variable that 
Adjuvant! uses is classified into categories namely: perfect health, average for age, 
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minor problems, major problem +10, major problem +20, and major problem +30. 
However, the categories used to define patients’ general health have not been clearly 
defined by Adjuvant!’s developers. Thus, how medical oncologists classify patients is 
subject to interpretation and not likely to be uniform. For example, if a patient has well-
managed diabetes, is that a minor problem or is it a major problem? There is no average 
diabetic. This disease can have a varying level of impact on patients’ health, and its 
impact on patients’ life expectancy may also vary. Therefore, it is understandable that 
providing standard classification rules for this general health variable is a challenge. 
However, the validation study by de Glas et al. suggests that the choice of general 
health category does significantly influence the prognostic estimates generated by 
Adjuvant!. If patients’ general health was classified systematically (using a system based 
on consensus among experts), Adjuvant!’s estimates of recurrence were significantly 
more accurate, but it overestimated overall survival (13). If the general health variable 
was set to ‘average for age’, Adjuvant! tended to overestimate both the recurrence and 
overall survival estimates (13). In sum, it seems that some more thought needs to be 
given to Adjuvant!’s general health variable, and it most definitely needs to be better 
defined in order for it to be of added value. 
Currently, validation studies mainly focus on assessment of the discriminatory accuracy 
and calibration of available prediction tools. However, applying methods such as net 
benefit modelling (19,20) could improve insights in the added value of prediction tools 
for decision-making. The net benefit method provides information on whether using 
a prediction tool leads to better decisions being made or not, i.e., is it safe to use a 
specific prediction tool to select patients that can forego chemotherapy for example. 
Additionally, comparison of the performance of a prediction tool across validation 
populations (e.g., different countries and in different clinical settings), could provide 
further insights in the strengths and weaknesses of the tool. 
Finally, it remains imperative for medical oncologists to exercise caution if they choose 
to use prediction tools. Such tools can be useful, and our work as well as that of others 
shows that in selected populations their estimates are accurate. However, such tools are 
inherently imperfect, and should serve as guidance, clinical judgment and deliberation 
between medical oncologists and patients remain important. 
II. Medical oncologists set higher thresholds for considering adjuvant systemic 
treatment worthwhile compared to the thresholds used in clinical guidelines (Chapter 
4)
Summary
Clinical guideline developers provide a recommendation about when treatment benefit 
outweighs the side-effects, in order to formulate guidance on eligibility for treatment. 




absolute treatment benefit in terms of 10-year survival is ≥ 3-5%. Thus, of 100 patients 
who meet the minimum required survival benefit for treatment, three will benefit from 
treatment and 97 will only experience the side-effects of treatment and no benefit. 
The difficulty lies in the fact that it is not possible to know a priori which patients will 
be amongst the 3% that will benefit from systemic treatment, and which patients are 
amongst the 97% that either do not require adjuvant treatment or will develop a disease 
recurrence in spite of treatment.
A survey by Stiggelbout et al. (21) conducted among medical oncologists in the year 
2000 showed that they felt that chemotherapy needs to yield between 6 to10% absolute 
10-year survival benefit to be worthwhile. We replicated this study among 42 medical 
oncologists and found that medical oncologists agreed that adjuvant systemic therapy is 
worthwhile if the expected 10-year survival gain is 10% or more, but not if the expected 
gain is less than 10% (Chapter 4). Medical oncologists’ minimally desired chemotherapy 
benefit was the same in our sample (Chapter 4) as in the sample Stiggelbout et al. 
surveyed over a decade ago (21). New compared to Stiggelbout et al. (21) was that we 
also assessed the minimally desired benefit to make endocrine therapy worthwhile. For 
endocrine therapy the minimal absolute 10-year survival benefit that made treatment 
worthwhile tended to be higher for medical oncologists (6 to 10%) compared to surgical 
medical oncologists (1 to 5%), but 50% of respondents felt that 1 to 5% survival benefit 
was sufficient to make treatment worthwhile (Chapter 4). 
To conclude, oncologists set higher thresholds for considering adjuvant systemic 
treatment worthwhile compared to the thresholds used in clinical guidelines, and set 
the thresholds higher for chemotherapy than for endocrine therapy.
Reflections and Future Directions
Over the past decades, the eligibility criteria for chemotherapy have become broader. 
This especially occurred following the publication of the early breast cancer trialists 
collaborative group’s (EBCTCG) meta-analyses of adjuvant systemic treatment effect 
(22,23). However, surgical and medical oncologists’ minimally desired chemotherapy 
benefit has not decreased. Our findings also suggest that medical oncologists deem 
the impact of endocrine therapy to be less serious than the impact of chemotherapy. 
Even though the side-effects of endocrine therapy might be relatively innocuous from 
a medical perspective, they can prove to be a heavy burden for patients during the 5 
years (or possibly even 10 years) treatment period, as may be the resulting constant 
reminder of the illness (24-26). Finally, our findings might denote a sense amongst 
medical oncologists that by having such broad guidelines, too many patients undergo 
treatment needlessly. This could influence oncologists not to adhere to the recom-
mendation in the guideline if they personally feel that the benefits do not outweigh the 
side-effects – i.e., undergoing treatment is not in their patients’ best interest. Even if 
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they do not explicitly communicate this to patients, the choices oncologists make in 
terms of what they disclose to patients and how they formulate this information, could 
imply their personal preference. The findings of the study we report in Chapter 8 support 
this hypothesis (this study is discussed under key finding VII). 
III. Adjuvant! is regularly used by medical oncologists to inform patients about their 
prognosis and the potential treatment benefit (Chapter 5 and 6)
Summary
In Chapter 5 we assessed surgical and medical oncologists’ frequency of use and moti-
vation for employing prediction tools using an online survey (N= 51). The best known 
(95%) and most frequently used (96%) prediction tool was Adjuvant!. Our respondents 
indicated they regularly used it to inform their own treatment advice (86%), to inform 
patients about their prognosis (>80%), and to convince patients either to forego or 
undergo treatment, particularly chemotherapy (74%). Three quarters of respondents 
felt that using Adjuvant! during the consultation helped patients to better understand 
their prognosis. 
As Adjuvant! was the most frequently used prediction tool, in Chapter 6 we focused on 
how often Adjuvant! was actually used prior to and during consultations with patients, 
and which factors were associated with its use. To this end, we used 287 audiotaped 
consultations. We found that medical oncologists consulted Adjuvant! prior to 70% of 
consultations to inform themselves, and it was used during two thirds of consultations. 
Adjuvant! was used less frequently during consultations with patients with TNM stage 
II/III than with stage I. Adjuvant! use was also associated with medical oncologists’ 
age, with the older medical oncologists using Adjuvant! less often, both prior to and 
during consultations, than their younger counterparts. 
In sum, medical oncologists frequently use Adjuvant! both prior to and during patient 
consultations to inform patients about their prognosis, convince them about their 
proposed treatment plan. A majority of surgical and medical oncologists believe that 
using Adjuvant! helps their patients to better understand their prognosis. Use of Adju-
vant! was less frequent in older oncologists and during consultations with patients 
with stage II/III disease.
Reflections and Future Directions
The higher the disease stage, the poorer the prognosis, and medical oncologists might 
be hesitant to communicate such probabilities. Receiving explicit information about 
poor prognosis might prove difficult for patients to come to terms with, cause them 
anxiety, and/or demotivate them. Also, medical oncologists might be more inclined 
to discuss the prognostic probabilities when treatment benefit is limited, in order to 




(Chapter 5), a large proportion of medical oncologists listed this as a reason to use 
Adjuvant!. Further, it is perhaps not surprising that older medical oncologists use 
Adjuvant! less often, as they were trained at the time before the use of prediction tools 
became commonplace. Older medical oncologists are also more experienced, and 
might feel that using prediction tools has little or no added value to their preparation for 
the consultation or information provision to patients. Our finding that younger medical 
oncologists also more often consulted Adjuvant! prior to the consultation to inform 
their own treatment advice is in line with this hypothesis.
It is interesting that medical oncologists use Adjuvant! frequently during consultations, 
as it would be reasonable to fear that conveying risk estimates from prediction tools 
might cost more time than what is allotted for consultations. Yet, additional analyses 
of the data used in Chapter 6, suggested that on average the use of Adjuvant! did not 
significantly increase the duration of consultations (on average 1.5 minutes longer if 
Adjuvant! was used, P= 0.69 (data not shown)). Even though a definitive answer would 
have required an RCT, this finding suggests that a lack of time should not be a reason 
to forego the communication of probabilities. It remains a question whether probabilities 
can be adequately explained without increasing the length of the consultation. We 
did not aim to explore this in-depth in Chapter 6, but we did observe two tendencies 
in how probabilities were communicated during patient consultations. First, of all the 
probabilities communicated, 93% were presented as percentages and 41% were 
(also) presented as proportions (e.g., 3 out of 100) (data not shown). This finding was 
irrespective of the use of Adjuvant!. Communicating probabilities only using percentages 
is not advised, as a significant proportion of people struggle to understand percentages 
(27,28). It is helpful to (also) present the survival estimates as frequencies (e.g., 1 out of 
4), but this was done in less than half of the consultations in which probabilities were 
discussed (data not shown). Second, in about one in five consultations the coders 
of the audiotaped consultations were unable to determine whether the probabilities 
communicated were for example overall or disease-free survival probabilities. Unclear 
risk communication undermines medical oncologists’ intent to help patients to better 
understand their prognosis. These are disconcerting findings that require replication. 
If confirmed, these findings suggest that adequately communicating probabilities may 
require more time, and they underline the need for increased attention for training in 
risk communication in pre- and post-graduate curricula.
IV. In spite of reservations about the robustness of Adjuvant!’s relapse estimates, 
medical oncologists usually only communicate the relapse probabilities to patients 
(Chapter 6)
Summary
Analyses of the 287 audiotaped consultations indicated that the medical oncologists 
communicated Adjuvant!’s relapse probabilities in more than 90% of patient consulta-
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tions, whereas the mortality estimates were only communicated in a quarter of those 
consultations (Chapter 6). Thus, in most consultations only the relapse probabilities 
were communicated.
Reflections and Future Directions
These findings contradict the findings of our survey (described in Chapter 5), in which 
medical oncologists indicated they seldom only communicated relapse probabilities. 
The frequent communication of relapse probabilities we observed in clinical practice, 
is also surprising given the available evidence that Adjuvant!’s relapse probabilities are 
significantly less accurate than its mortality estimates (as described in Chapter 2), and 
the concern medical oncologists expressed about the accuracy of Adjuvant!’s relapse 
estimates in our survey (as described in Chapter 5). Perhaps medical oncologists prefer 
to communicate the relapse probabilities in spite of their reservations because relapse 
is the nearest endpoint. Moreover, given the efficacy of currently available treatment, 
death due to cancer can often be postponed for a significant period of time even after 
patients develop a relapse. Additionally, it might be easier to discuss the possibility of 
relapse than to discuss the probability of dying due to the disease. Nevertheless, given 
the limitations in Adjuvant!’s relapse probability estimates, medical oncologists need 
to exercise caution when communicating these probabilities to patients. 
V. The uncertainty associated with Adjuvant!’s estimates is not always communicated, 
and patients struggle with the concept of epistemic uncertainty (Chapter 5 and 7)
Summary
Probabilities from prediction tools are intrinsically imperfect and embody two types of 
uncertainties: aleatory uncertainty arising from the unpredictability of future events, and 
epistemic uncertainty arising from limitations in the reliability and accuracy of proba-
bility estimates (29). Communication about the uncertainty surrounding the estimates 
of prediction models is a controversial topic. Risk communication experts argue that 
uncertainty also needs to be communicated to patients if medical oncologists discuss 
the prognostic estimates with them (30). However, given that even highly educated 
people struggle to understand probabilistic information (28), this raises the question 
whether also communicating uncertainty is of added value to patients, or will only serve 
to increase their anxiety, unnecessarily making it more difficult for them to understand 
their survival probabilities. 
In our survey amongst medical oncologists we assessed whether they wanted to know 
the uncertainty surrounding the probability estimates, and their views on communicating 
this uncertainty to patients (Chapter 5). Interestingly, only half of them wanted to know 
the width of the confidence interval around Adjuvant!’s prognostic estimates, and a 
third felt that this information was of no added value to them. However, more than 




the uncertainty associated with Adjuvant!’s survival estimates. 
In Chapter 7 we investigated how often and which type of uncertainty was communi-
cated during 198 audiotaped patient consultations in which Adjuvant! had been used 
(same sample as Chapter 6). In our consecutive sample of patients, medical oncol-
ogists communicated some form of uncertainty in about half of the consultations. If 
medical oncologists referred to uncertainty, it was mostly (4 out of 5 times) an allusion 
to aleatory uncertainty. When medical oncologists did discuss epistemic uncertainty, 
they were somewhat vague (e.g., “these are averages” or “of course there always is a 
margin associated with such statistics”). 
We also conducted interviews with patients in the week after the consultation with the 
medical oncologist, to gain insights in patients’ perceptions of uncertainty. In these 
interviews, the patients mainly made references to aleatory uncertainty. Further, the 
patients made more references to aleatory than to epistemic uncertainty, even when 
we specifically asked them about epistemic uncertainty (Chapter 7). One in 10 patients 
indicated that the probabilities were exact; they perceived no uncertainty associated 
with the survival estimates. Further, during interviews patients seemed to struggle with 
our questions about epistemic uncertainty. On the one hand, they seemed to think we 
were asking them whether the medical oncologists had been truthful with them or if 
their medical oncologists had gotten the probabilities correct. They seemed unable to 
reconcile the fact that probabilities can be both true and imprecise. Patients often con-
tradicted themselves when talking about epistemic uncertainty. They indicated that the 
probabilities gave them a sense of security amongst all the uncertainty. Thus, thinking 
about the limitation of the estimates was difficult. The interviewers struggled to find a 
balance between obtaining answers to the research questions, and not unnecessarily 
upsetting patients by pushing the subject too hard. 
In conclusion, we found that medical oncologists discussed uncertainty in less than 
half of the consultations, and if they discussed it, they more frequently communicated 
about aleatory uncertainty, Patients seem aware and comfortable talking about aleatory 
uncertainty, but they struggle with epistemic uncertainty. 
Reflections and Future Directions
We found that in about half of the consultations medical oncologists talked about some 
form of uncertainty during the consultation, and most often aleatory uncertainty. A pre-
vious study, by Politi and colleagues, found that breast cancer surgeons talked about 
the margin around estimates in 48% of consultations, and in 28% of consultations 
they discussed the uncertainty about the strength of the evidence in the literature (31). 
These findings are not in line with ours, as epistemic uncertainty was discussed only 
in 1 in 5 consultations in our sample. However, the surgeons in the study by Politi and 
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colleagues knew that the study intended to assess communication of uncertainty and 
decision satisfaction. Therefore, they might have communicated uncertainty more often 
that they usually would have. Our study was observational for one, and the question 
about uncertainty was not the primary focus. Thus, in comparison our study would 
not have stimulated the participating medical oncologists to discuss uncertainty more 
often than they normally would have. Our findings might be a better reflection of clinical 
practice, but on the other hand the context of the studies is somewhat different, and 
might therefore not be comparable.
Perhaps the fact that aleatory uncertainty is communicated more often and patients 
struggle least with it, might be because it is more intuitive and does not require under-
standing of the nature of probabilistic information, compared to epistemic uncertainty. 
People are generally aware that it is impossible to predict the future, therefore, it might 
also be easier to accept aleatory uncertainty. Further, the fact that Adjuvant!, like many 
other prediction tools, does not provide information about the width of the confidence 
interval around its estimates, might make it more difficult for medical oncologists to be 
more specific about epistemic uncertainty. This could explain the vagueness of medical 
oncologists’ utterances about uncertainty. Also, it is remarkable that half of the surgical 
and medical oncologists in our survey (Chapter 5) felt that knowing the width of the 
confidence interval was of no added value to them. This type of information could 
help clinicians gauge the precision of the estimates, and help them decide whether or 
not to disclose this to patients. Survival probabilities can strongly influence patients’ 
treatment preference and their decision-making, it is therefore, important that this 
information is as reliable is possible. Clinicians have the duty to ensure the reliability 
of the information they provide patients with.
That uncertainty was discussed in only half of the consultations might be partly explained 
by the fact that medical oncologists indicated they communicate probabilities to inform 
patients about their prognosis, and also to convince them about the merits of their 
proposed treatment plan (Chapter 5). Therefore, they might be hesitant to discuss the 
limitations of the probabilities as this could undermine the patients’ ability to ‘trust’ the 
estimates and use them in decision-making. Indeed, during our interview with patients, 
they indicated that they derive a sense of security from the probabilities. Also, one study 
reported that communicating scientific uncertainty was associated with decreased 
decision satisfaction among women facing cancer treatment decisions (31). However, 
there is no hard evidence to either support or refute this hypothesis. Most work in this 
area of risk communication has been conducted in healthy volunteers (e.g., (29)), and 
it is unclear to what extent it applies to patients facing real treatment decisions. 
Further, the difficulty we encountered in talking about uncertainty with patients meant 




We can only describe to what extent they perceive uncertainty, i.e., whether they are 
aware that there is uncertainty and how they viewed this uncertainty. Research is 
needed to get insights in patients’ understanding of uncertainty. Finally, the difficulty 
we experienced during the interviews also seems to be congruent with medical oncol-
ogists’ struggle with regard to communicating uncertainty. Whilst most efforts in this 
area of risk communication center around building an evidence base on how to best 
communicate uncertainty, our study raises the question whether uncertainty, especially 
epistemic uncertainty, should be communicated to patients. This also deserves careful 
consideration in further research.
VI. The suboptimal information provision about treatment side-effects during 
consultations suggests that adjuvant systemic treatment decisions are mainly driven 
by the potential treatment benefits (Chapter 6)
Summary
The use of Adjuvant! did not influence how many side-effects were communicated 
during audiotaped patient consultations (Chapter 6). Overall, fewer side-effects of 
endocrine therapy than of chemotherapy were communicated. Whether or not chemo-
therapy was discussed alongside endocrine therapy did not influence the number of 
side-effects of endocrine therapy discussed during consultations. Medical oncologists’ 
choices with regard to which side-effects he/she felt was necessary to communicate to 
patients also seem to be a driving force behind which side-effects are communicated. 
There was great variation within and between medical oncologists with regard to how 
many side-effects were communicated during the consultation (in Chapter 6). Medical 
oncologists seem to have delegated the task of informing patients about side-effects 
to breast cancer nurses or the nurse practitioner as they regularly told patients that 
the nurse would discuss the side-effects with them.
In sum, we observed a great variation within and between oncologists in terms of which 
side-effects they communicated, and not one side-effect of either chemotherapy or 
endocrine therapy was communicated in all consultations. 
Reflections and Future Directions
The variation we found in the communication of side-effects illustrates a lack of consen-
sus amongst medical oncologists on a core set of adjuvant systemic therapy side-effects 
that need to be communicated to patients. This finding is in line with a study in the 
UK (32). Some side-effects might be less relevant for some patients. However, as the 
majority of side-effects apply to all patients, the variation in side-effects communicated 
can hardly be explained by tailoring of side-effects to the patients’ situation. Currently, 
no guidance is provided in clinical guidelines on which side-effects minimally need to be 
communicated in order to enable patients to weigh the benefits and harms of treatment 
and develop informed treatment preferences. We conducted a pilot study, in which we 
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asked a panel of five experienced medical oncologists to create a list of side-effects of 
taxane-based chemotherapy (the most frequently prescribed chemotherapy regimen 
in our cohort) that patients minimally need to know in order to be able to weigh the 
treatment benefits against the harms. We considered that participants had reached 
consensus if 80% agreed on whether a side-effect should always be communicated to 
patients. Reaching consensus proved a difficult task. After three rounds, for a number 
of side-effects still no consensus could be reached. We applied the minimum list of 
side-effects on which the experts could reach a consensus (see Box 1) to a set of 70 
consultations (sample of the cohort used in Chapter 6). We found that in none of the 
consultations all the items on the minimum list had been communicated to patients 
(data not shown). These findings further underscore a need for guidance. Guideline 
developers need to take steps towards developing a core set of adjuvant systemic 











Box 1 Taxane-based chemotherapy side-effects that always need to be communicated
Further, fortunately, nurses provide patients with more extensive information about the 
side-effects than medical oncologists do during the consultation (Chapter 6). However, 
given that treatment decisions are made during the consultation with the medical oncol-
ogist, it is disconcerting that information provision about side-effects is limited during 
that consultation itself. Patients are essentially only basing their treatment decision on 
the benefits of treatment. This hampers a proper weighing of the expected benefits 
against the side-effects. If information provision is limited, patients might have erro-
neous expectations of treatment impact, which can lead to early treatment cessation 
if the treatment burden is greater than expected. Indeed, early discontinuation rates 
of up to 50% have been reported for endocrine therapy (24,34).
Finally, thorough information provision is not only relevant from an ethical or legal 
viewpoint. Studies have also suggested that feeling (fully) informed could improve 
patients’ mental health and wellbeing. It might give them a sense of being in control 
and being taken seriously, and thereby helping them cope with their new situation 
(35,36). Comprehensive information provision is a key premise of involving patients in 




more satisfaction with the treatment decision, better compliance, and less anxiety (37).
VII. In spite of the lack of a ‘best’ treatment option, medical oncologists use implicit 
persuasion to steer patients towards the treatment option they deem in their patients’ 
best interest (Chapter 8)
Summary
Medical oncologists are tasked with providing patients with information about the 
benefits and harms of relevant treatment options, in order to enable patients to weigh 
the pros and cons of these options and develop informed treatment preferences. Patient 
participation in decision-making about adjuvant systemic treatment is key, given that 
there often is no one best option from a medical perspective, and decision-making thus 
needs to be guided by patients’ preferences. In such preference-sensitive decisions, 
shared decision-making is especially relevant. A key premise of shared decision-making 
is that information provision is balanced. Ideally, it should be free from implicit value 
judgments, and thus not driven by clinicians’ own assessment of whether the benefits 
outweigh the side-effects. When the presentation of evidence implicitly steers patients 
towards a particular choice, patients may get the erroneous impression that a specific 
option is the only or ‘best’ one (i.e., implicit persuasion).
In Chapter 8 we evaluated medical oncologists’ use of implicit persuasion during patient 
consultations using a self-developed coding scheme. Some form of implicit persuasion 
was used in all the 105 audiotaped consultations we analyzed. Medical oncologists’ 
use of implicit persuasion was not primarily driven by the magnitude of the expected 
treatment benefit. Significantly more implicitly persuasive behaviors were observed 
when endocrine therapy was discussed as compared to chemotherapy. Moreover, 
the direction of steering (i.e., either towards or away from a treatment option) was not 
always congruent with the expected treatment benefit. About half of the patients with 
stage I or lymph node negative disease were steered towards undergoing treatment. 
For endocrine therapy, if implicit persuasion was used, it was always to steer patients 
towards undergoing treatment. Endocrine therapy was generally presented as ‘standard’ 
treatment for patients with hormone receptor positive disease, not as an option that 
could to be considered. Decisions were significantly less often postponed if more 
implicit persuasion was used during the consultation. 
In conclusion, medical oncologists regularly used implicitly persuasive behaviors during 
patient consultations, even though there is no best treatment option in this patient 
population. Their use of implicit persuasion nor the direction in which patient were 
steered was congruent with the expected treatment benefit. Use of implicit persuasion 
was associated with less decisions being postponed.
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Reflections and Future Directions
Our study is the first to systematically investigate the use of implicit persuasion in 
oncology. Karnieli-Miller and Eisikovits were the first to systematically assess the use 
of such behaviors by pediatric gastroenterologists (38). Undoubtedly, many studies 
have also described implicitly persuasive behaviors, but without naming them as such. 
For example, Ziebland et al. observed that surgeon did not present surgery for pan-
creatic cancer as a viable treatment option that could be considered, they presented 
the feasibility of a surgical procedure for pancreatic cancer as a ‘win’ – patients were 
lucky that they could be operated on (39). Our findings suggest that the provision of 
balanced information about treatment, a key premise of shared decision-making, is 
often not met in clinical practice. This is especially worrying as there is no best option 
medically speaking: essentially adjuvant systemic treatment is targeted at reducing 
the probability of a negative outcome, and not detectable disease. Whether or not it is 
worthwhile to undergo treatment, depends on a subjective trade-off that patients can 
only make on the basis of balanced information. That decision-making was significantly 
less often postponed if more implicit persuasion was used, suggests that steering is 
important in influencing the decision-making process. 
Noteworthy is that the implicitly persuasive behaviors medical oncologists used during 
the consultation were often attempts to comfort and reassure patients or assuage any 
perceived decisional conflict. However, if medical oncologists wish to stimulate patient 
participation in decision-making, and for decisions to be the result of a shared process, 
employing these behaviors undermines this intent. Especially, as medical oncologists 
generally do not tend to explicitly communicate that the purpose of the consultation 
is to discuss treatment options and make a decision whether or not undergoing treat-
ment is worthwhile (40). In only 3 out of the 100 consultations analyzed by Kunneman 
et al., medical oncologists explicitly stated that the purpose of the consultation was to 
make a treatment decision (40). This lack of explicit disclosure that there is a choice 
was more manifest in the endocrine therapy than in the chemotherapy consultations 
we analyzed in Chapter 8. This suggests that oncologists think that the benefits of 
endocrine therapy generally outweigh its side-effects.
The lack of explicit disclosure that there is a choice, is compounded by the fact that 
medical oncologists infrequently explored patients’ preferences during consultations 
(as discussed in Chapter 8). This is in line with available literature (41). It is likely that 
patients could consent to a treatment that does not match their preferences and 
goals, and is based on the medical oncologists’ nudges. Additionally, if the implicitly 
persuasive behavior used involves downplaying for example the impact of treatment 
on patients’ quality of life, this might cause patients to underestimate the impact of 
treatment. Decision-making about long-term treatment modalities is not solidified in a 




Realization over time that treatment does not meet the patients’ expectations – based 
on incomplete information – can lead to a change in resolve, and early discontinuation 
of treatment. To ensure that patients make decisions that best match their preferences 
and goals, medical oncologists need to be aware of their own preferences and care-
fully consider the implications of their potentially steering behavior towards patients. 
Preferably, implicit persuasion is addressed in medical teaching curricula to increase 
awareness amongst clinicians about the potential impact of such behaviors.
Concluding remarks
Relevance and limitations of our work
The work presented in this thesis focuses on current practice with regard to communi-
cation about the benefits and side-effects of adjuvant systemic therapy for early-stage 
breast cancer, particularly the use of prediction tools to communicate prognosis during 
patient consultations. The common thread running through most of the work presented 
in this thesis is Adjuvant!. We focus on this specific tool (offline as of November 2015, 
due to updating), but the work on information provision presented in this thesis can 
serve as a template for other prediction tools. 
Our findings suggest that prediction tools are becoming commonplace in clinical 
practice. Therefore, it is also becoming increasingly important that the influence of 
using such tools in clinical practice is investigated. Given the lack of information about 
the prevalence of use of prediction tools in clinical practice and current practices with 
regard to information provision about treatment, we opted for an observational design. 
We set out to explore current practices, and identify potential targets for research and 
education. Strength of our observational study is the fact that we approached con-
secutive patients and a large number of them participated (72% participation rate). 
The use of audio recordings of consultations is also a strength, as we did not need to 
solely rely on the recollections of patients and oncologists, and thereby avoided the 
associated potential for recall bias. However, the observational design of our study 
also has drawbacks. For one, it does not allow us to make causal inferences. Another 
limitation is that our study was not randomized, and therefore results on the use of 
Adjuvant! might have been confounded by specifics of the oncologists or the patient. 
Although we had a relatively large sample (N=287), the distribution of patients within 
medical oncologists, was not ideal. More than a third of the participating medical 
oncologists contributed fewer than five patients to the study. This limited our ability to 
perform meaningful analyses (e.g., multilevel analyses) to explore relationships between 
multiple variables and our outcomes of interest. Further, we were not able to assess 
non-verbal communication as we only had audiotaped consultations. Also, we mainly 
included patients treated at hospitals in Leiden, The Hague, and Delft. There might 
be differences in practice in other regions of the Netherlands. Thus, we do not know 
to what extent our findings are generalizable to the whole Dutch context, or clinical 
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practice outside the Netherlands. It is also important to keep in mind that although 
we explicitly instructed oncologists to conduct their consultations as they normally 
would, participating in this study might have influenced their use of Adjuvant!. In a 
survey participating medical oncologists completed after patient recruitment closed, 
we asked them whether their use of Adjuvant! had changed during the study period. 
Only two oncologists indicated to have used Adjuvant! more often than before our study.
Implications for research
The insights that we have gained from this work raises important questions that need 
to be addressed in future research. 
As prediction tools are frequently used to communicate prognosis to patients, it is 
important that the presentation of the survival estimates is clear. This holds for both the 
graphical presentation of the estimates by the tool itself, as well as how the clinician 
presents this information. Worrisome findings were that probabilities were not always 
communicated in a clear manner and they were usually only presented as percentages. 
It begs the question whether patients understand the probabilities from prediction tools 
communicated during the consultation. This needs to be investigated, especially since 
oncologists use prediction tools to inform patients about their prognosis in the belief 
that it helps them to better understand their prognosis. 
Further, there is no evidence about how patients experience the use of prediction 
tools during consultations, and the role the information from such tools play in their 
decision-making. This also needs to be explored in future research.
Our exploration of communication of uncertainty suggests that further evaluation of 
patients’ understanding of uncertainty is necessary, as well as whether communicating 
uncertainty is of added value at all to patients. Even though it is unclear whether or 
not communicating uncertainty to patients is beneficial to them or necessary for them 
to be able to better gauge probabilistic information, it remains important to develop 
guidelines on how best to communicate this type of information, if clinicians choose 
to do so. To that end, there is a need for more studies evaluating which presentation 
format best facilitates understanding of uncertainty, and how clinicians can best talk 
about uncertainty to patients. 
A recurrent theme in many of our analyses of current information provision practices 
is that the impact of endocrine therapy on quality of life appears to be underestimated 
by oncologists. Moreover, endocrine therapy was presented as standard treatment; the 
decision to undergo treatment often seemed a foregone conclusion. However, endo-
crine therapy starts after chemotherapy is completed. Perhaps the endocrine therapy 




extensive information on especially the side-effects is provided by medical oncologists 
at that time. Logistically it was not possible for us to also audiotape the consultation 
after completion of chemotherapy to assess this. In our sample, the extensiveness of 
information provision about endocrine therapy does not differ depending on whether 
chemotherapy was discussed alongside endocrine therapy or not, but the number 
of only endocrine therapy consultations we analyzed was small and predominantly 
conducted in patients over 70 years. Therefore, to confirm or refute our findings for 
endocrine therapy, future studies need to assess information provision in both the first 
consultation on adjuvant systemic therapy and the consultation after completion of 
chemotherapy. 
There is no consensus on which side-effects patients minimally need to be made aware. 
A core list of side-effects for the various chemotherapy and endocrine therapy regimes 
needs to be developed and incorporated in clinical guidelines. In the development of 
such core lists both patients and clinicians need to be consulted.
Finally, some general points are a) our work needs to be replicated, when possible, 
using a randomized design, and b) more work is needed to elucidate the underlying 
mechanisms of the associations we have found. 
Practice implications
Our work has raised more questions for future research than it has provided answers 
for current practice. We have identified subjects that need to be incorporated in clinical 
guidelines and addressed in pre- and post-graduate medical curricula. Specific areas 
requiring attention in medical curricula are: a) which elements need to be addressed 
during consultations to help patients develop an informed treatment preference (e.g., 
using the principles of shared decision making), b) how to best communicate probabil-
ities, and c) how to best frame information in order not to unintendedly steer patients 
towards a specific treatment option. Clinical guidelines need to include guidance on 
which side-effects minimally need to be communicated to patients facing adjuvant 
systemic treatment decisions.
Take home message
Even if, as researchers, we focus on methodology and statistics, the most important 
thing is to use the knowledge that our work generates to improve the care for patients, 
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Dit proefschrift bevat studies die nieuwe inzichten geven in de manier waarop borst-
kankerpatiënten worden geïnformeerd over de voordelen en de bijwerkingen van 
aanvullende behandelingen (c.q. adjuvante systemische therapie), namelijk chemo-
therapie en hormonale therapie. Er wordt ook specifiek gekeken naar het gebruik van 
predictiemodellen om patiënten te informeren over hun prognose. Het predictiemodel 
Adjuvant!, is wereldwijd misschien wel de beste predictietool. In ons onderzoek hebben 
wij ons vooral gericht op Adjuvant!, omdat dit het bekendste predictiemodel is wereld-
wijd en ook aanbevolen wordt in (inter)nationale klinische richtlijnen. De lessen die 
getrokken kunnen worden uit ons onderzoek naar het gebruik van Adjuvant!, kunnen 
mogelijk ook inzichten bieden bij het gebruik van andere predictiemodellen.
Uit het werk in dit proefschrift kunnen zeven kernbevindingen worden gedistilleerd, 
namelijk:
I Er zijn veel predictiemodellen beschikbaar om de besluit-
vorming rondom adjuvante therapie te ondersteunen, 
maar ze moeten nader gevalideerd worden
 (Hoofdstuk 2 en 3)
II Adjuvante therapie wordt in richtlijnen aanbevolen voor 
een minimale baat die lager is dan de baat waarvoor 
oncologen aangeven de therapie de moeite waard te 
vinden
(Hoofdstuk 4)
III Oncologen gebruiken Adjuvant! regelmatig om patiënten 
over hun prognose en de mogelijke baat van de behan-
deling te informeren
(Hoofdstuk 5 en 6)
IV Ondanks beperkingen m.b.t. de betrouwbaarheid van 
schattingen van de kans op recidief communiceren onco-
logen meestal alleen de recidiefkansen aan de patiënt
(Hoofdstuk 6)
V De onzekerheden rondom schattingen van Adjuvant! 
worden niet altijd besproken en patiënten worstelen met 
het begrip epistemische onzekerheid
(Hoofdstuk 5 en 7)
VI De suboptimale informatieverschaffing over bijwerkin-
gen suggereert dat beslissingen over adjuvante therapie 
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VII Ondanks het ontbreken van een “beste” behandeloptie, 
gebruiken oncologen impliciet sturende mechanismen 
die de patiënt in de richting van de therapie kan sturen 
die de oncoloog het beste voor de patiënt vindt
(Hoofdstuk 8).
I. Er zijn veel predictiemodellen beschikbaar om de besluitvorming rondom adjuvante 
systemische therapie te ondersteunen, maar ze moeten nader gevalideerd worden
We hebben een systematisch literatuuroverzicht uitgevoerd naar gepubliceerde risico 
predictiemodellen voor de besluitvorming rondom adjuvante therapie bij vroeg-stadium 
borstkanker (Hoofdstuk 2). We vonden dat de meeste predictiemodellen geen uitgebreide 
externe validatie ondergaan hebben, niet doorontwikkeld zijn en niet wijdverbreid zijn 
geïmplementeerd. Een uitzondering is Adjuvant! en ook tools die op bio-moleculaire 
profielen gebaseerd zijn, zoals Oncotype Dx en MammaPrint. Onze review suggereert 
dat Oncotype Dx en MammaPrint accuraat patiënten met hoog risico van die met 
laag risico op recidief kunnen onderscheiden (Hoofdstuk 2). Ofschoon over het geheel 
genomen de schattingen van Adjuvant! accuraat lijken, vonden de studies die wij 
hebben beoordeeld ook beperkingen in het onderscheidingsvermogen en de kalibratie 
ervan. In een volgende studie hebben we het onderscheidend vermogen en de kalibratie 
van Adjuvant! en PREDICT bepaald voor de overall sterfte van vrouwen onder de 50 
jaar op het moment van diagnose (Hoofdstuk 3). PREDICT is een predictiemodel dat 
erg op Adjuvant! lijkt en snel de weg naar de kliniek gevonden heeft. Dit is deels omdat 
dit tot op heden het enige model is dat automatisch de Her2neu-status en behandeling 
met trastuzumab (c.q. Herceptin) meeweegt. We vonden dat het onderscheidend 
vermogen van beide modellen zwak tot matig was en dat de kalibratie slecht was 
voor de uitersten (d.w.z. patiënten met de beste of juist de slechtste prognose). De 
grootte van de onderschatting van de overall sterfte door Adjuvant! en PREDICT was 
kleiner dan gerapporteerd in eerdere studies (namelijk, verschillen van wel 35% tussen 
geobserveerde en voorspelde sterfte). Desalniettemin onderschatten beide modellen 
de sterfte voor patiënten van 36-40 jaar (met 6.0 tot 6.6%). 
II. Adjuvante therapie wordt in richtlijnen aanbevolen voor een minimale baat die lager 
is dan de baat waarvoor oncologen aangeven de therapie de moeite waard te vinden
Richtlijnontwikkelaars geven aanbevelingen wanneer de verwachte baten van behande-
len groter zijn dan de verwachte bijwerkingen. Momenteel adviseren richtlijnen adjuvante 
therapie te bespreken met patiënten vanaf 3-5% toename in 10-jaars overleving. In een 
enquête vonden Stiggelbout et al.1 in 2000 dat oncologen dachten dat chemotherapie 
een absolute 10-jaars overlevingswinst tussen de 6-10% moest bieden om de moeite 
waard te zijn. We herhaalden deze studie en vonden dat alle oncologen in de studie 
het eens waren dat adjuvante therapie de moeite waard is bij een absolute 10-jaars 
1 Stiggelbout AM, de Haes JC, van de Velde CJ: Adjuvant chemotherapy in node negative breast cancer: patterns of use and 
oncologists’ preferences. Ann Oncol 11:631-3, 2000
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overlevingswinst van 10% of meer, maar er was geen consensus tussen oncologen 
als de overlevingswinst minder dan 10% was (Hoofdstuk 4). In de afgelopen 15 jaar 
zijn de criteria voor het adviseren van chemotherapie verruimd, maar de vereiste baat 
die oncologen wenselijk achten is niet gedaald. Voor hormoontherapie is de vereiste 
baat hoger voor medisch dan voor chirurgisch oncologen (6-10% vs 1-5%). Echter de 
helft van alle respondenten vond dat 1-5% voldoende winst was om behandeling met 
hormonale therapie de moeite waard te maken. Het lijkt erop dat men de impact van 
hormoontherapie minder groot acht dan die van chemotherapie. De bijwerkingen zijn 
inderdaad meestal milder, maar het kan een zware last voor patiënten zijn om lange 
periodes (wel 5-10 jaar) deze therapie te moeten ondergaan, ook vanwege het steeds 
herinnerd worden aan de ziekte. 
III. Oncologen gebruiken Adjuvant! regelmatig om patiënten over hun prognose en 
de mogelijke baat van de behandeling te informeren
We bepaalden hoe vaak chirurgisch en medisch oncologen aangaven predictiemodellen 
te gebruiken en hun redenen voor het gebruik (Hoofdstuk 5). Het bekendste en meest 
gebruikte model was Adjuvant!. Oncologen gaven aan het regelmatig te gebruiken om 
hun eigen advies de onderbouwen, om patiënten te informeren over hun prognose en 
om patiënten ervan te overtuigen juist wel of niet therapie, met name chemotherapie, 
te ondergaan. Driekwart van de deelnemers gaf aan dat het gebruik van Adjuvant! in 
de spreekkamer ertoe leidt dat patiënten hun prognose beter begrijpen. Deze gedachte 
was voor hen een reden om Adjuvant! te gebruiken tijdens consulten met patiënten.
Aangezien onze enquête aangaf dat Adjuvant! het meest gebruikte model was, richtten 
we ons onderzoek op het gebruik ervan in de spreekkamer. We bepaalden hoe vaak 
het vóór en tijdens het consult gebruikt werd en met welke factoren het gebruik ervan 
samenhing (Hoofdstuk 6). We vonden dat in tweederde van de 287 geanalyseerde 
consulten Adjuvant! gebruikt werd. Ook raadpleegden clinici het model in 70% van de 
gevallen vóór het consult. Adjuvant! werd frequenter gebruikt in consulten met patiënten 
met een lager TNM-stadium (I vs. II/III; m.a.w. patiënten met een lage kans op sterfte 
(stadium I) t.o.v. patiënten met een hogere kans op sterfte (stadium II/III). Oncologen 
zijn waarschijnlijk meer geneigd het model te gebruiken als er slechts beperkte baat van 
behandeling verwacht wordt, om de patiënt ervan te overtuigen dat het ondergaan van 
adjuvante behandeling geen zin heeft. Het gebruik van Adjuvant!’s hing ook samen met 
de leeftijd van de oncoloog: oudere oncologen gebruikten het minder vaak dan jongere 
oncologen. Wellicht komt dit omdat er in het verleden geen predictiemodellen beschik-
baar waren en ze gewend zijn hun consulten te voeren zonder het model. Ook hebben 
zij meer ervaring en ervaren daarom wellicht minder behoefte aan de schattingen.
IV. Ondanks beperkingen m.b.t. de betrouwbaarheid schattingen van de kans op 
recidief communiceren oncologen meestal alleen de recidiefkansen aan de patiënt
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Oncologen bespraken de recidiefkansen uit Adjuvant! in meer dan 90% van de con-
sulten, terwijl de sterftekansen slechts in een kwart van de consulten verteld werden 
(Hoofdstuk 6). Dit ondanks het feit dat men in onze enquête (Hoofdstuk 5) aangaf zelden 
alleen recidiefkansen te bespreken, dat de literatuur aangeeft dat de recidiefkansen 
minder accuraat zijn dan de sterftekansen, en dat artsen hier ook van op de hoogte 
waren. Het is waarschijnlijk makkelijker recidiefkansen te bespreken dan de kans te 
overlijden aan de ziekte.
V. De onzekerheden rondom schattingen van Adjuvant! worden niet altijd besproken 
en patiënten worstelen met het begrip epistemische onzekerheid
Kansen uit predictiemodellen zijn intrinsiek imperfect en omvatten twee soorten 
onzekerheid: “aleatoire onzekerheid”, voortkomend uit de onvoorspelbaarheid van 
toekomstige gebeurtenissen en “epistemische onzekerheid”, voortkomend uit beper-
kingen in de betrouwbaarheid en accuraatheid van de schattingen. Het bespreken van 
de onzekerheid rondom de schattingen is een controversieel onderwerp in de literatuur. 
Risico communicatie experts beargumenteren uit voornamelijk een ethisch perspectief 
dat als oncologen hun patiënten informeren over de overlevingsschattingen, zij hen ook 
moeten informeren over de onzekerheid geassocieerd met de overlevingsschattingen. 
Het is echter nog niet duidelijk hoe je patiënten het beste kunt informeren over onze-
kerheid. In onze enquête (Hoofdstuk 5) gaf slechts de helft van de oncologen aan zelf 
het betrouwbaarheidsinterval rondom de schattingen te willen weten en een derde gaf 
aan dat die informatie voor hem geen toegevoegde waarde had. Echter, meer dan 90% 
van de deelnemers gaf aan over de onzekerheid van de schattingen van Adjuvant! te 
spreken met hun patiënten. 
We onderzochten hoe vaak onzekerheid werd besproken in de consulten waarin Adjuvant! 
gebruikt werd en welk type onzekerheid er dan werd besproken. Ook bepaalden we in 
interviews òf en hoe de betreffende patiënten de besproken onzekerheid waarnamen 
(Hoofdstuk 7). In totaal includeerden 27 oncologen 198 consulten. Met ongeveer de 
helft van deze 198 patiënten besprak men enige vorm van onzekerheid. Oncologen 
bespraken viermaal vaker aleatoire dan epistemische onzekerheid. Als ze deze laatste 
vorm bespraken, waren ze veelal wat vaag (bijv. “dit zijn gemiddelden” of “natuurlijk zit 
er altijd een marge aan dergelijke statistieken”). Aleatoire onzekerheid is intuïtiever en 
daardoor mogelijk eenvoudiger te communiceren en te begrijpen. Men is zich over het 
algemeen bewust van het feit dat de toekomst niet met zekerheid te voorspellen valt. 
Tijdens de interviews refereerden patiënten ook vooral naar aleatoire onzekerheid, ook 
wanneer we hen specifiek naar epistemische onzekerheid vroegen. We merkten dat 
patiënten worstelden met het begrip epistemische onzekerheid. Zelfs wanneer ze het 
waarnamen, leken ze zich ongemakkelijk te voelen bij het bespreken ervan. Zij gaven 
aan dat de kansen hen een stuk zekerheid gaven te midden van alle onzekerheid, 
iets om zich aan vast te klampen. De moeite die wij hadden om de patiënten ernaar 
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te vragen, reflecteert waarschijnlijk ook de moeite die oncologen hebben met het 
bespreken van onzekerheid tijdens consulten. Dit doet de vraag rijzen of en wanneer 
het met de patiënt besproken zou moeten worden.
VI. De suboptimale informatieverschaffing over bijwerkingen suggereert dat beslis-
singen over adjuvante therapie vooral genomen worden op basis van de baten van 
de behandeling
Het gebruik van Adjuvant! beïnvloedde niet het aantal bijwerkingen dat besproken 
werd (Hoofdstuk 6). Wel was er een grote variatie binnen en tussen oncologen in de 
bijwerkingen die zij met hun patiënten bespraken. Voor chemotherapie werden meer 
bijwerkingen besproken dan voor hormonale therapie, dit was ook het geval in consul-
ten waarin alleen hormonale therapie werd besproken. Het lijkt erop dat de oncologen 
een deel van het bespreken van de bijwerkingen aan de verpleegkundige overlaten. 
Dit leidt er echter toe dat de beslissing genomen wordt op basis van alleen de baten 
en niet op basis van een kosten-baten overweging.
VII. Ondanks het ontbreken van een “beste” behandeloptie, gebruiken oncologen 
impliciet sturende mechanismen die de patiënt in de richting van de therapie kan 
sturen die de oncoloog het beste voor de patiënt vindt
De beslissing over het wel of niet ondergaan van adjuvante systemische therapie 
is een voorkeursgevoelige beslissing, omdat er niet één duidelijk beste optie is. Bij 
voorkeursgevoelige beslissingen is gedeelde besluitvorming (c.q. shared decision 
making) belangrijk. Een uitgangspunt hierbij is dat de informatieverschaffing neutraal 
gebeurd. Als de wijze waarop de informatie aan de patiënt wordt gepresenteerd de 
patiënt impliciet stuurt in de richting van een bepaalde behandeling, kunnen patiënten 
ten onrechte de indruk krijgen dat die behandeling de enige goede keuze is (impliciete 
overreding). We bestudeerden in hoeverre oncologen in hun consulten impliciete over-
reding gebruikten (Hoofdstuk 8). Enige vorm ervan was in alle 105 consulten die we 
evalueerden aan de orde. Het gebruik van impliciete sturing werd niet gedreven door 
de grootte van de verwachte baat. 
Een factor van belang was de behandeling die besproken werd: er vond meer sturing 
plaats voor hormoontherapie dan voor chemotherapie. De richting van sturen was niet 
altijd congruent met de verwachte baat. Meer patiënten met stadium II of lymfklier-
positieve ziekte werden weliswaar gestuurd in de richting van behandeling met 
chemotherapie ondergaan, maar ook bij de helft van de patiënten met stadium I of 
met lymfklier negatieve ziekte was dit het geval. Voor hormoontherapie werden vrijwel 
alle patiënten in de richting van behandeling ondergaan gestuurd, onafhankelijk van 
ziektestadium. Beslissingen werden minder vaak uitgesteld in het geval sprake was 
van impliciete overreding.
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